Development of Innovative Formulations for Paediatric Use by Trastullo, Ramona
Alma Mater Studiorum – Università di Bologna
DOTTORATO DI RICERCA IN
CHIMICA
Ciclo XXVIII
Settore Concorsuale di Afferenza: 03/D2
Settore Scientifico Disciplinare: CHIM/09
DEVELOPMENT OF INNOVATIVE
FORMULATIONS FOR PAEDIATRIC USE
Presentata da: Ramona Trastullo
Coordinatore Dottorato Relatore
Chiar.mo Prof. Aldo Roda Prof. Federica Bigucci
Prof. Beatrice Albertini
Esame finale anno 2016
Ramona Trastullo-University of Bologna Summary
i
SUMMARY
1. INTRODUCTION.................................................................................................................................1
1.1. REGULATORY ASPECTS ...............................................................................................................1
1.2. AGE-CLASSIFICATION..................................................................................................................3
1.3. PHARMACOKINETIC DIFFERENCES BETWEEN CHILDREN AND ADULTS ..........................4
1.4. PAEDIATRIC BIOPHARMACEUTICS CLASSIFICATION SYSTEM.............................................8
1.5. ROUTES OF ADMINISTRATION AND DOSAGE FORMS ............................................................9
1.5.1. Oral administration ...................................................................................................................9
1.5.2. Oral transmucosal administration ...........................................................................................15
1.5.3. Nasal administration ...............................................................................................................16
1.5.4. Rectal administration ..............................................................................................................17
1.5.5. Topical-transdermal administration ........................................................................................18
1.5.6. Parenteral administration ........................................................................................................19
1.5.7. Pulmonary administration.......................................................................................................20
1.6. MANIPULATION OF DOSAGE FORMS ......................................................................................20
1.6.1. Solid for constitution to a suspension .....................................................................................21
1.6.2. Solid for constitution to a solution..........................................................................................21
1.6.3. Concentrated solution diluted .................................................................................................22
1.6.4. Effervescent tablets.................................................................................................................22
1.6.5. Sprinkle solids ........................................................................................................................22
1.7. RISK ASSOCIATED WITH MANIPULATION OF ADULT DOSAGE FORMS ............................23
1.7.1. Splitting tablets into segments ................................................................................................24
1.7.2. Crushing tablets ......................................................................................................................24
1.7.3. Opening capsules ....................................................................................................................25
1.7.4. Dispersing tablets/capsules and taking proportions ................................................................25
1.7.5. Cutting/covering transdermal patches.....................................................................................25
1.7.6. Cutting suppositories ..............................................................................................................26
1.7.7. Injectable solutions administered by other routes...................................................................26
1.8. CHOICE OF EXCIPIENTS............................................................................................................27
1.8.1. Solvents ..................................................................................................................................28
1.8.2. Antioxidants and preservatives ...............................................................................................29
1.8.3. Sweeteners ..............................................................................................................................30
1.8.4. Fillers ......................................................................................................................................31
1.8.5. Colouring agents .....................................................................................................................32
1.8.6. Flavouring agents....................................................................................................................32
1.9. STEP DATABASE ..........................................................................................................................32
1.10. PALATABILITY: TASTE, SMELL AND TEXTURE .....................................................................33
Ramona Trastullo-University of Bologna Summary
ii
1.10.1. The physiology of taste in children.......................................................................................34
1.10.2. Methods to assess the taste of medications ...........................................................................35
1.10.3. General taste masking technologies in oral pharmaceuticals................................................38
1.10.4. Recent approaches and developments in taste masking........................................................44
1.11. REFERENCES .............................................................................................................................45
2. AIM OF THE WORK.........................................................................................................................50
3. CASE STUDY 1...................................................................................................................................52
3.0. PAEDIATRIC CHALLENGE: ADMINISTRATION ROUTE.........................................................53
3.0.1. TRANSMUCOSAL ROUTE.........................................................................................................53
3.1. INTRODUCTION ............................................................................................................................55
3.2. MATERIALS AND METHODS.....................................................................................................57
3.2.1. MATERIALS................................................................................................................................57
3.2.2. METHODS..................................................................................................................................57
3.2.2.1. Preparation of buccal films ..................................................................................................57
3.2.2.2. Solution viscosity.................................................................................................................58
3.2.2.3. Characterization of buccal films ..........................................................................................58
3.2.2.4. Physicochemical characterization of buccal films ...............................................................60
3.2.2.5. In vitro water-uptake studies................................................................................................60
3.2.2.6. In vitro residence time .........................................................................................................60
3.2.2.7. In vitro release studies .........................................................................................................61
3.2.2.8. In vitro permeation studies ..................................................................................................61
3.2.2.9. Statistical analysis................................................................................................................61
3.3. RESULTS AND DISCUSSION.......................................................................................................62
3.3.1. Solution viscosity....................................................................................................................62
3.3.2. Characterization of buccal films .............................................................................................63
3.3.3. Physicochemical characterization of buccal films ..................................................................64
3.3.4. In vitro water uptake studies ...................................................................................................65
3.3.5. In vitro residence time ............................................................................................................66
3.3.6. In vitro release study...............................................................................................................67
3.3.7. In vitro permeation studies .....................................................................................................68
3.4. CONCLUSION.................................................................................................................................69
3.5. REFERENCES .................................................................................................................................71
4. CASE STUDY 2...................................................................................................................................74
4.0. PAEDIATRIC CHALLENGE: DOSAGE FORM .............................................................................75
4.0.1. ORAL FLEXIBLE DOSAGE FORMS .........................................................................................75
4.1. INTRODUCTION ............................................................................................................................76
4.2. MATERIALS AND METHODS.....................................................................................................78
4.2.1. MATERIALS................................................................................................................................78
4.2.2. METHODS..................................................................................................................................79
Ramona Trastullo-University of Bologna Summary
iii
4.2.2.1. Preparation of granules ........................................................................................................79
4.2.2.2. Granules characterization.....................................................................................................80
4.2.2.3. Determination of drug content .............................................................................................81
4.2.2.4. Solubility studies .................................................................................................................81
4.2.2.5. Differential scanning calorimetry (DSC) studies .................................................................82
4.2.2.6. Fourier transform-infrared spectra (FT-IR) analysis............................................................82
4.2.2.7. X-ray powder diffraction (XRPD) analysis .........................................................................82
4.2.2.8. In vitro dissolution testing ...................................................................................................82
4.2.2.9. Laser diffraction...................................................................................................................83
4.2.2.10. Manipulation of granules with different beverages ...........................................................83
4.2.2.11. Stability studies..................................................................................................................84
4.3. RESULTS AND DISCUSSION.......................................................................................................84
4.3.1. Choice of excipients................................................................................................................84
4.3.2. Granulation experiments: 10 % (w/w) PZQ loading...............................................................86
4.3.3. Granulation experiments: 20 % (w/w) PZQ loading...............................................................93
4.3.4. Manipulation of granules in different food substrates ..........................................................101
4.3.5. Stability upon storage ...........................................................................................................103
4.4. CONCLUSION...............................................................................................................................104
4.5. REFERENCES ...............................................................................................................................106
5. CASE STUDY 3.................................................................................................................................110
5.0. PAEDIATRIC CHALLENGE: TASTE MASKING .......................................................................111
5.0.1. TASTE MASKING BY POLYELECTROLYTE COMPLEXES...................................................111
5.1. INTRODUCTION ..........................................................................................................................112
5.2. MATERIALS AND METHODS...................................................................................................114
5.2.1 MATERIALS...............................................................................................................................114
5.2.2. METHODS................................................................................................................................114
5.2.2.1. Preparation of biopolymer solutions ..................................................................................114
5.2.2.2. Complex formation ............................................................................................................115
5.2.2.3. Complex characterization ..................................................................................................116
5.2.2.4. Encapsulation efficiency....................................................................................................116
5.2.2.5. Stability studies..................................................................................................................117
5.2.2.6. In vitro dissolution analyses ..............................................................................................117
5.3. RESULTS AND DISCUSSION.....................................................................................................118
5.3.1. Complex formation ...............................................................................................................118
5.3.2. Complex characterization .....................................................................................................119
5.3.3. Encapsulation efficiency.......................................................................................................121
5.3.4. Stability studies.....................................................................................................................123
5.3.5. In vitro dissolution analysis ..................................................................................................125
5.4. CONCLUSION...............................................................................................................................128
5.5. REFERENCES ...............................................................................................................................129
Ramona Trastullo-University of Bologna Summary
iv
FINAL CONCLUSIONS ......................................................................................................................132
LIST OF TABLES.................................................................................................................................133
LIST OF FIGURES...............................................................................................................................134
Ramona Trastullo-University of Bologna 1. Introduction
1
1. INTRODUCTION
There are several reasons for the lack of paediatric medicines worldwide. Economic
factors certainly render paediatric research and development less attractive for
pharmaceutical companies in term of achieving an adequate return on investment. Age-
appropriate research makes the process more expensive and complex for organisations
that are active in this sector (European Medicines Agency, 2013). In addition,
undertaking clinical research in children presents unique challenges and the most obvious
of these are the ethical ones. These enormous practical and ethical difficulties may have
contributed to a dearth of high quality paediatric research (Smyth, 2001).
1.1. REGULATORY ASPECTS
Many drugs used in children are either not licensed (unlicensed) or are prescribed outside
the terms of the product licence (off-label) (McIntyre et al., 2000), with the associated
non-negligible risk of inefficiency and adverse reactions. Such a situation was contrary
to the general goal to provide high-quality medicinal products to the entire paediatric
population.
To address this problem, the establishment of a system of both obligations and rewards
and incentives has proven necessary. The Paediatric Regulation came into force in the
European Union on 26th January 2007 with the aim to improve the health by facilitating
the development and the availability of medicines for children aged 0 to 18 years. The
Regulation also aims at ensuring that medicinal products used to treat the paediatric
population are subjected to ethical research of high quality and are appropriately
authorised for use in children and at improving the information available for the use of
medicinal products in the various paediatric populations (European Union (EU), 2006.
REGULATION (EC) No 1901/2006). These objectives should be achieved without
subjecting the paediatric population to unnecessary clinical trials.
The Regulation introduced sweeping changes, for instance the creation and operation of
Paediatric Committee (PDCO), with expertise and competence in development and
assessment of all aspects of medicinal products to treat the paediatric population. PDCO
should be primarily responsible for the scientific assessment and agreement of the
Paediatric Investigation Plans (PIPs) and for the system of deferral and waivers thereof.
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Pharmaceutical industries have to submit early during the product development a PIP, a
plan including details of the timing and measures proposed to demonstrate the quality,
safety and efficacy of medicinal products in all subsets of paediatric population. It aims
at ensuring that the necessary data are obtained through safe studies in children to support
the authorisation to a paediatric medicine.
The paediatric investigation plan:
 includes a description of the measures to be carried out in children;
 describes the measures to adapt the medicine’s formulation to make its use more
acceptable to children;
 covers the needs of all age groups of children;
 defines the timing of measures in children compared to adults
(http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_c
ontent_000608.jsp&mid=WC0b01ac0580925b1b).
PDCO, in addition to assessing the PIPs, has to assess waivers and deferrals, compliance
of the application for a marketing authorisation, and to formulate an opinion on the
quality, safety or efficacy of the paediatric product. The Paediatric Committee has to
assist scientifically in the elaboration of any documents related to the fulfilment of the
objectives of this Regulation and to establish a specific inventory of paediatric medicinal
products and update it.
Where the intention is to apply for a marketing authorisation, a PIP shall be drawn up
and submitted to the Agency with a request for agreement. Within 30 days following the
request, the Agency may verify the validity of the request and prepare a summary report
for the PDCO. It shall adopt within 60 days an opinion as to whether or not the proposed
studies will ensure the generation of the necessary data determining the conditions in
which the medicinal product may be used to treat the paediatric population or subsets
thereof, and as to whether or not the therapeutic benefits justify the studies proposed
(European Union (EU), 2006. REGULATION (EC) No 1901/2006). Within the 60-days
period, the PDCO can request the applicant to propose modifications to the plan.
Once the product concerned is authorised or the product information is amended,
companies that have complied with the obligation of the Paediatric Regulation may
benefit from a reward. The reward takes the form of a six-month extension of the
supplementary protection certificate provided for the Regulation. In case of an orphan
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medicinal product, the reward is an extension of the ten-year period of orphan market
exclusivity to twelve years.
The ‘5-year Report to the European Commission’, a general report on the experience
acquired as a result of the application of the Paediatric Regulation, specified that the
assessment of PIPs was evaluated for 682 medicines up to the end of 2011. Among the
opinions adopted, 476 (70 %) were on the agreement of a PIP and 206 (30 %) of a full
waiver.
Between 2008 and 2012, 10 new medicinal products (new active substances) were
centrally authorised and received a paediatric indication (out of 113 new active
substances in total), under the requirements of the Paediatric Regulation. For one of the
10 products, a Paediatric Use Marketing Authorisation (PUMA) had been requested and
was granted.
For medicines already authorised centrally or nationally, 18 and 12 respectively received
a new paediatric indication developed under the Paediatric Regulation between 2008 and
2012. This means that the implementation has already had a positive impact in keeping
with the main objectives of the Paediatric Regulation, and that paediatric development is
increasing (EMA/428172/2012). A systematic paediatric development is leading to age-
appropriate medicines and increasing paediatric information. Achieving the objectives of
the Paediatric Regulation is a realistic goal based on the experience gathered so far, but
sufficient time is needed as medicines development spans decades. Meanwhile,
opportunities for improvement of the process have been identified and are being
addressed to increase the positive impact of the Paediatric Regulation and make
medicines available with appropriate information to children.
1.2. AGE-CLASSIFICATION
Paediatric patients represent a changing and dynamic population due to the anatomic and
physiological changes that occur during development (Abdel-Rahman et al., 2012).
As a starting point, the paediatric population can be divided in six age groups, in relation
to developmental stages:
 preterm newborn infants;
 term newborn infants (0-27 days);
 infants and toddlers (1 month to 23 month);
 children (2 years to 11 years);
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 adolescents (12 years to 18 years).
The first three groups are the most challenging, as regard the pharmacokinetic aspect,
due to rapid developmental changes in adsorption, distribution, metabolism and
extraction. It is important to consider that there may be large pharmacokinetic and
pharmacodynamic differences among preterm and term infants and within infants over
time, depending on their gestational or postconceptional age. However, it is advisable to
consider factors such as gestational age, postnatal age, birth and body weight, renal
function and the amount of serum albumin in pharmacokinetic studies within the
paediatric population. Determining the protein binding of highly bound drugs and their
active metabolites should be considered when studying newborns.
Children involves a large group of population, from 2 to 11 years, and the 2-4 years group
is the least predictable as regard the pharmacokinetic studies. With increasing knowledge
about liver maturation at the enzyme level, further extrapolations might be possible based
on the relationship between liver and body weight, especially in the older children.
The pharmacokinetics in adolescents is often similar to the pharmacokinetics in adults
(EMA/CHMP/QWP/805880/2012).
1.3. PHARMACOKINETIC DIFFERENCES BETWEEN
CHILDREN AND ADULTS
Children cannot be considered ‘small adults’, since differences in pharmacokinetics and
pharmacodynamics and in adverse reactions occur compared to adults. Gastrointestinal
(GI) fluid composition, pH and volume differences at each age group were identified as
critical for the development of paediatric formulation because these influence age-based
biorilevant solubilities and dissolution rates from the dosage form (Abdel-Rahman et al.,
2012).
As would be expected, saliva secretion increases with age, from 0.03 ml/min in neonates
to 1.2 ml/min in adulthood, with a pH of about 7-7.4.
The pH of the various parts of the GI tract is important in oral drug delivery in terms of
drug release, solubility and absorption (Kaye, 2011). It is established that neonatal and
birth gastric pH are very close to neutral (6-8) with significant acid secretion during the
first 48 hours, bringing the pH down into the more acid range (1-3). The gastric acid
secretions stabilize for the next 10 days, after that pH, increases back to neutral, then it
restarts to decrease toward the normal adult pH ranges at about 3 months of age.
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However, it is believed that the pH levels do not fully reach adult levels until 2 years of
ages. This difference is manifested in faster absorption of acid labile drugs in neonates
and infants as compared to adult population. The absorption of weak acid drug is
decreased whereas absorption of basic drugs is increased (Ali et al., 2014). Furthermore,
food acts as a buffer, and thereby increases the gastric pH, which in turn would decrease
the dissolution of weakly basic drugs and increase that of weakly acidic drugs (Kaye,
2011).
In addition, stomach capacity changes considerably with age, starting at 10-100 ml in
neonates and reaching 3 litres in adults.
As already stated, the major site of drug absorption is the small intestine, and thus, gastric
emptying into the small intestine can be the rate-controlling factor for drug absorption of
oral dosage forms. There was evidence that the gastric emptying rate appears to be slower
in preterm neonates and reaches adult values after six months. Because of this, drug
absorption is slower in neonates and the time required to achieve maximum plasma levels
is increased. For this reason, the European Medicines Agency (EMA) suggests giving
drugs to children intravenously or rectally. The situation is made more complex when
considering the fact that food can have various effects on gastric emptying. For instance,
fat reduces gastric emptying, which can delay the onset of action of certain drugs. On the
other hand, solid and liquid foods create stomach distension and peristaltic waves,
increasing the rate of emptying. Liquids empty more rapidly than solids, and this may be
one important criterion for selecting suspension dosage formulation over tablets dosage
forms for children (Kaye, 2011).
The intestine is more alkaline than the stomach due to the neutralising of the gastric acid
by sodium bicarbonate secreted by the pancreas into the duodenum, which neutralises
the highly acidic chyme from the stomach. The pH gradually rises along the length of the
small intestine, from 6 to 7.5. The colon has a lower pH (6-6.5) compared to that of the
small intestine, because of the colonic bacteria breaking down undigested carbohydrates
into short-chain fatty acids. The rectal pH of neonates and infants, partly depends upon
the type of milk they are being fed. The pH differences between age groups have the
potential to affect drug delivery from oral dosage forms.
The small intestine ranges from 275 cm at birth and continues to grow and mature into
the adolescence, when it reaches the adult size of 575 cm. The growth rate and length of
the small intestine increase most rapidly from the gestation until the 1 year of age, after
which it grows in direct proportion to the body length into the adulthood. The length of
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the small intestine directly affects small intestinal transit time; thus, variability is inherent
based on the growth rate and stage of development of the child. The regional liquid GI
transit time for a child were reported to be 4-7.5 and 17-34 hours for the small and large
intestine, respectively. However, the intestinal motility is irregular in neonates and
infants, leading to very variable transit time, which also contributes to the preference of
parenteral or rectal routes. Children generally have faster transit times, respect to the
other age groups, which may result in controlled release of the drug from the oral dosage
forms (Kaye, 2011). GI motility is also a function of disease states, particularly in smaller
children who are susceptible to GI conditions, such as diarrhoea. Furthermore, the surface
area of the small intestine in infants is proportionately greater than in adults, and so may
result in proportionally greater drug absorption.
Several age-dependent factors, such as body composition and plasma protein
characteristics, can influence the distribution of the drug within the body. As a percentage
of total body weight, the approximate total body water falls from 87 % and 75 % in the
premature and full-term neonate, respectively, to 60 % at 1 year and to 55 % in adulthood.
Extracellular water falls from 45 % of total body water in the full-term neonate to 20 %
in the adult. The clinical implication of this shift in body composition have not been fully
defined (McLeod et al., 1992).
Another factor which influences drug distribution in the young child is the amount of
binding proteins. Albumin, globulins, alpha-1 acid glycoprotein, lipoproteins and other
proteins bind drugs in plasma; in particular, albumin, the major drug binding protein,
binds primarily acidic drugs, while basic drugs bind more avidly alpha-1 acid
glycoprotein and lipoproteins. Many drugs have been found to be less bound to serum
proteins in neonates leading to an increase of the unbound fraction and thus an increased
pharmacologic or toxic response. Plasma proteins generally achieve adult value around
1 year of age. Many organs and tissues in the body, including blood, liver, lungs, kidney
and gastrointestinal tract, are capable of metabolising drugs.
Although most hepatic enzymes are functional in human foetal and neonatal liver, the
activity of some P-450 enzymes (phase I) is absent at birth. Because of this, newborn and
neonates metabolize drugs at a rate several times lower than adults. For example, the
oxidative metabolism of phenobarbital and phenytoin is severely impaired in infants. The
glucuronidation pathway (phase II) is also relatively undeveloped in newborns. The
insufficient metabolism of chloramphenicol by glucuronyl transferarses in the inactive
glucuronide metabolite causes the famous Grey Baby Syndrome.
Ramona Trastullo-University of Bologna 1. Introduction
7
The kidney represents the primary route of elimination for many drugs. Renal elimination
is dependent on glomerular filtration, tubular secretion processes and renal blood flow.
There is evidence of morphological and functional tubular immaturity at birth; tubular
function appears to be fully developed by 7 month of age and renal blood flow increases
with age. The immature renal elimination system leads to accumulation of many drugs,
such as aminoglycosides and penicillin, which necessitates less frequent dosing intervals.
Therefore, as the kidney function matures, there may be a shift from potential drug over-
dose to potential drug under-dose, for instance in the case of theophylline. Tables 1-3
summarize the differences of the physiological data within the different age groups of
paediatric population.
Table 1. Summary GI tract pH data in patients of different age groups in the fasted state.
Organ Neonates Infants Children Adolescents Adults
Birth 24 hours 1-27 days (1-23 months) (2-11 years) (12-18 years) (>18 years)
Saliva 7 7 7 - 7.1 7.4 6-7.4
Stomach 6-8 1-3 6-8 1.4 1.5 1.5 1-2.5
Small intestine - - - - 6.4-7.4 6.4-7.4 6-7.5
Colon - - - - 5.9-6.5 5.9-6.5 7-7.5
Table 2. Summary of physiological data in patients of different age groups.
Parameter Neonates Infants Children Adolescents Adults
Birth 24 hours 1-27 days (1-23
months)
(2-11
years) (12-18 years)
(>18
years)
Saliva secretion
(ml/min)
0.03-
0.04 0.03-0.04 0.03-0.04 0.47 0.25-0.66 1.2 0.3-1.2
Stomach
capacity (ml) 10-100 10-100 10-100 90-500 750-960 1.5 2-3
Small intestine
lenght (cm) 275 275 275 380 450 - 575
Table 3. Summary of GI transit time data in patients of different age groups.
Organ Neonates Infants Children Adolescents Adults
Birth 24 hours 1-27 days (1-23 months) (2-11 years) (12-18 years) (>18 years)
Oesophagus 3-4 s 3-4 s 3-4 s 4-8 s 5-8 s 5-8 s 10-14 s
Stomach 54-82 min 54-82 min 54-82 min 12-70 min 12-70 min 12-138 min 5-120 min
Small intestine 4 h 4 h 4 h 3-7.5 h 3-7.5 h 3-4 h 6-7.5
Colon 28-96 h 28-96 h 28-96 h 32 h 17-34 h 17-34 h 2-48 h
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1.4. PAEDIATRIC BIOPHARMACEUTICS
CLASSIFICATION SYSTEM
The concept of Biopharmaceutical Classification, born in 1995, allows drugs to be
classified because of their in vitro solubility and intestinal permeability. A molecule is
considered highly permeable, according to the Biopharmaceutics Classification System
(BCS), when more than 85-90 % of the administered drug is absorbed. Moreover, a
molecule is considered highly soluble when the highest dose (dose unit) needed is soluble
in 250 ml of aqueous liquid at a relevant pH range. The dose number is calculated as the
maximum dose (M0) divided by the saturated solubility (Cs), multiplied by the initial
gastric volume (V0).
D0 = M0/(Cs * V0)
In adults a value of 250 mL is used for V0 and for this reason, adult patients are
recommended to assume the medicine with 250 ml of water (Batchelor, 2014).
However, the above mentioned differences in anatomic and physiologic properties of
paediatric patients require adaptation of existing biopharmaceutical methods to ensure
that in vitro predictions are relevant for this population. It is difficult to predict
differences in permeability between adults and paediatric population, but it is generally
recognized that the permeability in children above 2 years is equivalent to that of adults.
As regard the in vitro solubility of a drug in paediatric population, the National Institute
of Child Health and Human Development Paediatric Biopharmaceutics Classification
System Working Group assumed an initial gastric volume of children, especially younger
children, of 25 ml.
Since paediatric population, and in particular children, is represented by a wide range of
age, from 2 to 11, it is clear that this wide range corresponds to several physiological and
anatomical differences. It is apparent that there is a need to establish an age specific
biopharmaceutics classification system for children to ensure that development work is
relevant in producing age appropriate medicines for children. In addition, standardisation
in conducting bioequivalence studies for paediatric products both in adult and in
paediatric populations would assist in understanding how medicines perform across wide
age bands.
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1.5. ROUTES OF ADMINISTRATION AND DOSAGE
FORMS
Paediatric patients require different drug delivery systems than other subsets of the
population because of their continuing development hence dosing and administration
requirements (Lopez et al., 2015). Due to this extensive variability in children, there is
also an obvious need for drug formulations tailored to children in all the target age groups
(Ivanovska et al., 2014).
The criteria for choosing a specific paediatric dosage form and a particular route of
administration should be discussed and justified for children in each of the target age-
groups.
1.5.1. ORAL ADMINISTRATION
Oral administration is an extremely useful route for the administration in children, and
several types of dosage forms can achieve it: solutions, syrups, suspensions, emulsions,
powders, granules, tablets, effervescent tablets, orodispersible tablets, etc. In general, the
main choice is between liquids and solid dosage forms
(EMA/CHMP/QWP/805880/2012).
Liquid formulations
Oral liquid dosage forms are normally considered acceptable for children from full term
birth and pre-term neonates who are able to swallow. Liquids are the best option in
paediatric treatment: they permit dose flexibility, the dose is easy to adapt to the body
weight and the body surface area and there are no problems with swallowing (Standing
et al., 2005).
Liquid oral formulations contain drug either in solution or in suspension in the vehicle
and may be supplied as solutions, syrups, suspensions and emulsions (Ali et al., 2014).
The dose volume is a major consideration for the paediatric acceptability. Typical target
dose volumes for liquid formulations are ≤ 5 ml for children under 5 years and ≤ 10 ml
for children of 5 years and older. Water is the preferred vehicle for drug substances with
high solubility and agreeable taste. A solubilized formulation is one of the most common
type of paediatric formulations as at least 24 commercially available solutions or syrups
were identified on European market. Oral solutions of very small volumes (i.e. oral drops
or concentrates) can be developed and diluted in suitable food or beverages, as fruit juice
or milk, to improve the palatability. Moreover, the volume of dilution should be
minimised to avoid the incomplete ingestion and under-dosage
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(EMEA/CHMP/PEG/194810/2005). Oral solution can be very simple formulations
containing only one solvent and one buffer, flavour and preservative, or can also be quite
complex with multiple solvents, solubilizing excipients, buffers, sweeteners, flavours
and preservatives (Stryckley et al., 2008). Aqueous-based oral solution formulations are
challenging for solubility, chemical stability, taste-masking and preservation. In general,
they require flavours, antimicrobial agents, sweeteners and colours. Commercial
examples of aqueous-based oral solution formulations include Emtriva® (emtricitabine),
Ziagen® (abacavir sulfate), Epivir® (lamivudine). Water-soluble and chemically stable
drugs, in which the taste can not be masked in an aqueous-based solution, can be often
successfully formulated in an aqueous syrup formulation. A syrup is a viscus solution
containing high concentration of sugar along with sweeteners or flavours which can mask
the poor taste of several molecules since only a fraction of the drug makes contact with
the taste buds. The low concentration of water makes the syrup resistant to the microbial
growth and thus no preservative is required if the syrup is used immediately after the
preparation, but in a multi-use product the antimicrobial preservation is needed.
Examples of commercially available aqueous-based oral syrups formulations include
Retrovir® (zidovudine), Zyrtec® (cetirizine) and Clarinex® (desloratadine).
Organic solvents are used in oral solutions and elixir formulations when the aqueous
solubility of the active ingredient is low, such that an impractically high dose volume
would be required to administer the intended dose. It is important to minimise the amount
of organic solvent to achieve the necessary solubility, chemical stability, taste-masking
and preservation. Many paediatric oral solutions contain small amount of ethanol,
propylene glycol or PEGs, and four commercially available products include very large
amount of organic solvents, for example Norvin® (ritonavir), Agenerase® (amprenavir)
and Sustiva® (efavirenz). Usually, alcohols are avoided in paediatric formulations due
to their toxicity. It is recommended an alcohol limit of 0.5 % and 5 % for patients under
6 years and between 6 and 12 years of age, respectively.
Suspension formulations should be considered when solubility cannot be modulated.
They are biphasic formulations containing chemically stable but not water-soluble
actives. The challenges associated with suspension formulations include physical-
chemical characteristics such as viscosity, pH-dependent chemical stability, solubility,
dose uniformity, potential for foaming, air entrapment, sedimentation, sticking of the
active substances to the primary container, rheology, particle settling, taste-masking and
preservation.
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Suspensions may be very useful for formulation of substances with poor taste
characteristics: by minimizing the amount of the drug in solution form, suspensions
improve palatability and allow increased drug load in reduced dose volume. Moreover,
taste-masking is normally accomplished by the use of sweeteners and flavours. When
sedimentation cannot be avoided, more information about how to shake the product to
ensure correct dosing is necessary, to avoid the risk of over or under dosing because of
inadequate shaking. Six commercially available paediatric oral suspensions were found
on European market, for example Zovirax® (acyclovir), Viramune® (nevirapine) and
Viravan Suspension® (phenylephrine tannate, pyrilamine tannate and
dextromethorphantannate).
Oral emulsions are liquid preparations for oral use containing one or more active
ingredients. They are stabilized oil-in-water dispersions, either of both phases of which
may contain dissolved solid; solids can also be suspended in oral emulsions. They can
show evidences of phase separation, but in general, they are readily re-dispersed on
shaking. A change in colour may indicate chemical degradation or microbial
contamination.
Despite all these advantages, liquid dosage forms have several limitations: they are bulky
and difficult to transport, require careful handling and have special storage requirements.
In liquid state drug is more susceptible to degradation and has a lesser shelf life than in
solid dosage forms. In addition, liquid dosage forms are prone to microbial growth; in
addition to being a risk to the health, microbial contamination may cause changes in pH,
appearance, odour, smell and palatability of the preparation. Therefore, preservatives are
usually added. Drugs undergoing hydrolysis in a liquid dosage form can be stabilized by
formulating them with buffers at pH of maximum stability; drugs undergoing to oxidative
degradation may be stabilized by antioxidants, or stored in containers containing nitrogen
or carbon dioxide.
Another limitation of liquid products about patient acceptability is the lack of controlled
release formulations resulting in the need to administer multiple doses throughout the
day. Several approaches have been investigated for the development of sustained release
liquids, such as ion exchange resins, coated microparticles in suspension or drug
microemulsions, among others (Lopez et al., 2015).
An interesting growing field related to liquid dosage forms is the development of
administration devices such as baby bottles, coupled to syringes for aiding the
administration of liquid formulations. Others include modified pacifiers and the dose
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‘sipping syringe’. The main potential limitation for their applicability is the overall cost
of the product.
Solid formulations
Solid dosage forms represent a better choice for paediatric administration rather than
liquid formulations because of the greater stability, the good dosage uniformity, options
for different doses, good portability and low manufacturing costs. One of the key
advantages of solid dosage forms is the possibility to develop taste-masking techniques
and modified-released formulations, which are technically more challenging for liquid
formulations.
Conventional and ready to use solid dosage forms, involve tablets, capsules, chewable
tablets and orally disintegrated tablets. The age at which children can swallow intact
tablets or capsules is highly dependent on the individual and the training they received.
In general, children aged < 6 years do not accept them easily and can learn to swallow
solid dosage forms, especially for chronic diseases (EMEA/CHMP/PEG/194810/2005).
However, the size of tablets or capsules has to be kept as small as possible even for
children > 6 years of age.
A drug molecule can be formulated as a tablet if the dose is low enough to make a small
tablet that can be easily swallowed. If it is necessary to have a partial dose, tablets can be
scored, or even double scored, or crushed and mixed with drink or food. Commercially
available tablets are: Dextrostat ® (dextroamphetamine sulfate), Malarone (atovaquone
and proguanil HCl) and Caduet® (amlodipine besylate and atorvastin calcium).
Commerial examples of capsules are: Strattera® (atomoxetine) and Vyvanse®
(lisdexamfetamine dimesylate).
Chewable tablets are also used to administer drugs to children of 2 years or older under
elderly supervision to ensure tablets are chewed and not ingested. They are growing in
popularity and the potential as drug delivery system is expanding thanks to the fact that
they are safe, well tolerated, palatable, stable, portable, and do not need water for
administration. Some of the problems related to this dosage forms include taste-masking,
grittiness, tooth picking and manufacturing issues. Taste-masking can be achieved by
using coated drug particles, or flavours and sweeteners; microcrystalline cellulose, along
with mannitol enhance smooth feel, eliminate grittiness and tooth picking (Ali et al.,
2014). Commercially available chewable tablets are Singulair® (montelukast sodium),
Videx® (didanosine) and Tegretol® (carbamazepine).
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However, conventional dosage forms are often not suitable for paediatric patients with
difficulties of swallowing and for the fact that they often allow poor dose flexibility.
Thus, tablet splitting has become usual daily practice to obtain various dose strengths,
with all the safety issues related. For infants aged < 2 years, a new promising
development is the orally disintegrated mini-tablets, which combine mini-tablets and fast
dissolving dosage forms.
Orally disintegrated tablets (ODTs), also known as fast dissolving, mouth dissolving,
orodisperse, fast melt, rapidly dissolving or disintegrating tablets rapidly disintegrate in
the mouth in small particles in few seconds in contact with saliva, thus overcoming
swallowing problems. They improve efficacy, safety and palatability respect to other
dosage forms. Some of the challenges associated with this dosage forms include taste-
masking, mechanical strength, fast disintegration, hygroscopicity, manufacturing, tablet
compression and packaging. ODTs available in the market are: Prevacid (lansoprazole),
Zofran (ondansetron) and Clarinex Redi-Tabs (desloratadine).
Dispersible tablets are another kind of dosage form suitable for children, because they
disintegrate within 3 minutes in water in a uniform dispersion, before administration.
They are manufactured with commonly available technology and packaging, and the
taste should be adequate for acceptability. Dispersible tablets are sensitive to moisture,
hence should be packed in stronger packaging.
Effervescent tablets have the same problems of moisture sensitivity, they have to be
manufactured at low humidity (< 30 % RH) and temperature (< 25°C). They are
dissolved or dispersed before administration, and contain acid and carbonates, which
react in the presence of water to release carbon dioxide. Effervescence creates a palatable
sparkling solution, which may enhance the drug permeability due to carbon dioxide
bubbling effect on the intestinal epithelium.
Tables 4 and 5 summarize the commercially available oral liquid and solid formulations,
respectively.
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Table 4. List of commercially available paediatric oral liquid formulations.
Marketed name/Drug name Marketed formulation Active in formulation Dose Excipients
Emtriva/emtrici tabine Oral  solution 10 mg/ml 6 mg/Kg up to 240 mg
Cotton candy flavor, EDTA, methylparaben,
propylparaben, propylene glycol  (2%),
sodium phosphate, water, xyl i tol , HCl/NaOH
to pH 7.2
Ziagen/abacavir sul fate Ora l  solution 20 mg/ml 8 mg/Kg up to 300 mg b.i .d. 3months  to 16 years
Arti ficia l  s trawberry and banana flavor, cytric
acid, methylparaben, propylparaben,
propylene glycol , saccharin sodium, sodium
citrate, sorbi tol  solution, water
Epivi r/lamivudine Oral  solution 10 mg/ml 4 mg/Kg up to 150 mg b.i .d. 3months  to 16 years
Arti ficia l  s trawberry and banana flavor, cytric
acid, methylparaben, propylparaben,
propylene glycol , sodium ci trate, sucrose
(200 mg/ml), water
Retrovir/zidovudine Syrup 10 mg/ml
160 mg/m2 t.i .d. not to exceed 200
mg every 8 h, neonate: 2 mg/Kg
every 6 h 6 weeks  to 12 years
Sodium benzoate 0.2%,  cytric acid, flavors ,
glycerin, l iquid sucrose
Zyrtec/ceti ri zine Syrup 1 mg/ml 6 months-5 years :2.5-5 mg perday,  6-11 years : 5-10 mg per day
Acetic acid, banana flavor, glycerin, grape
flavor, methylparaben, propylparaben,
propylene glycol , sodium acetate, sugar
syrup, water (pH 4-5)
Clarinex/des loratadine Syrup 0.5 mg/ml
6-11 months : 1.0 mg, 12 months-5
years : 1.25 mg, 6-11 years : 2.5 mg,
> 12 years : 5 mg a l l  q.d.
Propylene glycol , sorbi tol  solution, ci tric
acid, sodium ci trate, sodium benzoate,
EDTA, water, sugar, bubble gum flavor
Norvi r/ri tonavir Ora l  solution 80 mg/ml
<600 mg b.i .d. or >1 month: 350-
400 mg/m2 up to 600 mg b.i .d. ( 0.8-
7.5 mL)
Ethanol  43%, water 15%, polyoxyl  35 castor
oi l , propylene glycol ,  ci tric acid, saccharin
sodium, peppermint oi l , creamy caramel
flavor
Agenerase/amprenavir Ora l  solution 15 mg/ml 4-12 years : 22.5 mg/Kg b.i .d., or 17mg/Kg t.i .d. up to 2800 mg per day
Acesul fame potass ium, arti fi cia l  grape
bubblegum flavor, ci tric acid, TPGS, menthol ,
natura l  peppermint flavor, PEG 400 (17%),
propylene glycol  (55%), saccharin sodium,
sodium chloride, sodium ci trate
Sustiva/efavi renz Ora l  solution 30 mg/ml 270-600 mg Medium-chain triglycerides , benzoic acid,s trawberry/mint flavors
Zovirax/acyclovi r Suspens ion 40 mg/ml < 40 Kg: 20 mg/Kg q.i .d., >40 Kg: 800mg (20 mL) q.i .d.
Methylparaben, propylparaben,
carboxylmethylcel lulose sodium, banana
flavor, glycerin, microcrysta l l ine cel lulose,
sorbi tol , water
Viramune/nevirapine Suspens ion 10 mg/ml
4 mg/Kg q.d. for the fi rs t 14 days
fol lowed by 4-7 mg/Kg b.i .d.
thereafter. Maximum dai ly dose
400 mg
Carbomer 934P, methylparaben,
propylparaben, sorbi tol , sucrose,
polysorbate 80, NaOH, water
Viravan/phenylephrine
tannate, pyri lamine tannate,
dextromethorphane tannate
Suspens ion 2.5, 6, 5 mg/ml 2-6 years : 2.5 mL, 6-12 years : 5 mL,>12 years : 10 mL
Citric acid, glycerin, grape flavor, magnes ium
aluminium s i l i cate, methylparaben,
sucra lose, ammonium glycyrrhizinate,
sodium benzoate, sodium ci trate, sucrose,
xanthan gum, water
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Table 5. List of commercially available paediatric oral solid formulations.
1.5.2. ORAL TRANSMUCOSAL ADMINISTRATION
The oral transmucosal route offers many advantages over the oral route: the adsorption
is rapid thanks to the rich vascular supply and the lack of the stratum corneum
epidermidis. This allows a rapid increase in blood concentration and the achievement of
the peak blood levels within 10-15 min (American Academy of Pediatrics, 1997). Oral
transmucosal administration has the advantages of avoiding the enterohepatic circulation
and the immediate destruction by gastric acid. For a significant drug adsorption, the
dosage form, and thus the drug, must have a prolonged exposure to the mucosal surface.
Drug adsorption is generally greater from the sublingual, buccal and oral mucosa, than
from the tongue and the gingiva. The advantages of a rapid adsorption make it a
Marketed name/Drug
name Marketed formulation Active in formulation Dose Excipients
Dextrostat/dextroamphe
tamine sul fate
Tablet scored and
double scored
5 mg (scored), 10 mg
(double scored)
3-5 years : 2.5 mg/day, >6
years : 5 mg/day
Acacia , corn s tarch, lactose, magnes ium
stearate, sucrose, the 10 mg tablet
conta ins  sodium starch glycolate
Malarone/atovaquone,
proguani l  HCl Tablet
Fixed dose combination:
62.5 and 25 mg 1-3 tablets  q.d.
Hydroxypropylcel lulose, magnes ium
stearate, microcrysta l l ine cel lulose,
poloxamer 188, povidone K30, sodium
starch glycolate
Caduet/amlodipine
besylate, atorvastin
ca lcium
Tablet
Fixed dose combination:
2.5/10, 2.5/20, 2.5/40,
5/10, 5/20, 5/40, 5/80
mg/mg
6-17 years : 2.5-5 mg
(amlodipine) q.d.
Ca lcium carbonate, croscarmel lose
sodium, microcrysta l l ine cel lulose,
pregelattinized s tarch, polysorbate 80,
HPC, water, col loida l  s i l i con dioxide,
magnes ium stearate
Strattera/atomoxetine Capsule-hard gelatin 10, 18, 25, 40 and 60 mg 0.5-1.2 mg/Kg up to 100 mgq.d. Pregelatinized s tarch, dimethicone
Vyvanse/l i sdexamfetami
ne dimesylate Capsule 30, 50, 70 mg
20-70 mg/day q.d. in the
morning
Microcrysta l l ine cel lulose, croscarmel lose
sodium, magnes ium stearate
Singula i r/montelukast
sodium Chewable tablet 4-5 mg 4 mg q.d.
Mannitol , microcrysta l l ine cel lulose, HPC,
croscarmel lose sodium, cherry flavor,
aspartame, magnes ium stearate
Videx/didanos ine Chewable tablet 25, 50, 100, 150, 200 mg 120 mg/m2 b.i .d.
Ci tric acid, sucrose, aspartame, ca lcium
carbonate, microcrysta l l ine cel lulose,
magnes ium hydroxide, magnes ium
stearate, crospovidone, sorbi tol ,
mandarin-orange flavor
Tegretol/carbamazepine Chewable tablet-s ingle scored 100 mg
<6 years : 10-35mg/kg/day
q.i .d., 6-12 years : 50 mg
q.i .d. up to 1000 mg dai ly
Si l i con dioxide, flavors , gelatin, glycerol ,
magnes ium stearate, sodium starch
glycolate, s tarch, s tearic acid, sucrose
Prevacid/lansoprazole
Delayed release
ora l ly dis integrating
tablet
15 or 30 mg <30 mg: 15 mg t.i .d., >30mg: 30 mg t.i .d.
Lactose monohydrate, microcrysta l l ine
cel lulose, magnes ium carbonate, HPM,
HPMC, ti tanium dioxide, ta lc, mannitol ,
methacryl ic acid, polyacri late, PEG,
glyceryl  monostearate, polysorbate 80,
triethyl  ci trate, ferric oxide, ci tric acid,
crospovidone, aspartame, arti fi cia l
s trawberry flavor, magnes ium stearate
Zofran/ondansetron Oral ly dis integratingtablet 4-8 mg 4-11 years : 4 mg t.i .d.
Aspartame, gelatin, mannitol ,
methylparaben sodium, propylparaben
sodium, s trawberry flavor
Clarinex Redi -
Tabs/des loratadine
Oral ly dis integrating
tablet 2.5-5 mg
6-11 years : 2.5 mg q.d., >12
years : 5 mg q.d.
Mannitol , microcrysta l l ine cel lulose,
pregelatinized s tarch, sodium starch
glycolate, magnes ium stearate, butylated
methacri late copolymer, crospovidone,
aspartame, ci tric acid, sodium
bicarbonate, col loida l  s i l i con dioxide,
ferric oxide, flavors
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reasonable alternative to intravenous therapy. Important limitations associated with this
route of administration are: lack of cooperation of children, difficulties in coordination,
risk of choking and aspiration, and the accuracy of dosing because the dosage form can
be swallowed or spat out prior to sufficient adsorption taking place.
Buccal tablets are designed to dissolve slowly and give a prolonged release of the drug
in the mouth, while sublingual tablets are intended to a rapid release of the drug and
permeation into the systemic circulation. Limitations include the small number of drug
candidates, restrict buccal and sublingual area, the palatability and probable local
irritation. For these reasons, buccal and sublingual tablets are not useful for very young
children.
Mucoadhesive preparations are intended to be retained by adhesion to the mucosal
epithelium in order to control the release and the permeation of the drug at the site of
application. These dosage forms could be use in younger children.
Lozenges are hard solid preparation used for the release of active ingredients locally, in
the oral cavity or through the systemic circulation. They are accepted also by older
patients.
1.5.3. NASAL ADMINISTRATION
Intranasal delivery offers unique advantages in administration of paediatric actives. The
highly vascularized nasal mucosa and the olfactory tissue in direct contact with the
central nervous system, allow a rapid transport of the drug into the bloodstream and the
brain, with an onset of action very close to the intravenous therapy. Therefore, the nasal
delivery can represent a reasonable alternative to invasive intravenous administration.
On the other hand, this route of administration could lead to unwanted side effects,
irritation and pain on the mucosa, and inefficiency, due to abundant secretions. In the
case of local action, minimum drug absorption and maximum residence time are
necessary, whereas in the case of systemic action, an efficient absorption into the
bloodstream is needed. Nasal dosage forms are solid, semi-solid or liquid preparations.
Nasal powders are intended for paediatric delivery of active ingredients, particularly
stable in a dried and solid state (peptides and vaccines), by using special delivery devices.
Nasal sprays supply paediatric actives in the nasal cavity through squeeze bottles,
mechanical dispersing systems or pressurizing containers. The applicability of squeeze
bottles is restricted due to the dose variability, whereas pressurized devices are very
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reproducible in dosing and droplet size distribution. In this case, the problem is the strong
impact on the nasal mucosa, which may cause local irritation.
Nasal drops are intended for instillation into the nasal cavity and usually are supplied in
multidose containers, with a suitable dosing device. From an anatomical point of view,
nasal drops are preferred in infant treatment, because their nasal cavity is so small that
one or two drops can cover the whole mucosa (EMEA/CHMP/PEG/194810/2005).
1.5.4. RECTAL ADMINISTRATION
Active ingredients may be administered in children by the rectal mucosal route for
systemic effects, if other more preferable routes are not available (American Academy
of Pediatrics, 1997). Rectal administration is useful if the oral route is contraindicated,
the immediate systemic or the local effects are required, or if the oral dosage forms are
rejected because of the palatability issues. The rectal route is use for either local (laxative,
anti-inflammatory) or systemic (analgesic, antipyretic, anticonvulsive, sedative) actions;
it allows rapid absorption of many drugs and may be a reasonable alternative to the
intravenous route, having the advantage of being relatively painless. Many advantages
are associated with this route, especially for the treatment of paediatric population; rectal
dosage forms in fact avoid the problems of swallowing and taste-masking, along with the
fact that they can also be administered in emergency to unconscious or vomiting patients
(Jannin et al., 2014). Among all the marketed products available for rectal administration,
suppositories are prevalent and they are versatile and present in a variety of strengths for
various age groups. Alternative rectal dosage forms include gels, foams, creams, pastes,
ointments, gelatine capsules and solutions. The choice of suitable excipients for each
preparation has to consider the fact of avoiding any local irritation of the rectal mucosa
of infants or children. Polyethylene glycol bases lead to irritation of the rectal mucosa
due to their hygroscopic nature, which may be reduced by moistening the suppository
with water prior to insertion (EMEA/CHMP/PEG/194810/2005).
Rectal route presents few disadvantages: the introduction of a solid unit in the rectum
(leading to poor acceptability and compliance), the low absorption capacity of the lower
rectum to some drugs, and the high inter-individual variability of the drug bioavailability,
mainly depending on how the dosage form is inserted.
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1.5.5. TOPICAL-TRANSDERMAL ADMINISTRATION
Topical and transdermal routes offer some clear and specific advantages for paediatric
drug delivery (Delgado-Charro et al., 2014). Topical delivery permits the targeting of the
drug to the local area, minimizing systemic exposure; topical formulations usually
contain anti-inflammatory, anti-histaminic, antifungal, antiseptic and analgesic drugs
incorporated into gel, creams, and ointments. In children < 2 years of age, the application
area should be restricted; corticosteroids, in fact, present 2-10 folds systemic exposure.
In addition, water-impermeable materials, as well as high lipophilic vehicles may
increase the systemic exposure, while fever and external heat may increase the rate of
permeation.
Transdermal drug delivery offers a non-invasive approach to avoid the first-pass effect;
it is in general, well accepted, easy to apply and represents a valuable alternative when
oral administration is difficult or may result in erratic absorption. Transdermal drug
absorption depends on a variety of factors, as site of application, thickness and integrity
of the stratum corneum, size of the molecule, state of skin hydration, pKa of the drug,
etc. Moreover, important morphological and hence permeability differences occur
between mature skin and that of neonates (Table 6). At birth, the dermis is only 60 % of
its adult thickness and maturation takes 3-5 months after birth. Epidermis is perfused and
hydrated to a greater degree than in adults, and infants have a reduced capacity for
biotransformation and elimination of active substances, including those absorbed by the
cutaneous route. This leads to a better permeation for neonates, infants and children.
Thus, the potential for toxic effects, is particularly important for children, where the
blood flow and the thickness of the skin vary with age; if in some cases it represents an
advantage, in other case it causes important side effects.
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Table 6. Correlation between surface area/body weight ratio vs age.
1.5.6. PARENTERAL ADMINISTRATION
Parenteral administration is the most common route of administration for active
substances for unconscious and uncooperative children and for clinically unstable term
and preterm neonates. Medications administered via the parenteral route include
intravenous, intramuscular and subcutaneous, intrathecal, intra-osseous, intra-cardiac
and intra-arterial routes. There are suitable intravenous preparations available for
children in which the dose administered is complete and accurate; the onset of therapeutic
action is rapid, since the systemic access is direct, avoiding the first-pass metabolism and
the bioavailability is predictable. One of the main disadvantages is that, once
administered, the effect is not reversible. Moreover, the rate of administration should
take into account the potential for toxicity and adverse reactions. Compatible infusion
fluids include glucose 5 % and 10 %, sodium chloride 0.45 % and 0.9 % and combination
of glucose and saline. It is also possible to accurately administer small doses of
medications to children; however, adult preparations may require multiple dilutions, and
this is critical because every dilution creates an opportunity for an error, in terms of
contamination, safety and efficiency of the drug. Another important consideration about
parenteral administration is about the volume of medication to be infused or injected; this
is particular significant in neonatal population, who may only accept very small volumes
(200-300 ml) of medicines in order to avoid volume overload and to allow sufficient
room for essential fluid nutrition.
Even administrations through intramuscular and subcutaneous routes need particular
attention about the volume injected; in the case of intramuscular administration, it is
important to consider also the size/bulk of the muscle injected into.
Age Weight(kg)
Surface area
(cm2)
Ratio
(surface/weight)
Comparison
(adult = 1 )
Newborn 3.4 2100 617.6 2.4
6 months 7.5 3500 466.7 1.8
1 year 9.3 4100 440.9 1.7
4 years 15.5 6500 419.4 1.6
10 years 30.5 10500 344.3 1.3
Adult 70 18100 258.6 1.0
Ramona Trastullo-University of Bologna 1. Introduction
20
Some actives, compatible with parenteral nutrition are ampicillin, clindamycin,
fluconazole, insulin, metoclopramide; other actives are incompatible with this route and
they cannot be given with a parenteral solution under any circumstances: acyclovir,
cisplatin, mannitol and phenytoin. However, certain parenteral medications are known to
have increased toxicity in children, compared to adults. These includes dopaminergic
antagonist as metoclopramide or haloperidol, where younger children are at increased
risk of acute dystonic reactions and seizures (Magrath et al., 2007).
1.5.7. PULMONARY ADMINISTRATION
Inhalation route can be considered a valid alternative to oral administration thanks to the
capacity to avoid the hepatic first-pass metabolism and the possibility to reduce the dose
needed. It may be preferred to the parenteral route, especially for the administration of
peptides and protein, because it does not give pain during the application.
Medications delivered by inhalation include anaesthetic agents and those used for the
treatment of asthma. In the case of anaesthetic medications, the dose required is
proportional to the lung volume of the child, which is proportional to the weight.
However, the absorption of the drug into the systemic circulation is variable, depending
on the capacity of the paediatric patients to use the specific device. Obviously, this is
related to the age of the child.
Conventional devices include pressurized metered dose inhaler, dry powder inhaler and
nebuliser. Pressurized metered dose inhalers are efficient but require good coordination
between the actuation of the device and the inhalation action (press and breath), which
preclude its use in young children. The use of spacer/holding chamber avoids the problem
of coordination, and in particular the presence of a face mask allowing the utilization of
this device even in young children. Dry powder inhalers, instead, require a sufficient
inspiratory flow to permit the powder to achieve the nose, allowing the use of this inhaler
only in old children.
1.6. MANIPULATION OF DOSAGE FORMS
Several paediatric formulations have to be manipulated in order to be administered to
children. Examples of manipulated dosage forms are: drops for reconstitution to a
suspension, solids to form a solution or suspension, effervescent tablets, dispersible and
orally disintegrating tablets in water, and oral powders that are sprinkled into food or
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drink prior to administration. In these kinds of dosage forms, it is important to consider
the stability of both the active ingredients and the excipients, before and after
manipulation, and in proper long-term storage (Stryckley et al., 2008).
1.6.1. SOLID FOR CONSTITUTION TO A SUSPENSION
These formulations include a solid phase as powders, tablets, granules, microcapsules,
used for the preparation of suspension through the addition of water or other common
beverage such as milk, fruit juices or specific liquids given in the package. It is a useful
system for actives with a poor water solubility and bitter taste, and the chemical stability
of the compounds has to be evaluated in the solid form and in the suspension. The
formulation must also be physically stable as solid and as suspension with no foaming,
minimal (slow) particle settling and easily re-dispersed if the solid particles do settle, and
easy measurable. Four types of stability are at least necessary in solid for reconstitution
to oral suspension:
 solid-state chemical stability (extended storage);
 solid-state physical stability (extended storage);
 suspension chemical stability (in-use phase);
 suspension physical stability (in-use phase).
Chemical stability is required not only for the active, but also for all the other ingredients,
and special storage conditions are required in case of chemical instability, such as storage
at 2-8 °C in a refrigerator, or desiccation of the solid. Physical stability of the solid state
can be guaranteed by the addition of anticaking agents, such as starch, to avoid the
agglomeration, whereas the physical stability of the suspension can be achieved by
minimizing the foam with the addition of simethicone in the form of a powder.
When the solid phase is composed by powder or granules, other excipients, as
sweeteners, flavours, preservatives and dispersible agents are added to the formulation.
Commercially available suspensions involve 15 products with powders, 6 with tablets, 1
with granules and 1 with microcapsules as solid phase.
1.6.2. SOLID FOR CONSTITUTION TO A SOLUTION
Three powders (two drugs) for constitution to a solution are on the market. The drug
product is a powder formulation that had not been previously dissolved. The most
important requisite for this kind of dosage form is the high water solubility of the active
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ingredient that has to be able to dissolve in a relatively small volume of water.
Sweeteners, flavours, antifoaming agents, and preservatives improve the properties of
the dosage form.
1.6.3. CONCENTRATED SOLUTION DILUTED
Only two commercially available products are represented in this formulation. The
manipulation involves the easy dilution of a small amount of the original product, by
using a dropper, into a defined volume of a liquid (water or fruit juice) or in a semi-solid
substance.
1.6.4. EFFERVESCENT TABLETS
Effervescence is the release of carbon dioxide when a solid containing sodium
bicarbonate or sodium carbonate and an acidic excipient like fumaric acid or citric acid
are added to water. For the administration of the entire dosage, a tablet has to be dissolved
in a volume of water and the obtained solution is given by a dropper or a syringe or
directly drunk.
1.6.5. SPRINKLE SOLIDS
These formulations are represented by powders or granules with bad taste that cannot be
masked; thus, the dosage form is not directly administered, but can be formulated as a
oral powder/granule that is sprinkled onto the food immediately prior to administration.
Packaging is a critical component of sprinkle solids and various configurations are used
such as multi-use containers with bulk powder filled into a bottle and supplied with a
scoop, unit-dose filled into a sachet, unit-dose filled into capsules that can be opened.
In table 7, it is possible to find some of the commercially available formulations-
manipulation required, described above.
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Table 7. Selected listing of commercially available paediatric oral formulations-manipulation
required.
1.7. RISK ASSOCIATED WITH MANIPULATION OF
ADULT DOSAGE FORMS
Many medicinal products are authorised only for adult use and contain no validated
provisions for paediatric use. In these cases, where the adult-only products may also be
of benefit in the paediatric population, a number of practices have involved to manipulate
these adults medicinal products in order to render them suitable for dosing to paediatric
patients (EMEA/CHMP/PEG/194810/2005).
Sometimes there is little information about the bioavailability of the manipulated dosage
forms; some points have to be noted:
1. only simple manipulations can be carried out at home by caregivers (breaking or
crushing tablets, opening capsules);
Marketed name/Drug name Marketed formulation Active in formulation Dose Excipients Manipulation
Stavudine/Zeri t Powder for consti tution toa  solution 1 mg/ml
< 30 Kg: 1 mg/Kg
>60 kg: 40 mg
b.i .d
Methylparaben,
propylparaben, sodium
carboxymethylcel lulose,
sucrose, anti foaming and
flavoring agents
Consti tute with 202 ml
of water
Cefadroxi l /Cefzi l Powder for consti tution toa  sospens ion 25-50 mg/ml
7.5-15 mg/Kg
b.i .d. up to 500
mg/day
Aspartame, cel lulose, ci tric
acid, col loida l  s i l i con
dioxide, flavors , glycine,
polysorbate 80,
s imethicone, sodium
benzoate, sodium chloride,
sucrose
Consti tute with water
Cefurexime axeti l /Ceftin Powder for consti tution toa  sospens ion 25-50 mg/ml
20-30 mg/Kg/day
up to 500-1000
mg divided
b.i .d.
Acesul fame potass ium,
aspartame, povidon K30,
s tearic acid, sucrose,
flavors , xanthan gum
Consti tute with water,
must be adminis tered
with food
Clari thro-mycin/Biaxin Powder for consti tution toa  sospens ion 25-50 mg/ml
7.5 mg/Kg b.i .d.
for 10 days
Carbomer, castor oi l , ci tric
acid, hypromel lose
phthalate, maltodextrin,
potass ium sorbate,
povidone, s i l i con dioxide,
sucrose, xantham gum,
ti tanium dioxide, frui t
punch flavors
Consti tute with 27-55
mL of water
Montelukast
sodium/Singula i r Ora l  granules 0.8% w/w 4 mg q.d.
Mannitol , HPC, magnes ium
stearate
Directly in the mouth,
dissolved in 5 mL baby
formula  or breast mi lk,
mixed with spoonful  of
soft foodscarrots , rice
or ice cream
Topiramate/Topamax Sprinle capsule 15 and 30 mg
5-9 mg/Kg/day
starting with 25
mg b.i .d.
Sugar spheres , povidone,
cel lulose acetate, gelatin,
s i l i con dioxide, sodium
lauryl  sul fate
Swal lowed whole or
careful ly open capsule
then sprinkle the
enti re contents  on a
smal l  amount of soft
foods
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2. sophisticated manipulations of adult medicinal products have to be carried out by
healthcare professionals in a hospital or community pharmacy setting;
3. manipulation of adult medicinal products is always considered as a secondary option;
4. it is important to check the safety and security of the final paediatric formulations for
the presence of excipients, especially in neonates patients;
5. manipulated formulations have to be as simple as possible, avoiding additional
unnecessary excipients.
1.7.1. SPLITTING TABLETS INTO SEGMENTS
If we suppose that the active is uniformly distributed through the volume of the tablet,
splitting tablets is a very simple manipulation, especially because, often tablets are score
to facilitate this. Obviously, a possible error is more evident with small tablets and low
dosage. Enteric-coated tablets, layered tablets, and many modified-release dosage forms
should not be manipulated in this way. The manufacturer should provide some
information about the issues related to cutting tablets into smaller segments.
1.7.2. CRUSHING TABLETS
This manipulation consists in reducing the monolithic tablet to a fine powder in which
the drug is assumed to be uniformly distributed. This allows both the dose reduction and
the mixing in food or drinks to facilitate the administration. Sometimes, a mortar and
pestle may be sufficient; however, the division of the powder can be made by visual
inspection or by weight; some issues can occur, such as the segregation of the active
substance in the bulk powder, caused by a prolonged handling and vibration. The use of
a hammer mill in a hospital pharmacy is suggested to avoid these problems although it
can lead to changes in particle size, and thus in bioavailability, and temperature rises, and
thus solid-state transitions or chemical degradation.
Another important manipulation consist in blending the powdered tablets with lactose
diluent, and then filled into sachet or hard gelatine capsules. Primary amines cannot be
handled in this way because of their well-known interaction and instability in the
presence of such reducing sugars.
There is also the risk that modified-released tablet, once manipulated and crushed, may
lose their advantages.
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In this case, the manufacturer has to provide information about the suitability of tablets
for crushing and suitable powder diluents, as well as information about the compatibility
and stability of the crushed tablets with common foods and drinks.
1.7.3. OPENING CAPSULES
This manipulation is a refinement of the crushing tablets, and, as in that case, the division
of the powder can be made by visual inspection or by weight, or dispersed into foods or
drinks to facilitate the ingestion. In the presence of modified release preparations of
coated particles, they may be dispersed in the same way in foods or drinks.
As described above, the manufacturer should give information about the compatibility of
all the compounds with different foods and drinks, as well as all the information about
the effects on the bioavailability.
1.7.4. DISPERSING TABLETS/CAPSULES AND TAKING PROPORTIONS
A further manipulation of the powder prepared from tablets or taken from inside capsules
is to disperse it in a suitable suspending liquid, and achieve dose reduction in a volumetric
way and not gravimetrically. Sedimentation and settling of the obtained dispersion lead
to a risk of dosage errors, and this may be minimized by using a high viscosity suspending
medium. In some cases, this error is reduced when the active substance is dissolved from
the powdered matrix and taken into complete solution. Manufacturers may provide
information about the suitability of tablet and capsule dispersions for the purpose of
volumetric measurements to administer a proportion of the adult dosage form.
1.7.5. CUTTING/COVERING TRANSDERMAL PATCHES
Since the amount of drug delivered through the skin is proportional to the surface area of
the transdermal patch in contact with it, it is possible to halve the patch to obtain half of
the dose delivered. This is particularly useful for paediatric patients, where the surface
area of the skin is obviously reduced. In general, caregivers cut the patch by using
scissors, allowed some important errors:
 despite transdermal patches present a specific ‘release-controlling’ membrane, it is
likely that the main rate-controlling factor is the skin itself, and thus the most
important problem is the difference in the structure of the maturing skin in neonates,
and in particular of the stratum corneum;
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 it is difficult to decide what is exactly the area of the patch, especially in particular
area of the body, such as the eyes;
 cutting exposes the patch to the atmosphere, and thus to possible mechanism of
erosion and oxidative degradation;
 cutting is contraindicated in case of gel-filled patches.
Even in this case, manufacturers have to provide information about the possibility to cut
or cover transdermal patches and about any modifications on the release of the active
substances.
1.7.6. CUTTING SUPPOSITORIES
Adjustment of the dosage in the case of suppositories is difficult to achieve since very
few suppositories are present in a convenient way to facilitate halving by simple visual
inspection. By considering the active ingredient uniformly distributed in the whole
dosage form, a possibility is to cut along a plane of symmetry, although the resulting
shape may not be optional for rectal insertion.
Manufacturers may provide information on uniformity of dispersion of the drug in the
suppositories
1.7.7. INJECTABLE SOLUTIONS ADMINISTERED BY OTHER ROUTES
Injections for oral administration are expensive but they allow a reduction of the dosage
errors by using, if necessary, small syringe. They are aqueous and non-viscous solutions,
often presenting an unpleasant taste. In the case of preserved or multi-dose products, they
contain benzyl alcohol, propylene glycol, or have pH and osmolality potentially harmful
for neonates and children. Injections have sometimes been given by pulmonary route,
following nebulisation. Ignorance of the precise composition of the parenteral (adult)
formulation could pose a significant safety risk in the case of injections stabilised with
sulphite-based antioxidants, which may provoke bronchoconstriction.
Manufacturers may give information on the suitability of an injection solution for the
administration by other routes.
Table 8 lists the most common manipulations related to the conventional dosage forms.
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Table 8. List of manipulations of the conventional dosage form for adult administration.
Drug dosage form Manipulation of dose accuracy
Tablet a. split/broken/cut and a segment given
b. crushed and a portion of the powder given
c. dispersed in liquid and a portion of the liquid given
Capsule a. opened, dispersed in liquid and a portion of the liquid given b.
opened and a portion of the powder given
Sachet (powder) a. opened, dispersed in liquid and a portion of the liquid given b.
opened and a portion of the powder given
Oral liquid diluted and a portion given (to make the measurement of a small
volume dose easier)
Suppository cut/split and a segment given
Nebuliser solution a. portion given
b. diluted and a portion given
Enema/bladder irrigation a. portion of sachet/unit given
b. portion of the content removed and the remainder given
Transdermal patch a. patch cut and a portion applied
b. portion of patch uncovered and applied
Intravenous injection a. reconstituted or ready prepared solution, further diluted to
allow a smaller dose to be measured
b. volume of fluid removed from IV container, drug added (to
obtain accurate concentration for infusion)
1.8. CHOICE OF EXCIPIENTS
Paediatric formulations are often more complex than adult formulations due to taste
masking, dose volume, delivery and aesthetic requirements, which demand incorporation
of a broad range of excipients (Ali et al., 2014). In fact, the organoleptic appeal of a
paediatric formulation is usually improved by the addition of flavours, colorants and
sweeteners. Besides enhancing organoleptic properties, excipients are used to allow
physical/chemical stability, precision and accuracy of dosing, improve bioavailability,
control release and aid in manufacturing. Since they do not present pharmacological
activity, excipients have always been considered inert agents, and thus, their inertness
and innocuity were taken for granted, and their importance has been largely
underestimated (Salunke at al., 2012). However, it is commonly known that excipients
used in adult medicines have been associated with elevated toxicological risk and safety
issues in children (Salunke at al., 2012). There are several well-documented cases of
adverse effects of pharmaceutical excipients in the paediatric population; in fact, the
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toxicity may differ between adult and paediatric patients and across the paediatric sub-
sets. These differences are due to changes in developing child: paediatric patients, and in
particular, infants and neonates, are not able to metabolize or eliminate an ingredient in
the same manner as adult because of the immaturity of the liver and the kidneys (Salunke
at al., 2013). An example of toxicity caused by accumulation of excipients is represented
by the administration of Kaletra oral solution to neonates, especially those born
prematurely. Ethanol, when administered together with propylene glycol, inhibits its
metabolism, leading to adverse effects associated with the accumulation of propylene
glycol.
A general lack of knowledge of excipients has proved an effective barrier to the
development of novel materials, and pharmaceutical industries have tended to opt for
using well-known, but not necessarily safe, excipients. Important problems can occur
when excipients approved for one route of administration are applied to another route
with a different systemic exposure (Salunke at al., 2013). In other words, just because an
excipient is approved in a specific paediatric formulation, may not automatically qualify
its safe use in another paediatric formulation, route or age (Schmitt, 2015).
1.8.1. SOLVENTS
Water is the solvent mostly used as vehicle thanks to the lack of toxicity, the
physiological compatibility and the good solubilizing power. However, water causes
instability of hydrolytically instable drugs and it is a good vehicle for microbial growth.
Water-miscible co-solvents, as ethanol, glycerol, and propylene glycol are often use to
increase solubility, taste, anti-microbial effectiveness or stability, to reduce the dose
volume, and to optimise insolubility (in the case of bad taste). Water-immiscible co-
solvents are instead used to prepare emulsions or micro emulsions.
Ethanol
Ethanol is a common solvent in oral liquid dosage forms, found in many drug
preparations for newborns and infants, as in iron supplementations and in furosemide,
possibly exposing paediatric population to both chronic and acute toxicities. Acute
intoxication is caused by accidental overdose, and it is characterized by coma,
hypoglycaemia, and hypothermia, along with seizures, hypotonia, gastritis,
gastrointestinal bleeding, and respiratory depression. In the serious cases, acute
intoxication may cause acute hepatitis, pancreatitis, and cardiovascular toxicity. Chronic
toxicity is associated with routine use of chronic medications and the effect of long-term
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exposure to ethanol has never been studied in paediatric population. Studies and
observations on FAS (foetal alcohol syndrome) and FAE (foetal alcohol effects) children,
however, give direct evidence of the grave deleterious effects of chronic ethanol
exposure, for example, on neurological and cognitive developmental processes.
Moreover, ethanol has known to have synergic negative effects on central nervous system
when associated with some active substances. In fact, in a recent case report, 4-months
old infants suffered from acute life-threatening intoxication including altered mental
status, associated with an overdose of an over-the-counter cough syrup, which has been
attributed to the association of the synergic effect of the active ingredient,
dextromethorphan, and ethanol. As explained above, the concomitantly administration
of ethanol and propylene glycol, as in the case of Kaletra® oral solution, may cause
adverse effects, due to the inhibition of the metabolism of propylene glycol by the
presence of ethanol.
Propylene Glycol
Propylene glycol is a general solvent with antimicrobial activity, used in a wide range of
pharmaceutical preparation: oral, topical, and injectable medications, as well as in foods
and cosmetics. It is often useful for those substances with poor solubility in water, such
as phenobarbital, phenytoin, diazepam and dexamethasone. High doses of propylene
glycol have been associated with cardiovascular (hypotension, bradycardia, widening of
QRS interval), hepatic and respiratory adverse effects with depression of the central
nervous system, and nephrotoxicity (hyperosmolarity, osmol gap), especially in
newborns and infants. The US Food and Drug Administration has identified propylene
glycol as being ‘generally recognized as safe’ and the World Health Organization has
established that 25 mg/Kg represents an acceptable intake limit for adults (Lau et al.,
2012); however, this threshold is largely exceeded in preterm newborns, newborns and
infants. In fact, paediatric patients below 4 years have a limited metabolic pathway,
especially as regard the alcohol dehydrogenase, thus allowing an accumulation of
propylene glycol in the body, and all the adverse effects mentioned above.
1.8.2. ANTIOXIDANTS AND PRESERVATIVES
Oxidative degradation can be accelerate by the presence of light and mineral or metallic
impurities, due to the formation of free radicals. Antioxidants agents are important to
reduce the oxidation of active substances and excipients in the medicinal preparation.
They are divided in three categories: true antioxidants (butylated hydroxytoluene),
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reducing agent (ascorbic acid) and antioxidants synergists (sodium edetate). Other
antioxidants, like sulphites, are associated with bronchospasm in asthmatic children, and
thus with symptoms like wheezing, dyspnoea and chest tightness.
Benzyl alcohol is often use in injectable medicinal preparations as a preservative agents.
It should not be given to neonates due to their immature metabolism; it should be
avoided, especially in children up to 3 years, for the potential risk of developing Gasping
Syndrome in neonates and infants. The syndrome may include metabolic acidosis,
seizure, bradycardia, gasping respiration and cardiovascular collapse. The minimum
toxic level of benzyl alcohol, and therefore the safety of use of medicines containing
benzyl alcohol in neonates has not been established
(http://www.who.int/medicines/publications/newsletter/Newsletter_2_2012.pdf?ua=1).
In addition, benzyl alcohol, sodium benzoate and potassium benzoate when used in
parenteral dosage forms may increase the risk of jaundice in neonates.
Benzalkonium chloride is found in beclomethasone and ipratropium bromide nebuliser
solutions, and is associated with bronchospasm in asthmatic children after having inhaled
their medications. It causes bronchoconstriction with a non-IgE-mediated mechanism.
Another important source of benzalkonium chloride for children is represented by topical
medications like nasal saline, nasal corticosteroids and nasal decongestant solutions.
1.8.3. SWEETENERS
The use of sweeteners is particularly important in developing paediatric formulations,
because they are used to improve their organoleptic properties, such as smell and taste
and to increase the compliance of children to therapy. Sweeteners commonly used in
paediatric medications are divided in three main categories: natural origin sweeteners
(sucrose and sorbitol), semi-synthetic sweeteners (aspartame) and synthetic sweeteners
(saccharin).
Natural sweeteners
Sucrose is one of the most used sweetening agents; it is a disaccharide that is readily
hydrolysed in the intestine in the absorbable glucose and fructose; thus, it should be
avoided in patient suffering from hereditary fructose intolerance and diabetes
(EMEA/CHMP/PEG/194810/2005). For preparations intended for long-term therapies,
large amounts of sucrose have to be replaced by sugar-free preparations, because sucrose
causes a decrease in dental plaque pH, dissolving tooth enamel, and promoting dental
caries.
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Sorbitol is a mono-saccharide, not readily absorbed by the gut, and thus, it is considered
safe for patients suffering from diabetes. The medicinal intake of sorbitol in paediatric
population has been associated with gastrointestinal disorders, such as diarrhoea and
malabsorption (Fabiano et al., 2011). Since sorbitol is metabolised to fructose, it is
contraindicated in patients suffering from hereditary fructose intolerance and
hypoglycaemia. In severe cases, it causes liver damage and come, resulting in death
(EMEA/CHMP/PEG/194810/2005).
Semi-synthetic sweeteners
Aspartame is widely used in both food products and pharmaceutical preparations as
sweetening agent. It is a dipeptide of aspartic acid and a methyl ester of phenylalanine;
since it is a source of phenylalanine, it is harmful in children affected by phenylketonuria
and particularly in homozygotes patients on special phenylalanine-restricted diet, in
which the use of aspartame-containing products may allow a significant increase of
phenylalanine blood concentration. Lastly, aspartame has been associated with
hyperactivity in children; however, by now this association has remained unproven. The
US acceptable intake of aspartame is 50 mg/Kg/day.
Synthetic sweeteners
Saccharin is a synthetic sweetener, largely used for its sweetening power, 500 fold higher
than other common sugar. It is not metabolized and thus it is not a source of calories, so
it is particularly useful in hypocaloric food products. In some articles, the use of saccharin
has been associated with an increased risk of developing cancer, especially bladder
cancer. It has been indeed demonstrated the existence of cross-reactions between
saccharin and sulphonamides. The most common adverse reactions are dermatological
and include urticarial, pruritus, dermatitis and photosensitivity. Other systemic reactions
involve insomnia, irritability and strabismus in children assuming saccharin-containing
feed formulas.
1.8.4. FILLERS
Lactose is a disaccharide of glucose and galactose, and is absorbed after hydrolysis by
intestinal lactase. It is widely present in infant feed formulas, and in pharmaceutical
preparations is used as diluent in tablets and capsules and in lyophilised powders, as
sweetener in liquid formulations. In infants and young children, lactose intolerance may
be associated with prolonged diarrhoea, dehydration and metabolic acidosis.
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1.8.5. COLOURING AGENTS
Colouring agents are commonly used in paediatric medications to improve the appeal of
the dosage form and increase the compliance of paediatric population to therapies. Most
colouring agents used in developing paediatric formulations belongs to one of the
following groups: azo dyes (tartrazine, sunset yellow and coccine), quinoline dyes
(quinoline yellow), triphenylmethane dyes (FD&C blue) and xanthene dyes
(erythrosine). Several side effects associated with colouring agents have been reported
in literature, especially hypersensitivity and allergic reactions. For this reason, they
should be avoided unless necessary.
1.8.6. FLAVOURING AGENTS
Flavouring agents (flavours and aromatic substances) are both natural and/or synthetic
products. Several pharmaceutical paediatric formulations, especially liquid formulations,
contain flavouring agents for conferring an acceptable taste to the drug. They are
particularly accepted by children because they are represented by sweet fruit taste.
However, a number of allergic reactions have been possibly associated with flavouring
agents.
1.9. STEP DATABASE
Currently, most of the existing database are focusing in providing safety and toxicity
information related only to adults and animals. Therefore, there is no central repository
in public domain to capture, achieve, validate, manage, maintain and provide access to
safety, tolerability and toxicity data that have been generated for paediatric excipients in
drug development. In order to address this need, the European (EU) and United States
(US) Paediatric Formulation Initiatives (PFIs) are working together to create and
maintain a database of Safety and Toxicity of Excipients for Paediatrics (STEP) (Salunke
at al., 2012).
The purposes of the STEP database are:
 to serve as a freely accessible evidence base for safety and toxicity of excipients for
the pharmaceutical industries, academics and pharmacists clinicians to make
informed decisions;
 to identify the possible safety issues related to excipients at the initial stages of the
developmental process, when excipients are screened and selected;
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 to help highlight any relationship between exposure and toxicity in the paediatric
subpopulations;
 to identify possible differences in toxicity between adult and paediatric populations
that means a need for generating new data for paediatric medicines;
 to support pharmaceutical companies and academia with readily available
information, for both the regulatory aspect and research activities (Salunke at al.,
2012).
The potential users include professionals in paediatric drug development: formulation
scientists at pharmaceutical companies and academic centres, excipients manufacturers,
pharmacists, developmental toxicologists, paediatric toxicologists and pharmacologists.
The search may occur by using two different modules: ‘Search by excipients’ and ‘Search
for excipients’. The first module provides navigation tools for selection of specific
excipients and should be used when searching for safety and toxicity information of
particular excipients. The ‘Search for excipients’ modules instead provides enhanced
tools for complex queries allowing for searching of excipients associated with specific
studies, effects or pharmacological functions (Salunke at al., 2013).
1.10. PALATABILITY: TASTE, SMELL AND TEXTURE
Palatability is one of the main (but not exclusive) pharmaceutical attribute of the dosage
forms which affects children’s acceptability of an oral medicinal product and it is crucial
for compliance of their treatment. The non-acceptance of a medicine due to the bad taste
can have detrimental consequences on the treatment outcome if the medicine is partially
or not taken, leading to suboptimal therapeutic effect or no effect at all. Palatability is
defined as the overall acceptance of a (often oral) medicine by organolepting properties
such as vision (appearance), smell, taste, aftertaste and mouth feel (texture, cooling,
heating, trigeminal response) and possibly also sound (auditory clues). It is determined
by the characteristics of the active ingredients and excipients. Palatability is also relevant
for other routes of administration such as buccal, nasal administration or inhalation use,
and when the product may contact the taste receptors indirectly, for instance by
deposition on the throat and post nasal run off.
Although solid dosage forms are usually accepted by older children and adolescents, and
can be easily taste-masked by encapsulation and film coating techniques, younger
children tend to prefer liquid formulations. However, in this case, compounds with high
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solubility can be difficult to taste mask, as they often cannot be easily formulated as
suspensions. Even suspensions of poorly soluble substances may exhibit poor palatability
properties, if the mouth feel is compromised by the amount of the substance in
suspension, or if the amount of the dissolved substance exceeds the human taste
threshold. Also other kinds of dosage forms, such as chewable and orally disintegrated
tablets  may be challenging in terms of taste masking possibility (Cram et al., 2009).
In addition, there is a series of issues that should be overcome: in the era of age-
appropriate formulations, covering all age ranges of the target population is necessary
but also challenging. Different taste acuity and preferences occur between teenagers and
infants, male and female, and healthy and sick children (Cram et al., 2009).
Apart from the taste and smell of a dosage form, there are other potentially important
parameters, which determine if a preparation will be accepted by a child. Texture and
appearance for example play an important role in patient’s acceptability, but their effects
have little attention because preventive measures are limited.
1.10.1. THE PHYSIOLOGY OF TASTE IN CHILDREN
Taste sensations arise from the stimulation of specialized cells grouped in small clusters
called taste buds, which exist in bumps, all around the tongue: on the front of the tongue,
in folds of the side of the tongue, and in circular grooves on the back of the tongue surface
(EMEA/CHMP/PEG/194810/2005).  Each taste bud contains 50-100 taste cells and the
taste sensation is elicited when drugs or excipients dissolve in saliva and interact with
taste receptors (surface proteins) or ion channels (pore like proteins). Sweet and bitter
tastes interact with surface proteins whereas salt and sour tastes interact with ion
channels; the taste receptor stimulation increases the concentration of positive ions. The
varying ion concentration initiates electrical changes in the negatively charged taste cells
causing generation of chemical signals. This process allows the release of
neurotransmitters, which are perceived by brain as taste (Ali et al., 2014).
The human fetus seems to have specialized taste cells at about the 7th-8th weeks of
gestation, with structurally mature taste buds around the 13th-15th weeks of gestation.
This means that newborn presents all the capacities to perceive different taste, but as
explained above, differences in acuity and preferences occur between newborns and
infants, children and adults.
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1.10.2. METHODS TO ASSESS THE TASTE OF MEDICATIONS
It has been reported that children have a greater difficulty in recognizing the taste of a
formulation than adults, due to their limited analytical skills in perceptual tasks. Their
ability increases in pre-school period, until adolescence. However, it is unknown whether
children are able to analyze and recognize more than one flavour in a taste mixture and
the concentration of each flavour can influence the child’s assessment. It has been
reported instead that, in the case of sweetness and saltiness, paediatric patients have the
ability to recognize and analyse them from an early stage of life, and they are able to
recognize them in a mixture, and estimate the strength and the degree of sweetness and
saltiness. In general, children prefer more sweetness than adults do, and in particular,
female of 4-12 ages are more sensitive to sweetness and saltiness than male.
In addition, cultural influences can have strong effects on children’s attitude and
preference toward even the basic tastes and flavors. Market research has revealed
standard combinations of specific sweeteners with relevant flavours, which may vary by
country and target market. National favourites include “bubble-gum” and “grape” in the
United States, “citrus” and “red berries” in Europe and “liquorice” in Scandinavia. For
example, a bubble-gum or cherry flavour in combination with a high intensity sweetener
may suit the US paediatric market, while a less intense sweetness may be more
appropriate for Japan.
Children may find unpleasant and reject irritating sensations in the mouth such as
effervescence or peppermint. Peppermint may be described as “spicy” or “hot” and
rejected in the same way as bitter tastes.
For selection of the most suitable flavour for a paediatric medication, the type of flavour
(acid, alkaline, bitter, salty or sweet; see Table 9) as well the health condition of the target
population have to be considered (Table 10).
Table 9. Flavour type.
Basic sensation Flavours to cover this taste
Acid Cherry, lemon, lime, mandarin, orange, strawberry
Alkaline Banana, caramel, cherry, liquorice, passion fruit, peach
Bitter Cherry, chocolate, grapefruit, liquorice, strawberry, peach,
raspberry
Salty Caramel, grapefruit, lemon, orange, vanilla
Sweet Banana, caramel, cream, chocolate, grape, vanilla
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Table 10. Flavour preference in Europe as a function of the disease of the target group.
Condition Associated flavours
Pain, fever, allergy, infections Cherry, strawberry, banana, caramel
Vitamin deficiency (Multivitamins) Blackcurrant, lemon, lime, mandarin,
orange
Indigestion (Antacids) Lemon, lime, orange, peppermint
Quantitative evaluation of taste on the basis of analytical methods
The analytical method used is very similar to that used for the determination of drug
release, and it is based on the detection of substances within a short period in aqueous
medium. In general, it is used to measure the efficacy of coating and complexation within
formulation. Taste masking is achieved when drug substance is not detected in 1-2
minutes or the detected amount is below the threshold for identify its bitter taste.
Quantitative evaluation of the taste using a taste sensor
The electronic taste sensor (electronic tongue) is able to detect taste in a manner similar
to human gustatory sensation. Taste substances cause changes in electrical charge density
of the lipid/polymer membrane surface and/or ion distribution near the surface of the
membrane of the sensor. The total electric change is given as the response membrane
electric potential for the substances tested. Each taste gives a different response in
different membranes, which means that one membrane differs from the other one; the
result is given as membrane potentials.
The assessment of the taste of a formulation depends on the evaluation of a standard
(quinine hydrochloride or caffeine solution at different concentrations) or a reference
(formulation containing only the active substances without any taste masking agents).
This method is inexpensive and easy to conduct, useful of several formulations and
dosage forms.
Qualitative evaluation of the taste by a taste panel
In order to conduct a suitable panel taste, the best population, pre-screened and
considered the actual user has to be selected. Thus, children represent the best choice in
the assessment of the taste of a paediatric formulation. In the case of selection of
paediatric population, it is really important that the test is short, to match children’s
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attention span, and intrinsically motivating and fun to do. The procedure has to be easy
to follow by children and the number of variants to be tasted should be limited at a
maximum of four.
In general, children of 4 years and older are selected for the panel test, because younger
children are often shy and reluctant. In addition, they can lose attention and they can have
difficulties in concentrating during the entire period of the test, and then they are not able
to express their feelings. It is appropriate to increase the attention and concentration of
children, by using at first, high concentration of the taste agent, represented by common
flavours, and then try to use uncommon flavours (for example from strawberry and
cherry to passion fruit).
When a panel test is conducted, one of the most difficult thing to do is to determine the
objective, what exactly should be determined. Thus, questions as ‘which sample do you
prefer?’, or ‘how much do you like it?’ or ‘what don’t you like?’ are often addressed to
children. Ranking is a very useful method for the evaluation of preference and analytical
assessment (‘please rank samples in order of your personal preference’, or ‘please rank
samples in increasing order of bitterness’).
However, the questionnaire should be simple, intelligible and plain of all participants,
and characterized by simple terms, common for each age groups, to describe the
following properties:
 sweet, salty, sour and bitter characterizing the taste;
 thin, thick, viscous, gritty characterizing the tasting item;
 sweet, salty, sour, bitter but also numbness, astringent or freshness for aftertaste.
The evaluation of the taste of a medication is conducted by following two essentially
different methods in the assessment of the children’s preferences: the first is the
spontaneous verbal judgement followed by scoring in a scale 1-5 (score 1 corresponds to
very good, and score 5 corresponds to very bad). In the second method, the facial hedonic
scale allows the expression of preference using the pictorial scale in Figure 1. The child
is asked a standardised, specific question: ‘which one of these figures do you think has
tasted this medicine?’, and is then asked to indicate the appropriate figure on the form
(Sjovall et al., 1984).
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Figure 1. Hedonic scale used in a taste panel.
Children below 5-6 years are excluded from the panel tests, because they are not able to
express differences in taste perception. A reliable evaluation could be achieved by child’s
spontaneous verbal judgement, following a control question. The facial hedonic scale can
not be used in younger children, as they may associate the figures with other feelings (for
example, happy face: I will not stay longer in the hospital, sad face: pain and discomfort).
In general, older children judge more critically than younger ones, so they use both the
verbal judgement and the hedonic facial scale method to evaluate the taste of a
medication.
In all the cases, independent from the age or the method used, it is useful to ask simple
questions at the end of the test, like: ‘which formulation is the best?’, and ‘which
formulation tasted worst?’
1.10.3. GENERAL TASTE MASKING TECHNOLOGIES IN ORAL
PHARMACEUTICALS
Considerable progress has been achieved in the last few years in the development of
bitterness, tasteless and taste-masked formulations. Several approaches are used in
masking the unpleasant taste of some active substances: the use of excipients like
flavours, sweeteners and amino acids; taste masking by polymer coating; by common
granulation, spray congealing with lipids, inclusion complex with cyclodextrins, freeze-
drying process, multiple emulsions, ion-exchange resins,with gelatine, gelatinized starch,
liposomes, lecithin or lecithin-like substances, surfactants, salts and polymeric
membranes (Coupland and Hayes, 2014, Kaushik and Dureja, 2013).
 Taste masking with flavours, sweeteners and amino acids
Adding flavours, sweeteners and amino acids represents the simplest technique to obtain
the reduction of unpleasant taste of medications. However, it is not particularly
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successful for highly bitter and highly water soluble substances. Artificial sweeteners
and flavours are used along with other techniques in order to achieve the same purpose.
For example, in the case of dentifrices and mouthwashes, the active and unpleasant
ingredients, such as eucalyptus oil and benzethonium chloride are masked with fenchone,
borneol, isoborneol, the cooling effects of taste masking agents, menthol stevia-base
sweetener and glycine, and imitation flavours like grape, maple, raspberry and wild
cherry.
Zinc acetate dihydrate present in different lozenges, is covered by the use of saccharin,
anethol-β-cyclodextrin complex, magnesium stearate, polyethylene glycol and fructose.
Aspirin is prepared with anesthetizing agents such as sodium phenolate, to numb the taste
buds sufficiently for 4-5 seconds, rendering the taste of the aspirin imperceptible.
Another conventional technique consists in combining citric acid, sodium bicarbonate
and different flavours: orange and cream to mask chlorpheniramine and
phenylpropalamine HCl, lemon to mask famotidine and cherry to mask acetaminophen.
Starch, lactose and mannitol are always used to mask caffeine.
Aspartame is a common excipient useful as a prominent sweetener in providing bitterness
reduction. 0.8 % of aspartame in the formulation is sufficient to mask 25 % of
acetaminophen. Artificial sweeteners such as neohesperidine dihydrochalcone and
hesperidine dihydrochalcone 4’-b-D glucoside have the ability to mask bitterness and
saltiness by virtue of their lingering sweetness. A lingering sweetness provides taste
masking, primarily because the taste profile of a bitter substance appears later in time
than normal sugar sweetness generally lasts (Sohi, 2004).
 Taste making with lipophilic vehicles
Lipids, oils, surfactants and polyalcohols increase the viscosity in the mouth, and cover
the taste buds, acting as taste masking agents. For example, the taste of acetaminophen
is covered when the granules are sprayed with molten stearyl stereate, mixed with
suitable tablet excipients, and incorporated into a taste-masked, chewable tablet
formulation. The taste of guaifenesin is improved when mixed with carnauba wax and
magnesium aluminium silicate. Cimetidine has improved taste when granulated with
glyceryl monostearate and gabapentin taste is enhanced whit  hydrogenated soybean and
glyceryl monostearate.
Lecithin and lecithin-like substances are considered good ingredients in taste-masking.
Talampicillin HCl is known to have bitter taste; it is dissolved in or dispersed into an
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organic solvent such as chloroform. Magnesium aluminium silicate and lecithin are
added into the solution or dispersion in order to cover the unpleasant taste of the drug.
 Taste masking by inclusion complexation
β - cyclodextrin is the most common complexing agent in the formation of inclusion
complex. It is a sweet, non toxic, cyclic oligosaccharide obtained from starch. In general,
the substance characterized by bad taste fits into the cavity of β – cyclodextrin, through
different types of interactions, especially Van Der Waals forces. The taste is masked
thanks to two different mechanisms: by decreasing the oral solubility of the substances
on ingestion in the new system, and by reducing the direct interaction of the substance
with the taste buds.
The bitter taste of ibuprofen solutions is masked by preparing 1:11 and 1:15 complexes
of the drug and hydroxypropyl - β – cyclodextrin. The complex covers the bitter taste of
the drug but creates a sore taste, easily masked with sweeteners.
 Taste masking by ion-exchange resins
Ion-exchange resins are polymers characterized by high molecular weight, cationic and
anionic functional groups and a network based on the copolymer styrene and
divinylbezene. The interaction between the drug and the resins can occur thanks to a
repeated exposure of the drug to the resin in a chromatogram column, or thanks to the
prolonged interaction of the resin with the drug solution. The interaction is based on weak
ionic bound that do not break in the salivary environment, giving the possibility to mask
the bitter taste of the drug. Drug release from the resin depends on the properties of the
resin and the characteristics of the environments of the gastrointestinal tract. Ion-
exchange resins can be divided in four groups:
 strong acid cation-exchange resins;
 weak acid cation-exchange resins work at pH values above 6;
 strong base anion-exchange resins work to the entire pH range and can be used for
the taste masking of acidic drugs;
 weak base anion-exchange resins work well at pH values below 7.
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 Taste masking by coating with hydrophylic vehicles
This is the most feasible, common and easy way for taste masking purpose. The
unpleasant taste of a substance can be covered by creating a physical barrier and by
reducing the direct interaction with the taste buds. A specialized technique is applied to
powders, chewable tablets and liquid suspensions.
 Taste masking by coating with carbohydrates
The unpleasant taste of drugs in paediatric formulations can be masked by coating with
carbohydrates. In some cases, for example, paracetamol, ranitidine HCl, doxycycline
HCl, pseudoephedrine HCl, sodium naproxene, aspirin and theophylline, the core
element of the drug is covered by water insoluble polymer, such as cellulose, in order to
obtain taste masking and reduced dissolution profiles. Granules with bitter taste can be
masked and coated with water-soluble polymers of hydroxypropyl methyl cellulose and
sugars such as sucrose and lactose to reduce the bitter taste at the time of administration.
The bitter taste of basic pharmaceutical salts can be reduced or masked with weakly
alkaline compounds of good bioavailability. Table 11 illustrates some examples of
hydrophilic vehicles used to mask active substances.
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Table 11. Hydrophilic vehicles to mask active substances.
Active substance Hydrophilic vehicle
Pinaverium bromide Mixture of cellulose or shellac and a second film-forming
polymer soluble at pH less than 5
Propantheline bromide Hydroxypropyl cellulose and ethyl cellulose
Ibuprofen Methacrylic acid copolymer
Clorpheniramine maleate Avicel PH 101, xylitol
Triprolidine HCl Hydroxypropyl methyl cellulose
Dimenhydrinate Methacrylic acid copolymer or carboxymethyl cellulose or starch
Enoxacin hydroxypropyl cellulose and hydroxypropyl methylcellulose and
then coated with a mixture of ethyl cellulose and hydroxypropyl
methylcellulose
Aspirin Cellulose acetate latex and triacetin at not more than 1 % of the
coated medicament
Amoxicillin trihydrate Microcrystalline cellulose, hydroxypropil cellulose
Acetaminophen Cellulose acetate, cellulose acetate butyrate, and hydroxypropyl
cellulose, or cellulose acetate, methacrylic acid copolymer,
polyvinyl pyrrolidone
Morphine hydrochloride Cellulose, methacrilic acid copolymer, talc, avicel RC591NF,
sucrose, D-sorbitol, sodium saccharin, methyl paraben, vanilla
essence
 Taste masking by coating with protein, gelatine and prolamines
Gelatine, and a number of proteins, first of all prolamines, are often use for the taste
masking of antibiotics, vitamins, analgesics, dietary fibres, enzymes and hormones.
Although prolamine coatings do not affect the release of the drug, zein and gliadin in
combination with a plasticizer are able to mask the bitter taste and to control the release
of the drug from encapsulated particles. Hydrolized gelatine has been found to be
effective in improving the palatability of magaldrate and calcium carbonate. For mint-
flavoured oral pharmaceutical gums, incorporating a prolamine/cellulose ingredient of
high pH can reduce bitterness of flavour.
 Taste masking by effervescent agents
Effervescent agents are employed to mask unpleasant taste of substances in dosage forms
that are not dissolved in water before the oral administration. Recently, effervescent
tablets of fentanyl and prochlorperazine were developed for the administration of the
drug in the oral cavity, for buccal, sublingual and gingival absorption. The effervescent
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ingredient promotes the absorption and the taste masking to improve the palatability. The
bitter taste of caffeine may be masked by formulating it as a carbonated oral solid
preparation using sodium bicarbonate, ascorbic acid, citric acid, and tartaric acid.
 Taste masking by rheological modifications
The increase of the viscosity of the preparation through the addition of modifiers such as
xanthan gum or carbohydrate, reduce the diffusion of the bitter substances into the taste
buds. Thus, acetaminophen suspension can be formulated to address this purpose with
xanthan gum and microcrystalline cellulose. The bitter taste of tannic acid is masked by
gelatine and flavouring agents or adding sodium alginate to the aqueous solution.
 Taste masking by salt preparation
Another useful approach to mask the unpleasant taste of a substance consists in preparing
salts, as in the case of aqueous solution of ibuprofen salts. The addition of sodium
bicarbonate allows the increase of the palatability of the formulation.
 Taste masking by solid dispersion systems
The solid dispersion is defined as a dispersion of one or more substances in an inert solid
carrier. Taste masking of bitter ingredients can be achieved by the preparation of solid
dispersions with the addition of polymers, sugars and other suitable excipients. This is
the case of the dimenhydrinate whose bitter taste is masked by a solid dispersion, with
the addition of polyvinyl acetate phthalate.
 Taste masking by freeze-drying process
The high porosity derived from the freeze-drying process allows the preparation of tablet-
shape dosage forms able to dissolve in the mouth in few seconds (Zydis technology).
Gelatine and mannitol are the most common excipients used in this technology, although
other suitable excipients can be used, such as starches and gums. The palatability of the
formulation is achieved by the use of artificial sweeteners (aspartame) and flavouring
agents. A number of different actives, characterized by bitter taste are masked with this
technology: lorazepam, piroxicam, loperamide, loratadine, ondansetron and selegiline.
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1.10.4. RECENT APPROACHES AND DEVELOPMENTS IN TASTE
MASKING
Spray congealing is one of the recent approaches to achieve the taste masking of
substances characterized by unpleasant taste. The palatability of conventional granules
of clarithromycin is improved by using this technology and glyceryl monostearate and
aminoalkyl methacrylate copolymer E (AMCE) as the most suitable ingredients (Yajima,
1996).
It has been reported that the preparation of microspheres and the compression technology
may improve the palatability of Cefuroxime axetil and Pirenzepine HCl and Oxybutynin
HCl (Robson et al., 2000, Ishikawa et al., 1999).
Lunstroth et al. (1999) formulated a carboxymethyl cellulose gel with lemon flavour to
improve the taste of gut layer solution. The gel was quickly mixed with the lavage
solution and showed improved palatability.
The taste masking of Indeloxazine HCl was achieved by heat treatment of wax coated
microparticles. The coating was composed of hydrogenated oil and surfactants in a
fluidized bed (Sugao et al., 1998).
It was also developed a taste-masked microcapsule composition for oral administration
of a drug. The composition comprised microcapsules of drug and a substantially water-
insoluble polymeric material, typically a cellulosic polymer (ethyl cellulose). Taste
masking was done by phase separation coacervation technique in which the drug was
coated with relatively high levels of a polymeric material (Hu et al., 2012).
A method for the taste masking of Diclofenac Sodium was developed by
microencapsulation without interfering with an adequate rate of drug release. Diclofenac
sodium microcapsules were successfully prepared and masked by using a system of ethyl
cellulose-toluene-petroleum ether (Al-Omran et al., 2002).
In conclusion, taste masking of the bitter drugs and the improvement in preparing
palatable and acceptable dosage forms have significantly increased the quality of
treatment provided to patients, especially children. In the last decades, several
approaches and technologies have been developed with the aim to respond to the need of
taste masking. However, the applicability of these methodologies depends on the single
drug and dosage form needed and a huge research is needed when a new formulation is
in development.
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2. AIM OF THE WORK
Children around the world are still routinely being treated with medicines that have not
been designed or developed with their own specific physiologies and needs in mind,
putting them at risk of inaccurate and suboptimal dosing and side effects from potentially
toxic ingredients.
In the view of these considerations, the aim of my research project was the use of specific
formulation strategies for the development of innovative paediatric dosage forms.
The research has been structured in three case studies, concerning different oral
formulations: mucoadhesive buccal films, dispersible granules and liquid complex
suspensions.
The first part of the research was focused on the preparation and evaluation of
mucoadhesive polymeric films for transmucosal delivery of ondansetron hydrochloride
with the purpose to improve the conventional dosage forms already on the market, in
term of ease of administration, dosing frequency and dosage flexibility. Moreover, buccal
films have the advantages of allowing the reduction of the dose needed to achieve the
therapeutic effect, through the direct access of the drug into the systemic circulation,
avoiding the hepatic first pass metabolism. The selection of suitable polymeric mixtures
permits the modulation of the residence time of the dosage form on the application site,
the release of the active substance and the permeation of the drug through the buccal
mucosa.
In the second part of the work, dispersible granules were produced, as a flexible dosage
form for paediatric administration of Praziquantel, an anthelminthic drug, widely used in
developing countries for the treatment of Schistosome infections. The novel dosage form
is intended as an alternative to the conventional tablets, already on the market and
unsuitable for paediatric administration due to the size and inadequate dose flexibility.
In addition, the manipulation of the dosage form with milk and fruit juices, allows the
taste masking and the enhancement of the palatability, leading to an increase of paediatric
patient’s compliance.
The last part of the work has been carried out at the University of Birmingham, under the
supervision of Dr. Hannah Batchelor, member of EuPFI, European Paediatric
Formulation Initiative and faced one of the central challenge of administering medicines
to children: the taste masking of molecules characterized by bitter taste. To achieve this
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purpose, polyelectrolyte complexes, composed of whey protein and pectin, and able to
encapsulate active substances were developed. Caffeine was selected as model drug for
its particularly bitter taste. The potential of encapsulation to mask bitter taste was
evaluated by quantitative analytical method, through dissolution studies in biorelevant
medium, simulating the environment of the mouth.
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3. CASE STUDY 1
DESIGN AND EVALUATION OF
BUCCAL FILMS AS PAEDIATRIC
DOSAGE FORM FOR
TRANSMUCOSAL DELIVERY OF
ONDANSETRON
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3.0. PAEDIATRIC CHALLENGE:
ADMINISTRATION ROUTE
3.0.1. TRANSMUCOSAL ROUTE
Traditionally, drugs are administrated in children by oral and parenteral routes. Although
the oral route is preferred for the administration of drugs, particularly those required for
chronic therapies, it is often not feasible. The low bioavailability of drugs administered
through this route is largely due to a number of physical and physiological factors, such
as chemical and enzymatic degradation in the gastrointestinal tract, low permeability
across the gastrointestinal mucosa (Pauletti et al., 1997), and the hepatic first pass
metabolism and clearance, predominantly by the liver but also by the gut mucosa. In
addition, oral route is often not indicated in patients with nausea, sedated or unable to
swallow. On the other hand, parenteral administration avoids the degradation of the
active ingredients in the gastrointestinal environment, and the hepatic first pass
metabolism, but it may be cause of pain and discomfort during the injection, leading to
poor compliance by paediatric patients, especially if multiple daily injections are required
(Hinchcliffe et al., 1999). Risk of infusion of air, microorganisms and pyrogens, together
with the risk of sepsis and phlebitis are also associated with parenteral administration of
drugs.
Consequently, other routes are being considered as alternatives to oral and parenteral
ones and potential sites for drugs administration include the nasal, rectal, vaginal, ocular
and oral mucosae (Patel et al., 2011). These transmucosal routes offer several advantages
over the oral administration, such as the avoidance of the first pass metabolism and the
pre-systemic elimination by the gastrointestinal tract.
In particular, drug delivery by buccal route has gained success compared to the parenteral
administration, due to its potential for the high patient compliance. This is particularly
desirable during an emergency, when a rapid therapeutic response is required, or in a
case of patient’s unconsciousness, when swallowing is impaired.  Medications can be
easily administered by parents and carers without special professional skills and
techniques, although the cooperation of the child is often necessary (Lam et al., 2014).
Within the oral mucosal cavity, the delivery of drugs is classified in two main categories:
(i) local delivery and (ii) systemic delivery by either buccal or sublingual mucosa (Patel
et al., 2011). In the first case, the aim is to achieve a site-specific release of the drug on
the mucosa, while the second case involves drug absorption through the mucosal barrier
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to reach the systemic circulation (Rossi et al., 2005). Generally, the sublingual route is
employed for high permeable drugs and used in the treatment of acute disorders, whereas
the buccal route is generally used in the treatment of chronic disorders, when a controlled
release is required (Sangeetha et al., 2010).
The main challenges associated with the administration of active substances through the
buccal mucosa, are related to the limited absorption area and to the barrier properties of
the mucosa. There are two different permeation pathways for passive drug transport
across the oral mucosa: paracellular and transcellulare routes. Drugs may traverse these
two pathways simultaneously, but in general, one pathway is preferred respect to the
other, depending on the physicochemical properties of the active substance. Hydrophilic
compounds are more soluble in the intercellular space, because it has a less lipophilic
character, while the cell membrane is more lipophilic and thus, is more useful for the
permeation of the lipophilic compounds (Sharma et al., 2013).
In this contest, buccal films represent the most recently developed dosage form for buccal
administration. They have gained success as efficacious and novel drug delivery system,
especially for the treatment of paediatric patients (Madhavi et al., 2013). Buccal films
are dosage forms based on hydrophylic polymers and can be formulated to achieve both
local and systemic action; in this latter case, the active substance loaded in this dosage
form has direct access to the systemic circulation by the jugular vein, avoiding the hepatic
first pass metabolism leading to high bioavailability.
Potential benefits of buccal films involve:
 ease of administration in paediatric patients: no need of chewing or swallowing, no
risk of chocking;
 good mouth feel and possibility of taste masking;
 accurate dosing;
 increase of the systemic bioavailability of the drug, by avoiding the hepatic first pass
metabolism and by extending the residence time of the dosage form at the site of
absorption;
 rapid onset of action and minimum side effects.
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3.1. INTRODUCTION
The extensive changes into the regulatory environment for paediatric medicines,
designed to better protect the health of children, have stimulated the research into child-
appropriate dosage forms. These dosage forms should satisfy important requisites: easy
administration, possibility of weight-based dosing and dose titration, acceptability and
palatability, and finally minimum dosing frequency. Moreover, excipients should be safe
in the target age group (EMA/CHMP/QWP/805880/2012; Ernest et al., 2007; Strickley
et al., 2008; World Health Organization, 2012).
One approach in the process of implementation and innovation of paediatric dosage
forms for young children is represented by the use of buccal films for transmucosal
administration of drug (Borges et al., 2015). Buccal films are relatively new dosage form
intended to deliver drug substances through the oral mucosa directly onto the systemic
circulation, avoiding the hepatic first pass metabolism and similarly, the drug degradation
along the gastrointestinal tract, thus allowing the reduction of the dose necessary to
achieve the therapeutic action. Compared to conventional buccal tablet formulation, they
are thin, flexible and better adaptable to the mucosal surface, and therefore more
acceptable to younger patients. Moreover, buccal films are safe and convenient unit
dosage systems since they can be easily applied or removed from the application site,
even during a state of patient unconsciousness or when swallowing is impaired (Dixit
and Puthli, 2009; Lam et al., 2014; Patel et al., 2011).
From the technological point of view, buccal films are matrices fabricated using
mucoadhesive and film forming polymers and loaded with the active ingredient(s). The
use of mucoadhesive polymers is essential to maintain an intimate and prolonged contact
of the formulation with the oral mucosa allowing a longer duration of absorption
(Sudhakar et al., 2006). Polymers that are commonly used in the development of buccal
films include cellulose derivatives, chitosan, gelatin, hyaluronic acid, carrageenan,
pectin, sodium alginate and poly(acrilic acid)-based polymers (Salamat-Miller et al.,
2005).
Effective design of such delivery system requires careful consideration of other relevant
parameters, including the choice of the active substance (World Health Organization,
2010; World Health Organization, 2015). These involve good lipophilicity and water
solubility at physiological pH, as well as high potency. Ondansetron (ODS), a selective
inhibitor of serotonin (5-hydroxytryptamine) subtype 3 (5-HT3) receptors indicated in
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paediatrics for the prevention and treatment of nausea and vomiting caused by cytotoxic
chemotherapy or radiotherapy and postoperatively, represent a suitable candidate for
buccal delivery (octanol/water log P at pH 7.4: 2.4, water solubility at pH 7.4: 2.42
mg/ml, small molecular size: 365.9 Da) (Lam et al., 2014; Mashru et al., 2005; Patel et
al., 2011). ODS is commercially available as injection, oral liquid and solid oral dosage
form. All these formulations are indicated for administration in multiple daily dosing,
potentially for a series of days (recommended oral maintenance dose for children of 4-
11 years: 4 mg every 4-8 hours). This is due to the pharmacokinetic profile of
ondansetron, which has a half-life of approximately 3-6 hours and with a time to peak
plasma levels of approximately 2 hours. This profile is often associated with alternating
periods of increased side effects and lacking efficacy and therefore, there is a need to
develop sustained release formulations able to maintain a constant drug concentration for
a specific period of time with minimum side effects (Koland et al., 2011; Kumria et al.,
2013; Patil et al., 2015; Park 2012).
The objective of this study was to: (1) implement paediatric dosage forms for young
children with buccal films intended for ODS systemic absorption through the buccal
mucosa over a prolonged period of time; (2) prepare mucoadhesive films based on non-
toxic, biocompatible and hydrophilic polymers as hydroxypropylmethylcellulose
(HPMC), chitosan (CH), sodium hyaluronate (HA) and gelatin (GEL), and by using an
easy and economic method as solvent casting method; (3) investigate the influence of
preparative parameters on the physico-chemical properties of drug/dosage form; (4)
study the influence of polymeric composition (different polymer blends and different
weight ratio) on the drug loading, mucoadhesion potential, water uptake properties, and
drug release and permeation ability.
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3.2. MATERIALS AND METHODS
3.2.1. MATERIALS
Hydroxypropylmethylcellulose (MW 250 kDa, methoxyl content 19-24 %,
hydroxypropyl content 7-12 %) was purchased from Eigenmann & Veronelli (Milan,
Italy); chitosan (MW 150 kDa, deacetylation degree 97 %, pKa = 6.3) was commercially
obtained from Fluka (Milan, Italy); sodium hyaluronate (MW 1800-2300 kDa, D-
glucuronic acid > 42 %) was provided by ACEF (Piacenza, Italy); type B Gelatin from
bovine skin (MW 50 kDa, isoelectric point in the range of pH = 4.7-5.2) and ondansetron
hydrochloride (MW 365.85 g/mol) were commercially obtained from Sigma-Aldrich
(USA). All other chemicals and solvents were of analytical grade and supplied by Carlo
Erba (Milan, Italy). Release and permeation studies were conducted in NaCl solution (0.9
% w/v); mucoadhesion studies were carried out in aqueous buffer with the follow
composition (g/L): 4.609 KH2PO4, 16.748 Na2HPO4 x 12H2O adjusted with hydrochloric
acid to pH = 6.8 (healthy saliva pH = 6.7 - 7.4).
3.2.2. METHODS
3.2.2.1. PREPARATION OF BUCCAL FILMS
Buccal films were prepared by casting-solvent evaporation method. An aqueous solution
of GEL, an aqueous solution of HA and an acid solution (acetic acid 1 % v/v) of CH were
separately added to an aqueous solution of HPMC at different weight ratios (10:0, 9:1,
7:3, 5:5, 0:10 HPMC:GEL or HPMC:HA or HPMC:CH), in order to obtain 1 % w/w
polymeric mixtures. All mixtures were stirred at room temperature for 2 hours and
allowed to stand overnight to eliminate the air bubbles. 15 g of each polymeric solution
were spread on a Petri-dish (diameter = 5 cm) and oven-dried at 50 °C for 6 hours
(heating oven FD series, Binder, Tuttlingen, Germany). Loaded films were prepared by
the same procedure, adding to each mixture 17.45 mg of ODS. Circles of 1.3 cm in
diameter (surface area = 1.33 cm2) were cut to obtain a child-appropriate dosage form
and were used in the following experiments. Each circle contains theoretically 1.18 mg
of drug.
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Different films were named in this work as follows: HPMC:CH(HA,GEL) 10:0, loaded
film based on HPMC; HPMC:CH(HA,GEL) 0:10 loaded films based on CH(HA, GEL);
HPMC:CH(HA,GEL) 9:1, HPMC:CH(HA,GEL) 7:3, HPMC:CH(HA,GEL) 5:5 loaded
films based on HPMC:CH(HA,GEL) 9:1 (w/w), 7:3 (w/w), and 5:5 (w/w), respectively.
Table 12. Composition of the mixtures used for loaded film preparation (% w/w on wet basis).
FORMULATION HPMC CH HA GEL
HPMC:CH(HA,GEL) 10:0 1.0
HPMC:CH 9:1 0.9 0.1
HPMC:CH 7:3 0.7 0.3
HPMC:CH 5:5 0.5 0.5
HPMC:CH 0:10 1.0
HPMC:HA 9:1 0.9 0.1
HPMC:HA 7:3 0.7 0.3
HPMC:HA 5:5 0.5 0.5
HPMC:HA 0:10 1.0
HPMC:GEL 9:1 0.9 0.1
HPMC:GEL 7:3 0.7 0.3
HPMC:GEL 5:5 0.5 0.5
HPMC:GEL 0:10 1.0
3.2.2.2. SOLUTION VISCOSITY
The viscosity of the polymeric solutions used for the preparation of buccal films was
measured at room temperature with an Ubbelohde capillary viscometer equipped with an
electronic time-measuring unit ViscoClock (capillary tubes I and II; Schott, Mainz,
Germany) for CH and GEL solutions (1 % w/w) and with a rotational viscometer (spindle
TR8-TR9, RPM 60-200; Visco Star, Fungilab S.A., Barcelona, Spain) for all the others.
3.2.2.3. CHARACTERIZATION OF BUCCAL FILMS
Thickness
Thickness of the polymeric loaded films was determined at three different positions of
each film using a Mitutoyo pocket thickess gauge (Mitutoyo Mfc. Co. Ltd., Tokyo,
Japan).
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Scanning electron microscopy (SEM)
SEM analysis was performed to evaluate the morphologic characteristics. Films were cut
with a razor blade, fixed on supports and coated with gold–palladium under an argon
atmosphere using a gold sputter module in a high-vacuum evaporator. Samples were then
observed with LEO 420 (LEO Electron Microscopy Ltd., Cambridge, UK) using
secondary electron imaging at 15 kV in order to examine their surface morphology and
their internal structure.
Drug content
The uniformity of the distribution of the drug in the film was ensured with a content
uniformity test. Loaded buccal films have been dissolved in 20 ml of 0.9 % (w/v) NaCl
solution. The system was stirred for 2 hours until complete release and the amount of
drug in solution was evaluated. The results were expressed as milligrams of drug for
square centimetre (mg/cm2).
In these tests as well as in subsequent experiments the ODS concentration was
determined by HPLC equipped with a UV detector. The HPLC system consisted of
Shimadzu (Milan, Italy) LC-10ATVP chromatographic pump and a Shimadzu SPD-
10AVP UV-Vis detector set at 310 nm. Separation was obtained at room temperature on
a Phenomenex (Torrance, CA, USA) Sinergy Fusion-RP 80A (150 mm x 4.6 mm I.D., 5
µm) coupled with a Phenomenex (Torrance, CA, USA) SecurityGuard C18 guard
cartridge (4 mm x 3.0 mm I.D., 5 µm). The mobile phase was prepared by mixing
acetonitrile (33 % v/v) and 20 mM sodium hydrogen phosphate buffer pH = 4.0 (67 %
v/v). The flow rate was 0.4 mL/min and manual injections were made using a Rheodyne
7125 injector with a 20 µL sample loop. Data processing was handled by means of a
CromatoPlus computerised integration system (Shimadzu Italia, Milan, Italy). The
calibration curve of concentration versus peak area was plotted at concentration range of
0.24 - 24 µg/mL; good linearity was found (r2 = 0.9997).
Surface pH
The surface pH of loaded buccal films was determined in order to evaluate their
compatibility with the pH of buccal mucosa. The films were left to swell on a sponge
soaked with phosphate buffer (pH = 6.8) and the pH was measured after 3 hours by
placing universal pH paper on the film surface (pH: 6.0-8.1; Carlo Erba, Milan, Italy).
Ramona Trastullo-University of Bologna 3. Case study 1
60
3.2.2.4. PHYSICOCHEMICAL CHARACTERIZATION OF BUCCAL FILMS
Differential scanning calorimetry (DSC) and X-Ray Powder Diffraction (XRPD)
experiments were performed on loaded polymeric films to identify the solid-state
properties of the drug in the formulation and possible phase transitions of the drug during
the film formulation process.
The DSC analysis were performed using a Perkin-Elmer DSC 6 (Waltham, USA). The
experiments were conducted in non-hermetically sealed aluminum pans using nitrogen
as purge gas at a flow rate of 20 ml/min. Samples of 8.0 ± 1.0 mg were heated from 30
to 220 °C at the heating rate of 10 °C/min.
The XRPD analysis was performed using a Panalytical X’Pert PRO Diffractometer
(Almelo, The Netherlands). The voltage and current were 40 kV and 40 mA, respectively
and the measurement were carried out in the angular scan rage from 3° to 40° (2θ).
3.2.2.5. IN VITRO WATER-UPTAKE STUDIES
Water uptake ability was studied to investigate the maximum time required for films to
hydrate and the maximum capacity of swelling. A sponge (5 cm × 5 cm × 2 cm) fully
soaked in the hydration medium (0.9 % NaCl solution) was placed in a glass container
filled with the same solution to a height of 0.5 cm (Bertram and Bodmeier, 2012). Filter
paper was also soaked in the hydration medium and positioned on the top of the sponge.
The experimental set-up was equilibrated for 30 minutes. Accurately weighted films
(unloaded samples) were then placed on the filter paper and the water-uptake ability was
determined as weight increase of the film after 3 hours, according to the following
equation:
% Water Uptake (WU) = (W2-W1) x 100/ W1
where W1 was the initial weight of dried film and W2 is the weight of hydrated film.
3.2.2.6. IN VITRO RESIDENCE TIME
Mucoadhesion properties of unloaded buccal films were determined in terms of residence
time of films on a freshly excised mucosa. The porcine buccal mucosa, procured from a
local slaughter house and used as a biological membrane due to its similarity to the
human buccal tissue, was cut to an appropriate size (surface area = 1.54 cm2), wetted
with few drops of aqueous mucin solution (0.05 % w/v) and fixed on a microscope slide
with cyanoacrylate adhesive. The films were then attached to the porcine buccal mucosa
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by applying a light pressure for 2 min. The microscope slide was then placed in a beaker
filled with 40 ml of phosphate buffer pH = 6.8 and slowly stirred to mimic the
physiological conditions. The time taken by the films to completely detach from the
mucosa was considered as the residence time (Nair et al., 2013).
3.2.2.7. IN VITRO RELEASE STUDIES
In vitro release studies were performed in order to evaluate the drug amount released
from films over the time. Loaded films were attached on the internal side of a beaker
containing 40 ml of 0.9 % (w/v) NaCl solution. The system was stirred at 50 rpm and
maintained at 37 °C to simulate the physiological conditions. Samples of 500 µl were
withdrawn at predetermined time intervals and replaced by fresh medium. The
experiment were conducted for 5 hours and all samples were analized by HPLC analysis.
The results of the release experiments are shown as cumulative drug amount released
(expressed as fractional amount) plotted as a function of time.
3.2.2.8. IN VITRO PERMEATION STUDIES
In vitro permeation studies were performed in order to evaluate transmucosal absorption
of drug from buccal films. These studies were made through a buccal porcine mucosa
using Franz-type static glass diffusion cells (15 mm jacketed cell with a flat ground joint
and clear glass with a 12 mL receptor volume, diffusion surface area: 1.77 cm2) and
equipped with a VSA stirrer (PermeGear Inc., Hellertown, Pennsylvania, USA). The
buccal mucosa was excised using a surgical blade and immediately located in the donor
chamber. Loaded films were placed on the top of the porcine mucosa. The receptor
compartment was filled with 12 ml of 0.9 % (w/v) NaCl solution maintained at 37 °C by
means of a surrounding jacket and has been continuously stirred. Samples of 100 µl were
withdrawn from the receptor compartment at predetermined time intervals and replaced
by fresh medium. Sink conditions were maintained at any time. The experiment was
conducted for 6 hours and all samples were analyzed by HPLC analysis. The results of
permeation studies are shown as cumulative drug amount permeated (expressed as
fractional amount) versus time.
3.2.2.9. STATISTICAL ANALYSIS
All experiments were done in triplicate, while transport experiments were done with five
replicas. Results are expressed as mean ± SD. Anova and t-test were used to determine
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statistical significance of studies. The criterion for statistical significance was p < 0.05.
3.3. RESULTS AND DISCUSSION
The development of a suitable dosage form for paediatric patients still remains a
challenge. An ideal paediatric formulation must allow accurate dose administration and
be in a dosage form that can be safely handled by the target age group. Polymeric buccal
films offer an exact and flexible dose and ease of handling; they also allow the direct
access of the active into the systemic circulation avoiding the first-pass metabolism and
thus reducing the dose needed.
3.3.1. SOLUTION VISCOSITY
Casting-solvent evaporation method was employed to prepare buccal films, using non-
toxic and non-irritant polymers, such as HPMC, CH, HA and GEL, thus suitable for the
administration in children.
This method is based on the dissolution of the polymers in appropriate solvents (distilled
water or acetic acid 1% v/v), and on the subsequent mixture of polymer solutions in order
to obtain the desired polymer weight ratio. All the final solutions had the same total
polymeric concentration (1% w/w), but they showed different viscosities. As reported in
Figure 1, single polymer solutions had viscosities of 250  18, 38.77  1.60, 1150  101
and 3.20  0.08 mPa  sec for HPMC, CH, HA and GEL, respectively. Furthermore, as
regards the mixtures, the addition of increasing amount of HA to the HPMC solution,
proportionally increased the solution viscosity, while increasing amount of CH and GEL
decreased the viscosity of the HPMC solution. This behaviour is chiefly related to the
different molecular weight of the polymers used for the preparation of the films. In fact,
HA shows the highest molecular weight with respect to HPMC, CH and GEL. The
presence of the active into the solutions did not affect the solution viscosity (data not
shown).
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Figure 2. Viscosity of the solutions used for the preparation of unloaded buccal films.
3.3.2. CHARACTERIZATION OF BUCCAL FILMS
SEM analysis in Figure 2 showed that HPMC:CH 5:5 and HPMC:GEL 5:5 exhibited a
dense and compact cross-section, while HPMC:HA had a heterogeneous structure
characterized by flakes.
The results related to the measurement of thickness and drug content of buccal films are
reported in Table 1. Film thickness is directly related to the accuracy of dose and the very
low standard deviations suggested a uniform thickness all around the dosage form.
HPMC:CH(HA,GEL) 10:0 demonstrated the maximum thickness, while the other films
had a different thickness related to the different composition. In addition, the
measurement of ondansetron hydrochloride content in the dosage form showed that the
drug was uniformly distributed inside the films; the experimental drug content was very
close to the theoretical one (0.9 mg/cm2) for each formulation, indicating that casting-
solvent evaporation method is a suitable technique to produce polymeric buccal films
containing ondansetron.
The film surface pH was measured to investigate the possibility of any side effects due
to acidic or alkaline pH of films that could hurt the buccal mucosa leading to patient
discomfort (Nair et al., 2013). The surface pH of all prepared films was found near the
neutral pH indicating its compatibility with buccal pH, causing no irritation to the mucosa
and achieving patient compliance.
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Table 13. Characterisation of buccal films: film thickness (µm), drug content (mg/cm2)
and water uptake ability (%).
FORMULATION Film Tickness (µm) Drug content (mg/cm2) Maximum WU (%)
HPMC:CH(HA,GEL)
10:0
107 ± 6 1.03 ± 0.21 1246.46 ± 38.23
HPMC:CH 9:1 63 ± 6 1.05 ± 0.13 1862.66 ± 60.50
HPMC:CH 7:3 57 ± 6 1.02 ± 0.11 2000.02 ± 110.55
HPMC:CH 5:5 53 ± 12 1.05 ± 0.14 1934.25 ± 60.20
HPMC:CH 0:10 63 ± 1 1.15 ± 0.20 2767.78 ± 90.54
HPMC:HA 9:1 73 ± 12 0.98 ± 0.10 1713.68 ± 88.57
HPMC:HA 7:3 67 ± 6 0.91 ± 0.15 5001.29 ± 210.43
HPMC:HA 5:5 69 ± 6 0.95 ± 0.08 4933.55 ± 180.40
HPMC:HA 0:10 44 ± 6 0.82 ± 0.15 5208.63 ± 225.34
HPMC:GEL 9:1 93 ± 2 1.03 ± 0.01 1305.12 ± 42.20
HPMC:GEL 7:3 96 ± 3 0.87 ± 0.15 1249.03 ± 79.92
HPMC:GEL 5:5 101 ± 3 0.90 ± 0.01 1182.97 ± 67.91
HPMC:GEL 0:10 76 ± 2 0.98 ± 0.05 1371.65 ± 84.86
3.3.3. PHYSICOCHEMICAL CHARACTERIZATION OF BUCCAL FILMS
In order to evaluate possible phase transitions of the active during the film formulation
process, differential scanning calorimetry and X-ray powder diffraction were used.
The DSC profiles in Figure 3 showed a single endothermic peak at 187.54 °C, in
agreement with the melting point of ondansetron hydrochloride raw material and a large
dehydration process between 50-120 °C. The thermograms of all films presented a large
endothermic profile around 60-120 °C related to the dehydration of polymers.
Conversely, the melting peak of the active was absent in the DSC profiles of all loaded
films, except for HPMC:CH 0:10 and HPMC:CH 5:5. This means that in almost all the
cases casting-solvent evaporation method induced the amorphization of the active, while
in HPMC:CH 0:10 and HPMC:CH 5:5 part of it remained as crystalline material.
The same results were confirmed by the XRPD analysis. The diffractrograms of the
loaded films did not report the characteristic peaks of ondansetron hydrochloride raw
material (2θ values of 8.26°, 13.28°, 16.84°, 20.20°, 23.96°, 24.36°, 25.72°, 27.88°,
30.84°) (Pattnaik et al., 2011), indicating an amorphous profile of all the films, except
for HPMC:CH 0:10 and HPMC:CH 5:5. In fact, these films exhibited XRPD patterns
characterized by a peak of low intensity at about 7 °2θ, probably related to a crystalline
form of the active.
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(a)
(b)
Figure 3. Physicochemical characterization of loaded buccal films: (a) XRPD patterns of
HPMC:CH (all the mixtures) and HPMC:HA(GEL) (all the most significant mixtures), respect
to pure ODS; (b) DSC profiles of HPMC:CH (all the mixtures) and HPMC:HA(GEL) (all the
most significant mixtures), respect to pure ODS.
3.3.4. IN VITRO WATER UPTAKE STUDIES
In vitro water-uptake values after 80 min are reported in Table 1. The presence of HA
and CH in the polymeric mixtures increased the water-uptake ability of unloaded
HPMC:CH(HA,GEL)10:0. In particular, the increase of the hydration capacity was more
evident for unloaded HPMC:HA, respect to unloaded HPMC:CH. When GEL was
introduced in the polymeric mixtures, instead, it did not affect the hydration ability of
unloaded HPMC:CH(HA,GEL) 10:0. This behaviour can be mostly related to the
different polymeric charge density. In fact, in our operative conditions (0.9 % w/v sodium
chloride solution at pH = 6.3) HPMC resulted completely neutral, HA (pKa = 2.9)
resulted negatively charged with all its carboxylic group deprotonated, CH (pKa = 6.3)
showed positive charge with 50 % of neutral amine groups and 50 % of protonated amine
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groups and GEL (isoelectric point in the range of 4.7-5.2) was slightly negatively
charged. In particular, the highest charge density (HA in our case) allows the highest
entrance of water in the system and the highest hydration of the film, thus permitting the
formation of gels with different viscosities.
3.3.5. IN VITRO RESIDENCE TIME
Once administered into the oral cavity, the films have to hydrate, adhering to the buccal
mucosa, and forming a gel in order to allow an extended drug delivery. As shown in
Figure 4, unloaded HPMC:CH(GEL,HA) 10:0 demonstrated the highest residence time
(1320 min). HPMC is a long chained, non-ionic polymer and its mucoadhesion ability is
chiefly attributable to the interpenetration and entanglement of polymer chains into the
mucus layer. Furthermore, it possesses a large number of hydrophilic groups that are able
to form hydrogen bonds between the hydrophilic groups of mucus (Bertram and
Bodmeier, 2006). It has been reported that a minimum polymer molecular weight of 100
kDa is required for mucoadhesion (Lee et al., 2000). In our studies GEL has the minimum
molecular weight (50 kDa), and unloaded HPMC:GEL 5:5 and unloaded HPMC:GEL
0:10 demonstrated the minimum residence time (120 and 28 min, respectively). All the
other polymers have molecular weights higher than 100 kDa, even if the adding of CH
and HA to unloaded HPMC:CH(GEL,HA) 10:0 did not increase its mucoadhesion
properties. Unloaded HPMC:HA 5:5 and HPMC:HA 0:10 showed a residence time of
760 and 360 min respectively, a period of time sufficient to allow a prolonged delivery
of ODS. The high molecular weight of HA (1800-2300 kDa) and its charge density at pH
= 6.3 permit to attract and absorb water, associated with a consequent high hydration, a
formation of a viscous gel and an intimate contact with the layer of the mucus. HA also
presents numerous hydrophilic groups able to form hydrogen bonding with the mucus
glycoproteins. Unless CH has positively charged amino groups that can electrostatically
interact with the negatively charged sialic acid of mucin, it has less charged groups at pH
= 6.3 than HA, allowing a lower hydration and thus residence time (420 and 37 min for
unloaded HPMC:CH 5:5 and HPMC:CH 0:10, respectively).
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Figure 4. Residence time of unloaded buccal films on porcine buccal mucosa.
3.3.6. IN VITRO RELEASE STUDY
Drug release from gelled matrices is a complex phenomenon of water penetration,
relaxation of the polymer chains, swelling and spreading of the matrix, interactions
between drug and polymeric material, and drug dissolution and diffusion through the
rehydrated matrix. The release of ODS from HPMC:CH, HPMC:GEL and HPMC:HA
films were investigated; in particular, Figure 5 shows the release profiles of
HPMC:CH(GEL,HA) 10:0, HPMC:CH 5:5, HPMC:GEL 5:5 and HPMC:HA 5:5, as
representative formulations of the three different series. All the formulations exhibited a
prolonged release of the drug. Moreover, HPMC:CH(GEL,HA) 10:0 and HPMC:CH 5:5
released the maximum amount of the drug within 45 minutes, while HPMC:HA 5:5 and
HPMC:GEL 5:5 showed the maximum release of ODS after 120 minutes.
The inclusion of CH and GEL in the formulation allowed a higher cumulative amounts
of ODS released from the dosage form, rather than the inclusion of HA. As described
above, HPMC:HA 5:5 showed the highest molecular weight and the greatest hydration
ability due to the high charge density at pH = 6.3; this permitted higher viscosity of the
polymeric network in the gelled state, thus limiting the drug diffusion. HPMC:CH 5:5
and HPMC:GEL 5:5, once hydrated, created a less viscous gelled state, allowing a greater
release of ODS from the dosage form.
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Figure 5. In vitro release profile of ondansetron hydrochloride from HPMC:CH(GEL,HA)10:0,
HPMC:CH 5:5, HPMC:GEL 5:5 and HPMC:HA 5:5.
3.3.7. IN VITRO PERMEATION STUDIES
In vitro permeation studies were performed in order to establish the absorption of the
drug across the buccal epithelium to the systemic circulation. Even in this case
HPMC:CH(GEL,HA) 0:10, HPMC:CH 5:5, HPMC:GEL 5:5 and HPMC:HA 5:5 were
chosen for the permeation studies as representative of the three different series (Figure
6). All the formulations demonstrated a sustained permeation of the drug within 6 hours.
In particular the presence of HA in HPMC:HA 5:5 (J = 18.7 ± 2.5 g/cm2 h) did not
improve the permeation ability of HPMC:CH(GEL,HA)10:0 (J = 23.9  ± 3.3 g/cm2 h),
while both HPMC:CH 5:5 (J = 87.6 ± 14.4 g/cm2 h) and HPMC:GEL 5:5 (J = 99.6  ±
18.1 g/cm2 h) provided higher permeated drug amount at each time respect to
HPMC:CH(GEL,HA) 10:0. This behaviour is in agreement with the release profiles: the
more amount of drug released from the dosage form, the more absorption inside the
buccal mucosa. Moreover, since chitosan is believed to interfere with lipid micelle
organization in the intestine, Senel et al. (2000) explained that a possible mechanism of
action of chitosan in improving the transport of drug across the buccal mucosa is the
ability of interfering with the lipid organization in the buccal epithelium.
As concern the practical use of these formulations, the recommended oral maintenance
dose for children of 4-11 years is 4 mg every 4-8 hours. This dosage can be achieved by
use of film with a surface area of 7.7 cm2, 9.9 cm2, 1.9 cm2 and 2.1 cm2 for
HPMC:CH(GEL,HA)10:0, HPMC:HA 5:5, HPMC:GEL 5:5 and HPMC:CH 5:5,
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respectively. The surface area of the film was calculated according to the following
equation: Css = J·A/Cl, where Css is the concentration at the steady state (39.5 ng/ml)
(Simpson et al., 1992), Cl is the ondansetron clearance (0.39 L/h/Kg) (Spahr-Schopfer,
1995) and J is the permeation flux of film.
Figure 6. In vitro permeation profiles of HPMC:CH(GEL,HA) 10:0, HPMC:CH 5:5,
HPMC:GEL 5:5 and HPMC:HA 5:5.
3.4. CONCLUSION
With polymeric buccal films, a novel solid oral dosage form was developed, fulfilling all
current demands for child-appropriate dosage forms. HPMC mixtures with HA, GEL and
CH can be used as materials to develop sustained release films able to allow minimal
dosage and frequency, and characterized by minimal impact on lifestyle, and easy and
reliable administration. The selection of suitable polymeric mixture and appropriate
weight ratio allowed the modulation of the residence time of the dosage form on the
application site, the release of the drug and its permeation through the buccal mucosa.
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Further studies are in progress to optimize ODS release/permeation from buccal films
and to improve organoleptic characteristics of the dosage form. In particular, we are
applying a second film layer onto a first one to achieve unidirectional release towards the
oral mucosa, avoiding drug release in the oral cavity and covering the ODS bitter taste.
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4. CASE STUDY 2
DEVELOPMENT OF FLEXIBLE AND
DISPERSIBLE ORAL FORMULATIONS
CONTAINING PRAZIQUANTEL FOR
POTENTIAL SCHISTOSOMIASIS
TREATMENT OF PRE-SCHOOL AGE
CHILDREN
Trastullo, R., Dolci, L.S., Passerini, N., Albertini, B., 2015. Development of flexible and
dispersible oral formulations containing praziquantel for potential schistosomiasis
treatment of pre-school age children. Int. J.Pharm. 495, 536-550.
License number: 3815270768950; International Journal of Pharmaceutics, Elsevier.
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4.0. PAEDIATRIC CHALLENGE: DOSAGE FORM
4.0.1. ORAL FLEXIBLE DOSAGE FORMS
As many of the drugs prescribed for children were designed for and tested in adults,
logically they are predominantly available as single dosage units suitable for adults. This
implicates that in several cases tablets, capsules and suppositories are too large for the
administration in newborns, infants or children, leading to the failure of the therapy. In
addition, in most cases, the required paediatric dose is a fraction of the whole dose
available in a single dosage unit.
The lack of commercially available, age-appropriate formulations can make them
difficult to administer to children (Zajicek et al., 2013). As described in the introduction
of thesis, medicines may require manipulation at the point of administration, by opening,
splitting, crushing, dispersing or diluting the original dosage forms. The need for
calculations and extra steps (such as dilutions and measurements), leads to an increasing
of errors: the potential for error with the additional steps used during drug manipulation
may exacerbate risks that have been previously recognised with other known aspects of
paediatric medication administration, such as the use of unlicensed/off label drugs.
For oral medicines requiring precise dosing measurements, a new flexible platform
technology was proposed to produce solid multiparticulate dosage forms (minitablets,
pellets) and dosage forms dispersible in liquids or sprinkled on food (granules).
Granules were chosen in the following work thanks to their advantages:
 dose flexibility: ability to easily and accurately deliver dosing according to patient’s
individual needs (bodyweight);
 possibility of administration of a fine suspension in water, easy to swallow;
 manipulation of the formulation with beverages and food;
 possibility of taste masking with the use of sweeteners and flavours.
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4.1. INTRODUCTION
Nowadays, there are many challenges associated with formulating paediatric medicines
for developing countries and the demand of paediatric medicine still remains at large
(Sosnik et al., 2012; Ivanovska et al., 2014). In particular, there is a lack of paediatric-
acceptable dosage forms for most neglected tropical diseases as the majority of oral
dosage forms is designed for adult patients and lacks in dosing flexibility (World Health
Organization, 2007; Conway et al., 2013). Capsules or tablets are the most common
dosage forms but also difficult to swallow in small children, especially between the ages
of 2 and 6 years (Zajicek et al., 2013). In 2007, four children under 36 months died from
choking on albendazole tablets during a deworming campaign in Ethiopia. WHO
strongly recommended that manufacturers of anthelminthics for public health programs
targeted at pre-school children develop formulations that are appropriate for this age
group (World Health Organization, 2007). Praziquantel (PZQ) is an anthelmintic drug
widely used in developing countries for the treatment of schistosome infections.
Schistosomiasis is caused by the infection from parasitic worms (Schistosoma mansoni,
Schistosoma haematobium, Schistosoma japonicum) and results in chronic diseases such
as stunting, wasting, lack of fitness, cognitive impairment, infertility and genital disease
(Mutapi et al., 2011). Schistosomiasis affects more than 200 million people worldwide
out of a total of 783 million at risk (in 74 developing countries) (Skopp, 2014). The
affected population includes 24 million pre-school children and 65 million school-age
children, at risk of a total of 72 million and 200 million, respectively. After malaria, it is
the second most prevalent disease in African children (Skopp, 2014). PZQ is included in
the WHO Model List of Essential Medicines for Children (World Health Organization,
2011). This drug was discovered in the early seventies and is manufactured by several
companies such as Bayer (Biltricide1) and Merck (Cesol1 or Cisticid1). Nowadays, it is
mostly available on the international market as a 600 mg film-coated tablet of 22 mm in
length. The dosage is adjusted to the child bodyweight by administering in sets of 150
mg (a quarter of a tablet). The therapeutic regimen for the treatment of schitsosomiasis
consists of 20 mg/kg three times a day at intervals of 4–6 h (Bayer HealthCare
Pharmaceuticals Inc., 2011) or as a single dose of 40 mg/kg (depending on the parasite)
(Sousa-Figueiredo et al., 2012a). It is a one-day treatment. Recently, height intervals
instead of bodyweight for tablet division were also considered (Sousa- Figueiredo et al.,
2012b). Moreover, it is reported that keeping the tablet or segments in the mouth can
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reveal a bitter taste, which can promote gagging and vomiting. Therefore, the tablet
should be administered with food and swallowed whole with some liquid. From a
biopharmaceutical point of view, PZQ is classified a BCS class II drug (high
permeability, low solubility and extensive first-pass metabolism) (Lindenberg et al.,
2004). Therefore, the two main drawbacks of this drug are its bad taste and its poor water
solubility, related to the high dose required. Merck has distributed more than 160 million
PZQ tablets since 2007 and 38 million school children have been treated via the Merck
donation since 2008 (Skopp, 2014). Moreover, since 2003, several mass drug
administration campaigns have been implemented in sub-Saharan Africa treating
millions of school-aged children for schistosomiasis with PZQ (Sousa-Figueiredo et al.,
2012b; Coulibaly et al., 2012). However, younger children (_6 years) have been
consistently excluded from access to such medication, highlighting a PZQ treatment gap
for pre-schoolers and infants. WHO considers treatment with PZQ as being safe for
children as young as four years of age, but as parasite eggs can be found in children
within the first year of life, PZQ is widely used “off-label” (Sousa-Figueiredo et al.,
2012b). Hence, a common approach in high endemicity areas is to crush the 600 mg PZQ
tablets, mix with water or juice and then administer orally to pre-school-aged children at
a dose of 40 mg/kg (Coulibaly et al., 2012). In July 2012, a non-profit private public
partnership under Merck Serono’s leadership, named Paediatric Praziquantel
Consortium, was lunched with the aim to develop a paediatric PZQ formulation for
children younger than 6 years old. In particular, orodisperisble tablets of 150 mg PZQ
have been developed. Therefore, this scenario clearly highlights that the current standard
PZQ-based medications for pre-school children are not appropriate, making dose
adjustment and swallowing a challenging process in small children (Olliaro et al., 2013).
This research project focused on the development of a flexible dosage form suitable for
oral administration of PZQ to children from 2 to 6 years old. According to the EMA
guideline, powder, granules and pellets received “preferred acceptability” by this age
group of children (EMA/CHMP/QWP/805880/2012). In this study granule formulations
were investigated. Granules have the further advantage over tablets because they can be
given to children as solution or dispersion in beverages or administered with food, thus
improving the palatability of the formulations and the adherence to therapy. Moreover,
it is reported that the bioavailability of PZQ in adults is significantly influenced by
concomitant food intake and that the influence was greater with carbohydrates than with
lipids (Castro et al., 2000). As reported, the effect could be related either to some
Ramona Trastullo-University of Bologna 4. Case study 2
78
pharmaceutical factors (better tablet disintegration and drug dissolution) or to several
biopharmaceutical aspects (changes in hepatic blood flow or in the metabolism of the
drug during the first passage through the liver). Therefore, the development of granules
dispersible in water or in other common beverages such as fruit juice and milk was
investigated. The rationale for the choice of formulating dispersible granules is in line
with the characteristics of the drug itself, since it allows to minimize the dissolved PZQ
(acceptable palatability) in addition to maintaining the dose flexibility. The obtained
granules were characterized as regards the technological properties such as moisture
content, flowability, friability, particle size, drug content, solubility and dissolution
behaviour. The physicochemical properties by means of Fourier transformed infrared
(FT-IR) analysis, differential scanning calorimetry (DSC) and X-ray powder diffraction
(XRPD) were also characterized. Finally, granules stability in the solid state (30 °C and
75 % RH, trial conditions for climatic zones IVb) (World Health Organization, 2009)
and the short-term stability in milk were assessed.
4.2. MATERIALS AND METHODS
4.2.1. MATERIALS
Praziquantel (2-(cyclohexylcarbonyl)-1,2,3,6,7,11b—hexahydro 4H-pyrazino[2,1-
a]isoquinolin-4-one) was kindly donated by FATRO S.p.A., Ozzano Emilia, Bologna,
Italy. Flowlac 100 (a-lactose monohydrate, Meggle batch n. L0846), Neosorb P100T (D-
sorbitol, Rochette Freres batch n. E744B), Sweetpearl P90 (maltitol, Rochette Freres
batch n. EMR70), GalenIQTM 721 (isomalt, Platting-De GmbH batch n. L1213921U4)
and Sucrose (Platting-De GmbH batch n. 115404200) were kindly supplied by Giusto
Faravelli S.p.A., Milan, Italy. PVP K30, Lutrol micro 68 (poloxamer 188) and
Cremophor RH 40 (polyoxyl 40 hydrogenated castor oil) were kindly supplied by BASF,
Ludwigshafen am Rhein, Germany, while Avicel PH 102 (microcrystalline cellulose,
batch n. DT353743) was purchased from FMC Biopolymer and Tween 80 (polysorbate
80) was purchased from Merk. Milli-RX20 water (Millipore, Molsheim, France) was
used throughout.
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4.2.2. METHODS
4.2.2.1. PREPARATION OF GRANULES
The experiments were performed using a Mini-Glatt fluidised bed (Glatt GMbH, Binzen,
Germany) granulator equipped with a conical vessel volume of 0.75 L, three metallic
filters, a timing filter blowing (out time fixed set 8 s) and a product temperature probe
(±0.1 °C). A single granulation process (batch size 100 g) consisted of three steps:
mixing-heating, agglomeration and drying. First, the granulating liquid was prepared by
solubilizing in either the binder (PVP) or the surfactant (depending on the formulation)
and then by suspending the drug. The final suspension was sonicated three times for 1
min each to avoid nozzle clogging during the fluid bed processing. The powders were
placed at the centre of the bottom grid and were mixed by fluidising air with an inlet flow
rate of 9–10 Nm3/h at either ambient temperature or 70 °C. When the product temperature
reached approximately 30 °C, the pressure of the inlet flow air was then increased to 13
Nm3/h, reaching 18 Nm3/h at the end of the process and the binding solution (containing
or not the dispersed PZQ) was sprayed in the pressure range 1.12–1.14 bar onto the
powder bed. As a consequence, the temperature of the powders first decreased but then
gradually stabilized around 21–24 °C. The agglomeration phase lasted about 80–120 min,
according to the formulation. Once the binding solution finished, the drying phase (inlet
air at 50 °C) began and proceeded for about 3–5 min. At the end of the granulation
process, the granules were discharged (the temperature was around 30–35 °C), collected
and stored in polyethylene closed bottles and used for the characterization. The yield of
each granulation process was calculated by dividing the total weight of the granules by
the weight of the initial powder (in percentage). The composition of the different batches
is summarized in Table 14.
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Table 14. Composition of PZQ-loaded granules.
4.2.2.2. GRANULES CHARACTERIZATION
For the detection moisture content (MC) of the granules at the end of the granulation
process, the weight loss of the samples on thermal drying was measured using a Top Ray
(Alessandrini, Modena, Italy) thermal balance at a fixed temperature of 105 °C. In
particular, 3 g of each sample were heated in the thermal balance until a constant weight
was achieved (max 15 min). The equilibrium MC of those formulations melting lower
than 105 °C was ensured by keeping the batches in an oven at 40 °C overnight.
Flowability tests were performed on both the raw materials (PZQ and excipients) and the
finished product. The determination of bulk and tapped densities was assessed using a
tap density apparatus (Erweka SVM 12). Each sample was weighted and poured into a
100 ml graduated cylinder. The apparent volume V0 and the final tapped volume Vf after
1250 taps were measured and the mean of three determinations of each granules was
calculated. The Carr Index (CI %) values were calculated as follows:
CI (%) = (V0- Vf)/V0 x 100
The mean of the three determination (± SD) was reported. The friability was determined
by introducing 10 g of the granules (75–500 mm) together with 20 stainless steel beads
(mean diameter 3 mm) in a friabilator (Erweka TA20, Erweka GmbH, Germany) for 10
min at a rotational speed of 25 rpm. Then, the beads were removed and the granules were
sieved over a 75 mm sieve. The friability of the granules value was calculated as follows:
Batches Fluidized powder bed Aqueous binding solution/suspension
PZQ Flowlac
100
Avicel
PH102
Neosorb
P100
GalenIQ
721
PVP
K30
PZQ PVP
K30
Lutrol
F68
Cremophor
RH40
Tween
80
Amount (%, w/w) Amount (%, w/w)
1 10 35 45 - - 5 - 5 - - -
2 40 30 - - - 10 - 20 - -
3 40 - - - 30 - 20 - -
4 40 20 - - 10 - 20 - -
5 - 20 40 - 10 - 20 - -
6 - 30 40 - - - - 20 -
7 - - 40 30 - - 10 10 -
8 - - 30 45 - - - 15 -
9 - - 25 40 - 20 - - 15 -
10 - - 25 35 - - - 15 5
11 - - 35 30 - - 5 10 -
12 20 - 35 - 10 - - 15 -
13 35 - 20 - 10 - 15 - -
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Friability (%) = (Initial weight - Final weight)/Initial weight x 100
The size distribution of raw materials and granules was evaluated by sieve analysis, using
a vibrating shaker (Octagon Digital, Endecotts, London, UK) and 4 standard sieves
(Scientific Instruments s.r.l., Milano, Italy) of 75, 150, 250 and 500 mm.
4.2.2.3. DETERMINATION OF DRUG CONTENT
The determination of the PZQ content into the granules was determined by dissolving 15
mg of each sample in 20 ml of methanol. The sample was shaken for 30 min while
protected from light. Then, the solution/dispersion, depending on the batch formulation,
was filtered through a 0.20 mm nylon filter syringe, diluted 1:20 with mobile phase and
the drug content was assayed by HPLC. Each formulation was analyzed at least in
triplicate and the mean ± SD was reported. Reverse phase HPLC method was used for
the quantification of PZQ, using a method adapted from literature (Sun and Bu, 2012)
and validated according to a slight modification in column length. PZQ standard solution
was prepared by dissolving 10 mg of PZQ in 20 ml of methanol for few minutes and then
diluting 1:200 with mobile phase in order to have a final PZQ concentration in the
standard solution of 2.5 mg/L. The HPLC system consisted of two mobile phase delivery
pumps (LC-10ADvp, Shimadzu, Japan) and a UV–vis detector (SPD-10Avp, Shimadzu,
Japan). An autosampler (SIL-20A, Shimadzu, Japan) was used to inject samples (20 ml)
onto a Kinetex 5 mm C18 column (150 mm x 4.60 mm; Phenomenex, Bologna, Italy).
The mobile phase comprised of methanol and water (65:35 V/V). The flow rate was 1
ml/min and the detection wavelength was set at 220 nm. The retention time of PZQ was
about 5.5 mins and the run time was set at 12 mins. Quantitation was carried out by
integration of the peak areas using the external standardization method. Under these
conditions, the linear calibration curve of PZQ was obtained in the range of 0.3–10 mg/L
(r2 = 0.99996).
4.2.2.4. SOLUBILITY STUDIES
Solubility measurements of pure PZQ and of all granules were performed in 50 ml of
purified water, protected from light with aluminum foil. The samples were magnetically
stirred at 37 °C for 72 h. The suspensions were first filtered through a paper filter and
then through a 0.20 mm membrane filter and the filtrates were diluted 1:20 with the
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mobile phase and finally assessed by HPLC. The measurements were performed in
triplicate for each formulation and the mean ± SD was reported.
4.2.2.5. DIFFERENTIAL SCANNING CALORIMETRY (DSC) STUDIES
DSC analysis was performed using PerkinElmer DSC 6 (PerkinElmer, Beaconsfield,
UK) equipped with Pyris Software. The instrument was calibrated with indium and lead
for temperature, and with indium for the measurement of the enthalpy. Granules,
weighting 7–8 mg, were placed in an aluminum pan and heated from 25 °C to 240 °C at
a scanning rate of 10 °C/min under a nitrogen flow rate of 20 ml/min. For comparison,
the same procedure was followed for the raw materials. DSC analysis studies were then
repeated following storage.
4.2.2.6. FOURIER TRANSFORM-INFRARED SPECTRA (FT-IR) ANALYSIS
Studies of infrared spectra of pure drug, raw materials and granules were conducted with
an IR spectrophotometer (Jasco FT- IR A-200) using the KBr disc method. The samples
were diluted with KBr and then compressed into a tablet, 10 mm in diameter and 2 mm
in thickness, using a manual tablet presser (PerkinElmer, Norwalk, USA) at 300 kg for 3
min. Due to the pasty form of Cremophor RH40, Nujol instead of KBR was used for the
analysis of the raw material.
4.2.2.7. X-RAY POWDER DIFFRACTION (XRPD) ANALYSIS
Raw PZQ, granules and the corresponding physical mixture were studied by X-ray
powder diffraction technique using a X’Pert PRO (PANanalytical, Almelo, NL)
diffractometer with CuKa radiation (l = 1.5418 Å) monochromatized by a secondary flat
graphite crystal. The voltage was 40 kV and the current 20 mA. The scanning angle
ranged from 5 to 25° of 2u (minimum step size 0.001° of 2u).
4.2.2.8. IN VITRO DISSOLUTION TESTING
Dissolution tests in non-sink condition were performed to reproduce the actual condition
of a child of approximately 4 years old and 16 kg weight swallows the granules.
According to the therapeutic regimen of 20/mg kg three times a day, 320 mg of PZQ was
required, corresponding to 1.6 g of granules (when the theoretical drug loading was 20
% w/w). As dissolution medium, a volume of 200 ml and 50 ml of water, simulating
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different glasses of water, was used at room temperature. The studies ran over a period
of 120 min during which 2.2 ml aliquots of the release medium were collected at specific
time intervals. The samples were filtered (0.2 mm), diluted 1:20 with the mobile phase
and assayed for PZQ by HPLC. For comparison, the test was performed also on raw PZQ.
The mean of at least three determinations was used to determine the dissolved PZQ from
each formulation. Finally, the fine suspension obtained at the end of the dissolution test
in non-sink condition was added to a 500 ml of pH 1.5-buffer solution at 37 °C,
simulating the fasted state of a child (Batchelor et al., 2014), using the paddle apparatus
rotating at 100 rpm. The studies ran over a period of 60 min during which 2.2 ml aliquots
of the release medium were collected at specific time intervals. The samples were filtered
(0.2 mm), diluted 1:20 with the mobile phase and assayed for PZQ by HPLC.
4.2.2.9. LASER DIFFRACTION
The particle size measurements of the selected granules in terms of water dispersion were
carried out using the laser diffractometer (Malvern Mastersizer Hydro 2000, Malvern,
UK). Granules were dispersed in deionized water corresponding to 320 mg of PZQ in
200 ml and stirred for 1 min. The dispersions were then poured in the Hydro 2000
dispersion unit containing about 200 ml of dispersant medium until the obscuration
reached a value between 10 % and 20 %. The results were finally expressed as the
diameter (mm) at 10 %, 50% and 90 % of the distribution volume (dV10, dV50 and
dV90, respectively). The Span Index, given by the expression: Span Index = (dV90–
dV10)/dV50 was then calculated; a high value of this index indicated a wide size
distribution.
4.2.2.10. MANIPULATION OF GRANULES WITH DIFFERENT BEVERAGES
The solubilisation test was carried out by placing about 1.6 g of granules, depending on
the PZQ experimental content, in 200 ml of fruit juice (Santal mixed red fruits and Santal
orange juice) and of whole milk (Granarolo, 3.6 % fat) and gently stirred at room
temperature for up to 2 h. Sample aliquots were withdraw at specified times of 1.5, 3, 5,
10, 30, 60 and 120 mins. The sample taken from fruit juice (2.2 ml) was filtered with 0.2
mm syringe filter and diluted 1:20 with the mobile phase and injected in HPLC. In the
case of milk, the procedure reported by our group was used (Albertini et al., 2014).
Precisely 1.5 ml of an acetic acid solution (12 %, V/V) was added to the milk samples (5
ml), mixed for 1 min in a vortex (IKA-VIBRO-FIX) and then centrifuged for 12 mins at
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10,000 rpm, to precipitate the milk proteins. The supernatant was then collected, filtered
through a 0.2 mm filter syringe, diluted 1:20 with the mobile phase and then analysed by
HPLC as previously described.
4.2.2.11. STABILITY STUDIES
To assess the granule stability, storage studies were performed according to the ICH
stability zones; in particular 30 °C/75 % RH were set for accelerated trial conditions used
for all the climatic zones (I–IV). Therefore, granules were stored in PE closed bottles in
a forced air oven (Friocell, MMM medcenter, Germany) at 30 °C and the 75 % RH was
obtained using a saturated NaCl solution (Hsieh and Taylor, 2015).
4.3. RESULTS AND DISCUSSION
4.3.1. CHOICE OF EXCIPIENTS
Focusing on PZQ characteristics, there are concerns about the palatability of the final
dosage form as the racemic form (±) of the drug is characterized by a strong bitter taste
together with the high dose needed. Taste masking is normally accomplished by using
sweeteners and flavours. In this study different sweeteners, acting also as diluents, were
assessed: a-lactose monohydrate, sorbitol, maltitol, isomalt and sucrose. Lactose mostly
acting as diluent cannot be used in case of lactose intolerance and can induce diarrhoea;
sorbitol has also a laxative effect at high dose and it is non-cariogenic and non-calorific.
Maltitol is a polyol made by hydrogenation of the disaccharide maltose. The Joint
FAO/WHO Expert Committee on Food Additives has determined the “Laxative
Threshold Value” (LTV) for a number of polyols and maltitol is one of the less laxative
polyols. Sucrose may promote dental caries and should be avoided in patients suffering
from fructose intolerance. Isomalt, a mixture of two compounds, glucosyl-mannitol and
glucosyl-sorbitol, has a great bitter suppression activity with a low cooling effect (Sentko
and Willibald-Ettle, 2006). On the other hand, the use of these excipients associate with
the schistosomiasis treatment limits their daily intake since it is a one day treatment. In
addition, by minimizing drug in solution form, suspension improves palat- ability and
allows the increase in drug load as a reduced dose volume (Stryckley et al., 2008).
Moreover, in certain instances, the presence of a drug in suspension imparts more
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chemical stability to the formulation (Ali et al., 2014). Stryckley et al. (2008) also
reported that when the taste cannot be easily masked, a molecule can be formulated as
powders/ granules that is sprinkled immediately on beverage or food before swallowing.
PZQ is available as micronized form, thus with very poor flowability and wettability. To
reduce interfacial tension between solid and liquid during manufacture and to promote
the formation of a fine suspension before administration, several surfactants suitable for
oral administration, for instance Lutrol micro 68, Cremphor RH 40 (ADI = 0–25
mg/kg/day) and Tween 80 (ADI = 0– 10 mg/kg/day), were examined. Moreover it was
reported that Cremophor RH 40 can act as taste masking agent probably due to the
coating of taste bud receptors in the mouth (BASF, 2011). Before proceeding with
granulation experiments, the techno- logical properties of the excipients were analysed
in order to identify those most suitable to the process, also in relation to their effect of
taste masking, as well as safety issue in paediatric patients. The size, the powder flow
and the lipophilicity of the raw materials that can be processed in the fluid bed are the
main limiting factors of this technology. Very fine materials, such as micronized powders
and very hydrophobic powders are certainly not ideal for this technology. In the case of
PZQ, we were faced with a highly hydrophobic molecule (log P = 2.5) with limited ability
to flow (CI ~ 37 %) (Table 15). The ingredients selected for this study can be divided
according to their function in diluents (Avicel PH102, Flowlac 100), binders (PVP K30)
and sweeteners (Neosorb P100, GalenIQ 721, Sucrose, Sweet Pearl P90). Lactose is an
excellent choice of filler but can exhibit poor flow characteristics, so it is often combined
with free-flowing microcrystalline cellulose in wet granulation formulations. The results
of the particle size analysis and flowability are shown in Table 2. Flowlac 100 showed
excellent flow properties as the 95 % w/w of the powders was lower than 250 mm and
only the 10 % w/w was lower than 75 mm. GalenIQ and Neosorb showed similar flow
properties (CI ~ 15 %), although the latter had lower dimensions. Sucrose and
Sweetpearl P90 owing to the very fine particle size (more than 75 % are <75 mm) and to
the high Carr Index values (about 21 %) were discarded by the granulation trials.
Table 15. Particle size analysis and flowability, expressed as Carr Index value, of raw materials.
PZQ PVP K30 Avicel PH102 Flowlac 100 GalenIQ 721 Neosorb P100 Sucrose SweetPearl P90
Particle size (µm) Amount (%, w/w)
<75 100 20.38 30.13 11.52 2.51 10.49 78.00 72.41
75-150 - 52.38 39.38 34.44 23.09 53.85 18.60 20.59
150-250 - 22.38 30.25 49.50 34.34 34.87 3.40 7.00
250-500 - 4.88 0.25 3.70 39.96 0.80 - -
>500 - - - 0.88 0.10 - - -
Carr Index (%) 36.99 ± 0.03 23.4 ± 0.31 21.70 ± 0.80 6.67 ± 0.20 14.58 ± 0.01 14.93 ± 0.32 21.05 ± 0.60 21.46 ± 2.06
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4.3.2. GRANULATION EXPERIMENTS: 10 % (W/W) PZQ LOADING
In order to evaluate the performance of different excipients during the granulation
process and their effect on the granule properties, preliminary experiments were
performed using formulations with 10 % drug loading (batches 1–8). Among the several
available granulation technologies, the fluid bed was chosen because it produces less
dense and smaller granules and mostly more uniform particle size without oversized
granules than high shear mixer granulators (Gao et al., 2002). These characteristics are
fundamental for the PZQ granules that have to be dispersed in water and to quickly form
a finely subdivide aqueous suspension. In particular, granules were produced in a top
spray fluid bed using two different methods. In the traditional wet granulation the binding
solution is spraying on a powder mixture containing the drug. In these studies PZQ was
incorporated either in the powder mixture (batch 1), according to the traditional way, or
in the liquid phase containing the wetting agents (batches 2–8). The characteristics of the
obtained granules are summarized in Table 16 and their particle size distribution is shown
in Figure 7.
Table 16. Granulation yield, technological characteristics and solubility of granules.
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Figure 7. Particle size distribution of granules containing 10 w/w of PZQ.
As regards batch 1 formulation and its process-related parameters, a high-pressure drop
and thus, an improper fluidization required a frequent filter cleaning to incorporate the
fines (especially micronized PZQ) back in the process material, causing continuous
interruptions in the process. Therefore, despite the experiment was conducted until the
end, the yield was low (Table 16) and mostly a non-uniform distribution of PZQ within
the granule size fractions was obtained, as clearly shown in Table 17.
Table17. Drug content of the granule size fractions.
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To overcome this problem, PZQ was suspended in the aqueous liquid phase instead of
using the traditional binding solution based on PVP. This second approach resulted more
successful than the first one and all the other batches were prepared using this novel
strategy. Lutrol F68 (20 % w/w) and Cremophor RH40 (20 % or 15 % w/w) were selected
to ease the PZQ dispersion into water. Cremophor RH40 resulted the most suitable
excipient to prepare the PZQ suspension, allowing a faster dispersion of the drug. All
granules (batches 2-8) displayed good flow properties (Table 16), especially batch 4; the
distribution of PZQ within the granule size fractions (Table 17) improved respect to batch
1 and the drug content uniformity was greater in batches containing Cremophor RH40.
Conversely, these granules appeared fluffier than those containing Lutrol, resulting in
negligible values of friability (Table 16). Granulation of batch 7 failed due to the severe
filter clogging. Then the 15 % of Cremophor RH40 was selected as the moist suitable
concentration to produce 10 % loaded-PZQ granules (batch 8). These preliminary
granulation experiments showed that Flowlac 100, Neosorb and GalenIQ were all good
excipients for granulating PZQ inside the fluid bed. Due to its tendency to clog the filter,
a high concentration of PVP could not be used in the powder mixture. Despite the good
flow properties of Avicel inside the fluid bed, it was removed from the last two
experiments due to its water insolubility where in order to obtain a very fine water
suspension, PZQ would be the only dispersed powder. The results reported in Table 16
evidence that the PZQ granulation with hydrophilic excipients and solubilizers did not
increase the water solubility of the drug, suggesting no solid-state modification of the
drug during the granulation process. To investigate the drug solid state and possible
interactions between the components of the formulation, DSC, XRD and FT-IR analysis
were then performed. Figure 8 shows the DSC curves of raw materials (Figure 8a) and
of the batches 2–8 with the corresponding physical mixtures (Figure 8b).
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Figure 8. DSC curves of: (a) raw materials and of (b) loaded-PZQ granules in comparison with
their corresponding physical mixtures and raw PZQ.
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The DSC curve of PZQ showed only a single endothermic peak at 143.14 °C (ΔH = 98.3
J/g), in agreement with the melting point and enthalpy of fusion of the racemic form of
the drug (El-Arini et al., 1998; Liu et al., 2004; Passerini et al., 2006). DSC thermogram
of lactose monohydrate showed an endothermic peak at 143.3 °C, due to the loss of
hydration water, and a melting endothermic peak at 218.4 °C with decomposition. Lutrol
F 68 melted at 60.5 °C while PVP K30 and Avicel PH102 showed only a large
dehydration peak between 50 ° and 100 °C. Four crystalline polymorphs and one
amorphous form of sorbitol have been identified (Shur, 2009): it is reported a melting
point of 110–112 °C related to the anhydrous form, a g-polymorph at 97.7 °C and the
metastable form at 93 °C. As regards Neosorb P100T, it exhibited a melting peak at about
103 °C and two very small endothermic peak at 72.9 °C and at 145.8 °C, corresponding
to D-iditol and maltitol, respectively. GalenIQ 721 (isomalt) revealed two thermal events:
the first one at 66–99 °C and the second one at 140–165 °C, corresponding to the melting
of 6-O-a-D-glucopyranosyl-D-sorbitol (1,6-GPS) and of 1-O-a-D-glucopyranosyl-D-
mannitol dihydrate (1,1-GPM), respectively, as reported for a 1:3 mixture of 1,1-GPM
and 1,6-GPS (Fritzsching et al., 2009). Analysing the thermal behaviour of the 10 %
loaded-PZQ granules (Figure 8b), all the components evidenced a lowering of their
thermal event due to the dilution effect in the formulation. Batches 2–4 clearly showed
the melting peaks of Lutrol (at about 54 – 55 °C), the broader dehydration peak of lactose
shifted at about 120 – 125 °C (onset at 100 °C and end at 137 °C) and the lactose melting
at about 210 – 230 °C. The peak of the drug at 143 °C disappeared and may be hidden
by the lactose dehydration peak and/or by the partial dissolution of the drug into the
molten poloxamer. The curves of the corresponding physical mixtures were very similar
to those of granules, but it was possible to see a minimum variation of the baseline around
141 °C, probably imputable to the PZQ fusion. In batch 5, the PZQ melting peak was not
present in both the granulate and the physical mixture curves. Despite a higher scale
magnification, a weak broad endotherm between 114 °C and 138 °C attributable to the
drug was displayed in both samples and the enthalpy of fusion was very low (ΔH ~ 2 ±
0.6 J/g). In the case of batch 6, a clear peak at 138.8 °C (ΔH = 9.20 J/g) corresponding
to PZQ melting appeared only in the physical mixture, while a weak broad endotherm
between 111 °C and 136 °C attributable (ΔH = 1.97 J/g) to the drug can be detected at
high scale magnification of the granule DSC scan. Finally, in batch 8 the PZQ thermal
event was covered by the second melting peak of GalenIQ, both shifted at a lower value,
while the physical mixture clearly showed a peak from 135 to 153 °C (the PZQ peak was
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at about 138 °C). These results suggest either a possible modification of the drug solid
state or other interactions within the formulation. To clarify the PZQ solid state within
the granules, XRD analysis was then conducted on batches 5 and 6 selected as
representative samples containing Lutrol and Cremophor as surfactant, respectively. Due
to the complexity of the formulations, XRD analysis of granules were performed and
compared to the corresponding physical mixtures. The XRD trace of raw PZQ (Figure
9a) showed the characteristic scattering peaks of the racemic drug: double scattering
angles at 6.5° – 6.8° and 8° – 9.8° (2 ± ) (El-Subbagh and Al-Badr, 1998; El-Arini et
al., 1998; Liu et al., 2004). The XRD patterns of granules of batch 5 and 6 were
superimposed to those of the physical mixtures, indicating the maintenance of PZQ in its
original crystalline state. Therefore, interactions between the drug and the excipients
could happened in those formulations. The FTIR spectrum of PZQ (Figure 9b) shows
characteristic peaks at 2930 and 2852 cm-1, due to the C-H and C-H2 stretching vibration
and at 1650–1600 cm-1, due to the region of amide stretching vibrations. In particular, an
intense band with two separate and equal spikes at 1623 cm-1 and 1645 cm-1 correspond
to the C=0 and C-N stretching vibrations of the two tertiary amide groups. Moreover, the
peaks in the region 3300–3700 cm-1 and in the fingerprint region below 1500 cm-1
confirmed the racemic form of the drug (Liu et al., 2004).
The IR spectra of physical mixture and granules (batch 6) displayed the major bands of
each component alone, a broad band between 3000 and 3600 cm-1 due to -OH stretching
vibrations and to the formation of hydrogen bonding within the formulation and no new
bands or peak shifts were seen. The only functional groups in the PZQ molecule are two
tertiary amide moieties. These would only be expected to form weak intramolecular
interactions. In fact, looking at the amide region of batch 6 and of its physical mixture, a
clear splitting of the band appeared (1625 cm-1 and 1648 cm-1) and the stretching
vibration at 1625 cm-1 resulted in a higher intensity, especially for granules. Such
difference suggests that the carbonyl group could serve as proton acceptor in hydrogen
bond formation with the several -OH groups of the other excipients. This interpretation
can be supported by the smaller values for ΔH of granules than that of the physical
mixture, as shown in Figure 8b (Prankerd and Ahmed, 1992). This behaviour was also
observed for the other granule formulations (not shown). To confirm this hypothesis
different binary mixtures between PZQ and each excipient were prepared at the weight
ratio of the batches 1–8 (PZQ:Flowlac 1:4, PZQ:Neosorb 1:4, PZQ:GalenIQ 1:4,
PZQ:Lutrol 1:2 and PZQ:PVP 1:1 and 1:3) and analysed by DSC. The results (graph not
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shown) evidenced that Lutrol was the excipient that most influenced the PZQ enthalpy
of fusion and its melting peak, followed by Neosorb and GalenIQ.
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Figure 9. (a) XRD pattern of 10 % loaded-PZQ Granules (batch 5 containing Lutrol F68 and
batch 6 containing Cremophor RH40) in comparison with physical mixtures and raw PZQ; (b)
FTIR spectra of batch 6, physical mixture and raw materials.
4.3.3. GRANULATION EXPERIMENTS: 20 % (W/W) PZQ LOADING
To reduce the dose burden, subsequent studies were carried out to increase the drug
loading up to 20 % w/w. Five different batches (9 – 13) were thus prepared and Flowlac
100, Galeniq 721, Neosorb P100 and PVP K30 were incorporated in the powder mixture
(Table 14). Due to better processability, Cremophor RH 40, calculated at 15 % w/w on
the solid material was first selected. In particular, batch 9 was produced with similar
formulation to batch 8, to evaluate the feasibility of the process with double PZQ amount.
The granulation process was well controlled despite that the system was very sensitive
to the particle movement in the bed, to the spraying of the liquid and to the drying
capacity. The main disadvantage was the adhesion of the particles on the walls and upon
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filters. Nevertheless, the yield remained high at 94 % (Table 16). Then, the addition of a
different surfactant, Tween 80 (batch 10) and the combination of Cremophor RH40 and
Lutrol (batch 11) was also examined to evaluate their influence both on the formation of
the PZQ suspension and on particle aggregation and granule densification. In fact, it is
reported that surface active agents improve the fluidized bed granulation (Parikh and
Mogavero, 2005). Comparing the different surfactant-based suspensions, the stirring rate
must be low in presence of Tween 80 to reduce foam; while Lutrol and Cremophor do
not produce foam but required enough time to obtain a fine PZQ dispersion, especially
with Lutrol at 20 % w/w. In fact, in batch 13 the amount of Lutrol was decreased to 15
% to ease the formation of the suspension. Experiment 11 failed due to the whole
adhesion of the powder bed on the walls of the equipment. PVP was then reintroduced
within the formula (batch 12 and 13) to increase the granule strength and reduce granule
friability. All granulation experiments had a high process yield and granules displayed a
very low relative humidity and good flow properties (Table 16). The main particle size
of granules (50 – 70 % w/w depending on the formulation) ranged from 150 to 250 mm
(Figure 10) and all granules had uniform distribution of the drug within the size fractions
(Table 17).
Figure 10. Particle size distribution of granules containing 20 % w/w of PZQ.
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This fact indicates size uniformity of the atomizing suspension and confirms the optimum
selection of the liquid spray rate and the nozzle atomizing pressure. Results from detailed
analysis of batches 9, 10 and 12 containing Cremophor RH40 show evidence that the
addition of a second surfactant (batch 10) did not improve the granule characteristics as
both the drug content uniformity and PZQ solubility decreased respect to batches 9 and
12. Finally, in the last experiment, Cremophor RH40 was replaced with Lutrol and the
lactose amount was increased to enhance the powder flow in the fluid bed. The obtained
granules were denser than batch 12 with a good friability (Table 16) and a uniform PZQ
distribution within the size fractions (Table 17). Moreover, doubling the drug
concentration, the solubility of granules was similar to that of raw PZQ and of 10 % PZQ-
loaded granules. The thermal analysis results from these batches is reported in Figure 11.
Figure 11. DSC curves of 20 % loaded PZQ granules in comparison with their corresponding
physical mixtures.
Batches 9 and 10, having similar composition, showed analogous DSC traces: granules
displayed a broad endothermic peak comprised of the PZQ melting peak and of the 1,1-
GPM moiety of GalenIQ; while physical mixtures clearly evidenced a sharper peak
referable to both PZQ and GalenIQ in the range 130– 155 °C. The DSC curve of granules
of batch 12 was similar to that of corresponding physical mixture. In both cases, a weak
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broad peak included the dehydration peak of lactose at about 120 °C and the PZQ peak
from 126 to 136 °C, both hardly distinguishable. Considering the higher drug content of
this batch than the 10 %-loaded ones, the lowering of the drug melting event and of its
enthalpy suggest that some modification/interactions might be occurred, even in the
physical mixture. To verify the solid state of the drug in batches 9, 10 and 12, X-Ray
Powder Diffraction (Figure 12a) was assessed and the results confirmed that PZQ
remained in its original crystalline state both within granules and physical mixtures. The
FTIR analysis (Figure 12b) show similar spectra of batch 12 granules and the
corresponding physical mixtures indicating the formation of hydrogen bonding between
the components of the formulation, as previously observed for batch 6. These results
show the absence of strong interactions between PZQ and excipients after the granulation
process. On the contrary, in batch 13 (Figure 11) the endothermic peaks of each
component were lowered due to the presence of Lutrol but clear and quite distinct: Lutrol
at 54 °C, Neosorb at 100 °C, dehydration peak of lactose at 120 °C, PZQ at 135 °C (ΔH
= 3.3 J/g) and the melting peaks of lactose at 188 and 210 °C. The DSC curve of the
physical mixture was superimposed, suggesting the absence of drug modifications and
of further chemical interactions, apart from hydrogen bonds.
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Figure 12. (a) XRD pattern of 20 % loaded-PZQ granules in comparison with physical
mixtures and raw PZQ; (b) FTIR spectra of batch 12, physical mixture and of the raw materials.
The next step of the study tried to reproduce the actual condition in which a child of 4
years and of 16 Kg weight might assume the granule suspension. According to the
therapeutic regimen, 320 mg of PZQ are required three times a day, corresponding to 1.6
g of granules. Therefore, in these experiments non-sink condition was used as the PZQ
dose was higher than its saturated solubility (Table 16). Batch 13 (main fraction) was
selected for these experiments, having a drug loading equal to the theoretical one. The
solubilisation test was first performed in 200 ml of water simulating a glass of water. The
system was stirred at room temperature and granules formed a very fine suspension easy
to disperse in water unlike the pure drug, as shown in Table 18.
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Table 18. Images of PZQ and of the granule dispersion in different liquid substrates taken at
different time.
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In particular, PZQ formed a coarse dispersion in which particles were still floating after
30 min, while granules formed a very fine opalescent suspension. The analysis of the
particle size distribution revealed that dispersed particles had dV10 = 6.40 mm, dV50 =
16.80 mm and dV90 = 39.92 mm with a Span Index = 1.994. The amount of PZQ
solubilized in the aqueous suspension is shown in Figure 13.
Figure 13. Dissolution test of granules and raw PZQ in water in non-sink condition.
After 5 min the PZQ dissolved from batches 9, 12 and 13 was about 12 % while only the
3 % of drug was dissolved in the same time. In the case of batches 9 and 12, the dispersion
in water was very prompt: the granules did not float and were immediately wetted due to
the presence of PVP and Cremophor without the formation of foam. Already after few
minutes, the suspension was free of coarse particles and aggregates, and the walls of the
beaker did not show residues of particles. Batch 10 dispersed well, but less quickly than
batches 9 and 12, probably due to the not synergistic effect of the two surfactants. As
regards batch 13, granules showed a similar behaviour to batch 12 and were quickly
wetted. At the end of the test, it was possible to observe the formation of a very fine
foam, mainly adherent to the walls of the beaker without any residual particles.
Considering the granule dispersion in a lower volume (for instance 50 ml), the PZQ
saturation solubility was promptly reached displaying a plateau after 5 min and the
amount of PZQ dissolved from granules of batch 13 was about 3 % (data not shown).
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The appearance of the final suspension was similar to that obtained in 200 ml of water,
with a milky appearance. Therefore, batch 12 and 13 displayed very similar
characteristics and a similar solubilisation ability towards poorly soluble PZQ. In both
cases, Cremophor RH 40 and poloxamer 188 did not demonstrate a high solubilisation
capacity, but they were very useful to improve the PZQ wetting and dispersion during
the granulation set up and to enable the formation of the final water suspension prior to
oral administration. After granule dispersion the amount of PZQ available for taste
perception was very low (3 %) or using a higher volume at least reached the 12 %, which
could make the medicine unpleasant to take. Adding the finely subdivide 200 ml aqueous
suspension (batch 13) to 500 ml of buffer solution pH 1.5 (Figure 14) simulating the
fasted state of a child (Batchelor et al., 2014), the dissolution profiles revealed that after
30 min about the 50 % of the drug was dissolved, reaching the equilibrium solubility of
the drug (batch 13) in this medium. An increase of dissolved drug available for adsorption
might create sink condition and might saturate the PZQ biotransformation pathways
leading to an increase of the PZQ bioavailabilty. Therefore, the potential effect of
enhanced dissolution of PZQ might require a dose adjustment and a specific paediatric
clinical study design.
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Figure 14. Comparison between the dissolution rate of the reconstituted suspension in pH 1.5
buffer and of granules (batch 13) and raw PZQ in water.
4.3.4. MANIPULATION OF GRANULES IN DIFFERENT FOOD SUBSTRATES
To ameliorate children’s compatibility, the dosage form was manipulated with different
beverages. A current practice of mixing drug products with food/beverage involves the
use of milk or other common foods as ice cream, yoghurt, fruit puree and jam, used as a
prequel or chaser for the medicine either as a reward or to aid taste masking. Even EMA
recognizes that the practice of dosing drug products with food does occur
(EMA/CHMP/QWP/805880/2012). On the other hand, manipulation can also involve
several risks of wrong dosage, instability and incompatibility, if not previously studied
and indicated on labels and a simple process of reconstitution of oral powder can become
a risk even for safety (World Health Organization, 2007). Therefore, the study focused
the attention on the granules manipulation with milk and on the short-term stability of
the samples in this substrate. Moreover, in addition to milk, different fruit juices, which
are commonly used to dose medicines to children, were tested. The pH of these beverages
is likely to vary across types of juice and brands of juice and may have a severe impact
on the stability of the active ingredient. In Figure 15a are reported the dissolution profiles
of the granules (batch 13) in the various substrates compared to PZQ in pure water.
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Figure 15. (a) Solubilisation rate of PZQ from batch 13 in different drinking media; (b)
Chemical stability of PZQ and of granules (batch 13) in milk.
The recovery in milk was about 14 % after 5 min, indicating that the solubility of the
PZQ was higher to that in water and fruit juice. This fact can be attributable to the ability
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of the milk to emulsify the drug by forming micelles. In both the fruit juices, the
solubilisation of PZQ decreased (≤ 1 %) due to the lower amount of free water because
of the high concentration of dissolved sugars within the juice. Further, the pH of milk
(5.75) and of juices (red juice = 3.24, orange juice = 3.28) did not change after the
addition of granules. The chemical stability of the dosage form in milk was then
investigated in 2 h by HPLC (Figure 15b). Due to minimum amount of PZQ dissolved
after granule dispersion into the juices, their short-term stability was not assessed. No
modification of the drug peak was observed during time (if not an increase of the peak
area related to the solubilisation of PZQ in the first minutes), indicating that PZQ was
stable in this medium, at least for the examined time.
4.3.5. STABILITY UPON STORAGE
Granules of batch 13, which showed the best properties, were subjected to stability in
different conditions and possible solid-state modification and/or interaction within the
components of the formulation were investigated by means of DSC. The results reported
in Figure 16 show that the DSC trace of the physical mixture and granules at t0 were very
similar. In particular the following peaks, Lutrol F68 melting peak at 55 °C, slight
deviation of the baseline at 74 °C and endothermic peak at 100 °C due to Neosorb
melting, two narrow spikes at about 120 °C and 133 °C due to Flowlac and PZQ and the
final melting peaks of Flowlac at 185 °C and 207 °C followed by decomposition,
remained unchanged. The DSC traces of granules stored at ICH zone IVb conditions (30
°C/75 % RH) reveal no significant modifications of the DSC curves apart from the
disappearance of the small peak at 74 °C. Furthermore, a slight shift of the first melting
peak of lactose at higher temperature was evidenced. Therefore, these results indicate
that PZQ remained in its original crystalline form and the storage conditions at high
temperature and humidity did not alter the stability of the granules. In fact granules
displayed the same flowability (CI % = 15.80 ± 0.75), despite the permeability of the
polyethylene container to water vapour.
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Figure 16. Stability of batch 13 at different storage conditions.
4.4. CONCLUSION
An age-appropriate flexible dosage form intended for the oral administration of PZQ to
paediatric patients was developed. A number of formulation challenges related to PZQ
characteristics (e.g. low solubility, high dose, bad taste and very poor flowability) were
faced. The formulations were considered in relation to dosage and pharmaceutical form
and targeted to younger children, which have difficulties in swallowing tablets currently
available on market. In particular, safe excipients (lactose, sorbitol and poloxamer 188)
were used to obtain granules loaded with 20 % w/w of PZQ. The production process
based on fluid bed wet granulation was rapid and easy to control. Granules displayed
good flow properties and a uniform distribution of the drug within the size fractions.
Granules administered with either water, milk or fruit juice formed a fine suspension that
can be easy to swallow and their ease of dose manipulation may contribute to increased
compliance and drug bioavailability. Finally, the results of the short-term stability in milk
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and upon storage can support the use of this formulation for the potential treatment of
schistosomiasis in children of 2–6 years old. Further studies are in progress in order to
optimize praziquantel treatment for preschool-aged children focusing on different
technological strategies able to enhance the drug solubility and hence to reduce the final
dose to be administered.
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5. CASE STUDY 3
DEVELOPMENT OF POLYELECTROLYTE
COMPLEXES AS POTENTIAL TASTE
MASKING SYSTEMS IN PAEDIATRIC-
FRIENDLY FORMULATIONS
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5.0. PAEDIATRIC CHALLENGE: TASTE MASKING
5.0.1. TASTE MASKING BY POLYELECTROLYTE
COMPLEXES
Following the implantation of European Regulation with respect to medicinal products
for paediatric use, scientist community has to speed up for making medicine available
for children by encountering multiple problems of paediatric formulation. Indeed, the
taste of oral medicine is one of the most crucial factors influencing adherence to
therapeutic regimens and therapeutic outcomes. Bad taste of medicine may represent the
failure of the treatment.
As reported in the introduction of the thesis, numerous methods are employed for the
assessment of the taste and for effective taste masking, for example, use of flavours and
sweeteners, microencapsulation, complexing with ion exchange resin, use of insoluble
prodrugs, formation of inclusion complexes, gelation, liposome, multiple emulsions,
granulation, and so forth.
The following work focused on polyelectrolyte complexes based on natural molecules,
protein and polysaccharide, as potential encapsulating agent of active pharmaceutical
ingredients characterized by bitter taste. The drug molecule fits inside the complex,
through chemical bonds or by physical entrapment. If the complex is stable in the
environment of the oral cavity and at the salivary pH, it covers the molecules of the drug,
decreasing the amount of particles exposed to taste buds, thereby reducing the perception
of bad taste.
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5.1. INTRODUCTION
Nowadays, there is a strong interest in designing supramolecular structures to provide
multifunctional particles with potential stabilizing, encapsulating and texturing
properties for both pharmaceutical and food applications (Jones et al., 2010). These
innovative systems can be useful for the encapsulation of pharmaceutical compounds,
nutraceuticals, vitamins, flavors, bioactive peptides, colors and preservatives. In the
specific case of active pharmaceutical ingredients, the main purposes of their
encapsulation are both the delivery to specific sites of action and the taste masking of
their bitter taste (McClements, 2015). In fact, once the drug has been encapsulated,
through electrostatic interactions, hydrophobic or covalent binds, depending on the
nature of the molecules involved, it may be possible to design the particle properties as
to deliver the drug to a specific site of action, such as mouth, stomach, small intestine or
colon (Jones et al., 2011). Moreover, this system is also of particular interest for the
administration of drugs in specific groups of patients, like the paediatric population, in
which the unpleasant taste of the drug administered by oral route represents a big
challenge. In fact, the drug entrapped in the complex is not able to interact with the taste
buds, and thus the bitter taste is masked.
Another property of the multifunctional particles is the stabilization of the so called
‘Pickering emulsions’, system in which they can surround the oil droplets, reducing the
interfacial tension (Guzey et al., 2007, Binks, 2002, Frasch-Melnik et al., 2010).
In fact, over the past decades, surfactant-free emulsions have attracted increasing
attention to avoid the well-known adverse effects associated with some small molecules
surfactants on human health (Soltani et al., 2015). Solid particles can replace surfactants,
since they are able to stabilize the emulsions by means of their adsorption at the interface.
Partial wetting of the surface of the particles by water and oil is the origin of the strong
anchoring of them at the oil-water interface; thus, particles do not need being amphiphilic
to ensure the stabilization of the emulsion (Chevalier et al., 2013,  Guzey et al., 2004,
Moreau et al., 2003).
Multifunctional particles include polyelectrolyte complexes, based on proteins and
polysaccharides, which are able to encapsulate active pharmaceutical ingredients and
surround the oil droplets of emulsions. Architectural manipulation of the oil-water
interface through conjugation of proteins with polysaccharides is a widely attended
approach for increasing emulsion stability. In this way, a protein-stabilized interface is
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deposited electrostatically with an oppositely charged polysaccharide, leading to an
increase of steric hindrance (Hu et al., 2015, Hu et al., 2015).
Pickering emulsions have been studied also for their ability to encapsulate lipophilic
drugs, to control their delivery in specific site of action and to ensure their protection
against the external environment. Even in this case, drugs entrapped inside the droplets
of oil are not able to interact with the taste buds in the mouth, ensuring the masking of
bitter taste and improving the compliance of children (Frelichowska et al., 2009, Simovic
et al., 2007).
The main idea of the work is based on the development of an innovative structuring
approach that enables the simultaneous encapsulation and targeted delivery/release of
two actives within/from simple oil-in-water (o/w) emulsions. The system is based on an
external aqueous phase and an internal oil phase, stabilized by a polyelectrolyte complex
able to place at the interface between the two phases and loaded with the first active. The
second active is solubilized into the oil phase of the emulsion.
In particular, the present work is mainly focused on the development of
proteins/polysaccharides complexes loaded with the first active. Whey protein and pectin
were chosen as natural and nontoxic compounds, especially suitable for the
administration in children.  Whey proteins are a group of milk proteins classified as
globular proteins consisting of mostly β-lactoglobulin and α-lactoglobulin. They can
adsorb to the oil droplet surface, reduce the interfacial tension and form a protective
membrane around the droplets to prevent the aggregation (Teo et al., 2015, Gunasekaran
et al, 2007). Pectin is a nontoxic, biodegradable, biocompatible and anionic
polysaccharide extracted from the cell walls of most plants, such as apples, oranges and
pears. It is characterised by gelling property and branched heteropolysaccharides, which
consists predominantly of linear chains of partially methyl-esterified (1,4) -d-
galacturonic acid residues. Depending on the degree of substitution of d-galacturonic
carboxyl groups by methoxyl groups (OCH3), defined as the degree of esterification
(DE), pectins are classified as high-esterified pectins (DE > 50 %) or low-esterified
pectins (DE < 50 %) (Marciel et al., 2015). Caffeine, a methyl xanthine alkaloid, was
chosen as a model drug for its bitter taste. Complexes were loaded with caffeine and
analysed in terms of the particle size, the zeta potential, the encapsulation efficiency, the
stability and the in vitro release profile in different fluids simulating the gastrointestinal
tract.
Ramona Trastullo-University of Bologna                                                5. Case study 3
114
The second part of the work will consider the preparation and characterization of
emulsions as a system for the simultaneous encapsulation and release of two different
active compounds.
5.2. MATERIALS AND METHODS
5.2.1 MATERIALS
Pectin Betapec RU 301 (PEC, DE > 50 %, pKa = 3.5) was donated by Herbstreith & Fox
KG (Neuenbürg, Germany). It is a beige powder of neutral smell, extracted from sugar
beet chips and soluble in water to a viscous and colloidal solution.
Whey Protein (WPI, MW 14000-18000 Da, IEP = 5.2) was purchased from Volac
(Orwell, United Kingdom). The composition of the whey protein was: 91.0 % w/w
protein, moisture 4.0 % w/w, fat 1.0 %, ash 3.5 % w/w and lactose 0.5 % w/w. Mineral
content of the WPI was: 0.50 % w/w Ca, 0.65 % w/w P, 0.10 % w/w Na, 0.15 % w/w K,
0.02 % w/w Mg, and 0.02 % w/w Cl.  Caffeine (anhydrous) (CAF, MW 194.19 g/mol)
was purchased from Sigma-Aldrich (UK).
Sodium hydroxide pellets (NaOH) and hydrochloric acid (HCl) concentrated were
purchased from Fisher Scientific Chemical (Loughborough, UK) and used to prepare
diluted solutions in distilled water.
All the other chemicals and solvents used for the preparation of buffers were of
analytical grade and purchased from Sigma-Aldrich (UK).
5.2.2. METHODS
5.2.2.1. PREPARATION OF BIOPOLYMER SOLUTIONS
In order to obtain polyelectrolyte complexes, preliminary solutions of the two
biopolymers were prepared. PEC and WPI were both solubilized in Millipore water, at
double the concentration with respect to the final concentration needed in each case. PEC
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was stirred with a magnetic agitation for at least 2 h and slightly heated to facilitate the
dissolution and ensure the hydration of the powder in order to obtain 0.4 % (w/w) and
0.8 % (w/w) solutions. The pH of the final solutions was around 4, and adjusted to 7 with
diluted NaOH. WPI was dissolved at room temperature until complete dissolution of the
powder for at least 2 h, using a magnetic stirrer to obtain 1.0 % (w/w) and 2.0 % (w/w)
solutions. The final pH of the solutions was adjusted to 7 with few drops of diluted
NaOH.
5.2.2.2. COMPLEX FORMATION
The complex formation involves the mixing of 50/50 (v/v) WPI and PEC solutions at pH
7, a value at which they are both negatively charged and the electrostatic attraction does
not occur. In particular, 0.4 % (w/w) of PEC solution was added to 1.0 % (w/w) of WPI
solution and 0.8 % (w/w) of PEC solution was added to 2.0 % (w/w) of WPI solution, by
mixing with magnetic stirrer at room temperature for 30 min. The final contents of the
solutions containing the two biopolymers were 0.2 % (w/w) PEC and 0.5 % (w/w) WPI,
0.4 % (w/w) PEC and 1.0 % (w/w) WPI respectively, with total biopolymer
concentrations of 0.7 % w/w and 1.4 % w/w respectively.  Complex formation was
achieved by acidifying the mixtures at pH 4 with few drops of HCl 1M and leaving them
at room temperature for 1 h under gentle magnetic agitation. In these conditions,
electrostatic interactions can occur between PEC, negatively charged, and the positive
charges of WPI (Cooper et al., 2005, Hong et al., 2007, Santipanichwong et al., 2008,
Peinado et al., 2010). Caffeine (CAF) was added in the protein solutions before
complexing, at a final concentration of 5 mg/ml, 10 mg/ml and 20 mg/ml. A thermal
treatment of the complex was also investigated. It has been applied in order to overcome
some obstacles that limit the widespread application of complex coacervation, as the low
stability over a large range of pH values, the possible increase in the mean particle size
and eventually the macroscopic phase separation. (Kruif et al., 2014, Hong et al., 2007,
Jones et al., 2009). For this reason a controlled heating of electrostatic complexes
conducted after complexation, has been also evaluated. This has been proposed to
increase the stability of complexes to environmental conditions such as changes in pH
and ionic strength. One part of each complex at pH 4 was immediately stored at 4 °C,
one part was placed in water bath at 95 °C and heated  at 87 °C for 1 min. The solutions
were kept stirred using a submersible magnetic stirrer, cooled down with ice and stored
at 4 °C.
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5.2.2.3. COMPLEX CHARACTERIZATION
Particle size measurements.
PEC-WPI complex size analysis was performed by dynamic light scattering (DLS) using
the Zetasizer Nano Series (Nano ZS, Malvern Instruments, Worcestershire, United
Kingdom). The instrument infers the size of the particles from measurements of their
translational diffusion coefficients. Two drops of concentrated PEC-WPI complex
suspension were diluted into 50 ml of water at pH 4; this was immediately transferred to
a polystyrene cuvette and analyzed. The analyses were conducted on at least three freshly
diluted samples.
Zeta-potential analysis.
Zeta-potential analyses were performed on the Zetasizer Nano Series (Nano ZS, Malvern
Instruments, Worcestershire, United Kingdom), equipped with MPT-2 multipurpose
titrator. The zeta-potential was determined by measuring the direction and velocity that
the molecules or complexes moved in the applied electric field. A mathematical model
was used by the software to convert the electrophoretic mobility measurement into zeta-
potential values. For the analyses of complexes, the suspension was diluted in the same
way as for the size analyses and added to a zeta cell. Zeta-potentials were reported for
triplicate readings of three freshly diluted samples.
5.2.2.4. ENCAPSULATION EFFICIENCY
In order to evaluate the amount of CAF entrapped inside the complexes, encapsulation
efficiency (EE %) was determined for each sample. 1.5 mL of complex suspension were
transferred to separate Eppendorf tubes and centrifuged for 60 min at 15,000 rpm and 20
°C; this centrifugation time was determined in preliminary experiments as sufficient to
separate the complex as an insoluble pellet. The supernatant was isolated, filtered with
0.2 µm filters and analysed by HPLC, using an Agilent 1100 series chromatography
system. 20 μl of each sample was injected onto a reverse phase Onyx monolithic C18
column, (100 x 4.6 mm). The mobile phase was prepared by mixing 500 ml of deionized
water and 500 ml of methanol and the flow rate was 0.8 ml/min. UV detection was
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performed at 275 nm. A calibration curve showed that the peak area was linearly related
(r2 = 0.999) over the CAF concentration range 0.125-10 mg/ml.
EE % was then calculated with the following equation:
EE % = (1- Csup/Cmax) x 100
Where Csup represents the concentration of the CAF isolated in the supernatant after
centrifugation (it is assumed that this concentration is that which was not complexed),
and Cmax is the theoretical concentration of CAF previously added into the system. Some
preparative conditions were modified in order to increase the CAF encapsulation
efficiency, as the total biopolymer concentration (TBC), the concentration of CAF and
the temperature of complexation. All the analyses were conducted in triplicate.
5.2.2.5. STABILITY STUDIES
Once biopolymer particles have been formed, it is important to establish their stability in
particular conditions. This type of information is useful to determine the range of
commercial products where the biopolymer particles can be successfully utilized. In
order to assess the stability of the complexes, each sample was stored at 4 °C for 30 days
in closed glass bottles and the zeta-potential, the size and the encapsulation efficiency
have been evaluated in predetermined time points, by using the same methods described
above.
5.2.2.6. IN VITRO DISSOLUTION ANALYSES
In vitro dissolution studies of CAF from the complexes were carried out using a USP II
paddle apparatus (Tablet Dissolution Tester DIS 6000, Copley Scientific), rotating at 100
rpm and at constant temperature of 37 °C. Glass vessels of convenient capacity and size,
and covered with lids to minimize and avoid the evaporation of the fluids were used.
Different biorelevant media were chosen to mimic the gastrointestinal tract and to
evaluate the potential of these complexes to enable drug release at specific locations
(Kostewicz, et al, 2014).  The oral cavity has been mimicked using 25 ml of buffer at pH
= 7.4 (potassium dihydrogen phosphate 12 mM, sodium chloride 40 mM, calcium
chloride 1.5 mM, sodium chloride to pH = 7.4, demineralized water to 1 L). Dissolution
was monitored over a period of 60 sec in this medium. The stomach has been simulated
with 50 ml of Simulated Gastric Fluid (without pepsin) USP-30NF45 at pH < 2 (sodium
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chloride 2.00 g, HCI 1.0 M 70.0 mL, deionized water to 1 L), during a period of 30 min.
Finally, 1000 mL of Blank Fasted State Simulated Intestinal Fluid (FaSSIF) was used at
pH = 6.8 to mimic the intestinal environment (sodium hydroxide pellets 0.348 g, sodium
dihydrogen phosphate 3.954 g, sodium chloride 6.186 g, deionized water to 1 L) over a
period of 2 h. At predetermined time points 2 ml samples were withdrawn, filtered (0.2
μl), analyzed for drug content using HPLC and replaced with fresh 2 ml (preheated at
37°C) dissolution media after each sampling. Each experiment was performed in
triplicate.
5.3. RESULTS AND DISCUSSION
5.3.1. COMPLEX FORMATION
Polyelectrolyte complexes based on whey protein and pectin were prepared by
electrostatic attractions between oppositely charged groups, anionic polysaccharide and
cationic protein surface groups, under pH controlled conditions. Complexes were formed
at pH 4, which is a value less than the isoelectric point of WPI (IEP = 5.2), where protein
possesses a net positive charge and less than the pKa of PEC, (pKa = 6.3), where pectin
is negatively charged. This provides a system in which electrostatic interactions can
occur, eventually resulting in charge neutralization of the protein-polysaccharide
complex and subsequent coacervation or precipitation.
The thermal treatment has been applied in order to overcome some obstacles that limit
the widespread application of complex coacervation, as the low stability over a large
range of pH values, the possible increase in the mean particle size and eventually the
macroscopic phase separation. (Kruif et al., 2014, Hong et al., 2007 , Jones et al., 2009).
For this reason a controlled heating of electrostatic complexes conducted after
complexation, has been also evaluated. This has been proposed to increase the stability
of complexes to environmental conditions such as changes in pH and ionic strength.  The
compositions of the different formulations are reported in Table 19.
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Table 29. Composition of CAF loaded complexes.
Formulation WPI (%) PEC (%) CAF (mg/ml) heated unheated
F1a 0.5 0.2 1.0 X
F1b 0.5 0.2 1.0 X
F2a 0.5 0.2 5.0 X
F2b 0.5 0.2 5.0 X
F3a 0.5 0.2 10.0 X
F3b 0.5 0.2 10.0 X
F4a 1.0 0.4 10.0 X
F4b 1.0 0.4 10.0 X
F5a 1.0 0.4 20.0 X
F5b 1.0 0.4 20.0 X
5.3.2. COMPLEX CHARACTERIZATION
Particle size measurements.
Particle size distribution is one of the most important factor influencing complex
physicochemical properties and functional performance, such as stability and release
characteristics. The mean particle diameter of the nanoparticles was measured at pH 4
and the results are shown in Figure 1. There are no significant differences among the
formulations; unheated complexes demonstrated a slight increase in the particle diameter
from F1a to F5a, with a mean value of about 363 nm. In general, there are no differences
between unheated and heated complexes, for each formulation, except for F3, where
heated complex has a diameter significant less than unheated complex. Heated
complexes apparently remained more stable respect to the others with a mean value of
about 304 nm. This means that the biopolymer weight ratio, the total biopolymer
concentration and the concentration of CAF in the system did not affect the size of the
particles. The thermal treatment instead seemed to permit more stability and a reduction
of the main particle size (Jones et al., 2011).
Zeta potential analysis.
The electrical characteristics of biopolymer particles, depending on the type,
concentration and localization of any ionized groups at their surface, and measured at
pH 4, was not strongly affected by the modifications of the preparative conditions (data
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showed in Figure 17), showing no significant differences among the different
formulations.  Zeta potential values resulted around -22 mV and -22.5 mV for unheated
and heated complexes, respectively. The negative charge of the complexes confirms the
core-shell structure and is the result of the placement of the anionic PEC molecules onto
the surface of cationic WPI core. The fact that the net charge on the nanoparticles was
negative is due to the formation of an outer coating and not all the anionic groups of the
pectin molecules were bound to the cationic groups of the protein molecules (Hu et al.,
2015). The CAF was included inside the complexes and it did not affect their electrical
surface properties.
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Figure 17. Complex characterization: particle size and zeta potential of unheated (white) and
heated (grey) complexes.
5.3.3. ENCAPSULATION EFFICIENCY
Biopolymer particles could be developed to encapsulate, protect and release active
pharmaceutical ingredients, such as CAF.  The drug should be mixed with protein-
polysaccharide solution at ambient temperature, before the formation of the complex and
the heating of the system. Preliminary experiments were carried out in order to verify the
stability of the drug in our experimental conditions, and they showed that CAF does not
undergo any modifications at 87 °C (Tm= 234-236.5 °C).
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The measurement of encapsulation efficiency is an efficient method to verify the ability
of the system to incorporate the active and to determine its concentration within the
nanoparticle. PEC-WPI complexes were prepared with a final concentration of 5 mg/ml,
10 mg/ml and 20 mg/ml, as showed in Table 19, and the results suggest that the increase
of CAF concentration, in both unheated and heated complexes, led to an increase of the
encapsulation efficiency of the system (Figure 18). In particular, complexes prepared
with 20 mg/ml of CAF, achieved an encapsulation efficiency around 50 % (52.66 ± 1.07
and 49.11 ± 3.16 for unheated and heated complexes respectively). This behaviour could
be mostly attributed to the fact that the more concentration of CAF, the more chances to
create physical and chemical interactions between the active and the biopolymers. All
the other modifications of the preparative conditions, did not significantly affect the
encapsulation efficiency of CAF inside the complexes.
Figure 18. Encapsulation efficiency % of CAF inside complexes for each formulation.
Ramona Trastullo-University of Bologna                                                5. Case study 3
123
5.3.4. STABILITY STUDIES
Formulations F5a and F5b, which showed the best properties in terms of encapsulation
efficiency, were subjected to stability studies, under storage in closed glass-bottles at 4
°C for 30 days. The stability, evaluated in terms of zeta potential, particle size and
encapsulation efficiency at predetermined time points, is reported in Figure 19. The
results showed that both the complexes, unheated and heated, remained stable after 7, 14
and 30 days, without any significant modifications as regards the main properties and the
encapsulation efficiency of the system. This means that the structures of the two
biopolymers, their interactions, the core-shell structure of the complex and the
encapsulation efficiency of the active inside the system are maintained during time,
allowing the possible use of the formulations one month after their preparation.
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(b)
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(c)
Figure 19. Stability studies: (a) particle size, (b) zeta potential, (c) encapsulation efficiency.
5.3.5. IN VITRO DISSOLUTION ANALYSIS
Liquid formulations are usually the preferred model of delivery bitter drug, especially in
pre-school aged children (Nunn et al., 2005), and in particular, the delivery system may
have to release the functional component at a particular site of action (Mc Clements et
al., 2009). In fact, the structure protecting the bitter ingredient must breakdown not in the
mouth, but during later digestion to release the active compound so that it becomes
bioavailable (Coupland et al., 2014). In order to verify these conditions, F5a and F5b were
selected for in vitro dissolution studies, as the best formulations in terms of encapsulation
efficiency and for the good stability upon a storage of 30 days at 4 °C. For comparison,
an equivalent amount of pure CAF was analysed by using the same buffers and the same
conditions. Sink conditions were used to study the dissolution behaviour in fluids
simulating the whole gastrointestinal tract. The solubilisation test was first performed in
25 ml of simulated saliva fluid (SSF). More than 85 % of pure CAF was solubilized in
SSF in 30 seconds (Figure 20a), while the amounts of CAF released from the complexes
were of 18.2 % and 11.2 % after 60 seconds, for F5a and F5b, respectively. Then the
analysis was conducted in 50 ml of simulated gastric fluid (SGF) (Figure 20b); in these
conditions 100 % of the pure active was dissolved after 5 minutes, and only 17.4 % and
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4.2 % were released from the complexes in 5 minutes for unheated and heated complexes
respectively. Finally the dissolution studies carried out in 1000 mL of fasted state
simulated intestinal fluid (FaSSIF), revealed a complete solubilisation of the pure active
within 5 minutes, while 81.4 % and 45.1 % of CAF were released from the complexes
after 5 minutes for F5a and F5b respectively (Figure 20c). The dissolution analyses
highlighted a decrease in solubilisation and dissolution rate of CAF for F5a and F5b
formulations, when compared with the pure active. CAF was completely dissolved in
each medium in a short time while both the formulations permitted a controlled release
of the drug, especially in the media simulating the oral cavity and the stomach. This
behaviour could be related to the charge density of the system, in fact at high pH values,
the system is characterized by an excess of negative charges that promote the water
uptake, the hydration of the biopolymer, and the subsequent release of the active
substance. Another important consideration concerns the difference in the dissolution
profiles of unheated and heated complexes; in all the simulated fluids, heated complex
demonstrated a lower release of CAF respect to the unheated complex. This behaviour is
in agreement with literature data for which the heating of protein-polysaccharide
complexes leads to the aggregation of the biopolymer through hydrophobic interactions
and/or disulfide bonds and the formation of more stable particles in a large range of pH
(Jones O. et al., 2010).
(a)
Ramona Trastullo-University of Bologna                                                5. Case study 3
127
(b)
(c)
Figure 20. Dissolution test of complexes and pure caffeine in different media: (a) simulated
saliva fluid, (b) simulated gastric fluid and (c) fasted state simulated intestinal fluid.
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5.4. CONCLUSION
Biopolymer particles intended for the encapsulation and oral administration of caffeine
to paediatric patients were developed. Polyelectrolyte complexes based on whey protein
and pectin, loaded with different concentrations of caffeine and stable during one month
were prepared with a rapid and easy production process, by mixing the aqueous solutions
of the two biopolymers and adjusting the pH at 4, value at which the electrostatic
interactions can occur. Complexes displayed uniformity in terms of the mean particles
size and the zeta potential, whereas the encapsulation efficiency increased with the
increase of the concentration of the drug in the system. Heating the complexes did not
affect the particles size, the zeta potential and the encapsulation efficiency respect to the
unheated complexes, but the heated system were more stable, allowing a lower release
of caffeine in the three different biorelevant media. Dissolution profiles of caffeine from
these systems in simulated saliva fluid demonstrated that a low amount of drug was
released from heated and unheated complexes, with respect to the other media, providing
the confirmation about the fact that these biopolymer particles is a suitable system for
the taste masking of molecules characterized by unpleasant taste. Nevertheless, further
work is needed for the assessment of the compliance of paediatric patients.
The second part of the study will be focused on the ability of biopolymer particles based
on polyelectrolyte complexes in stabilizing emulsions, intended for the simultaneous
encapsulation and delivery of two different drugs.
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FINAL CONCLUSIONS
The considerable attention that paediatric medicines has gained in the last few years is
mainly due to the lack of appropriate formulations suitable for the administration in
children.
Taking into account the peculiar needs, together with anatomical and physiological
characteristics of the paediatric population, it was possible to discover novel
technological platforms and improve formulations and dosage forms already available
on the market, with the ultimate goal to ensure greater adherence to the therapy and
success of the treatment, avoiding the risk of errors.
The results discussed in the first ‘case study’ have showed that transmucosal route was
successfully employed for systemic delivery of ondansetron hydrochloride, through the
buccal mucosa, by polymeric mucoadhesive films. The retention time of the dosage form
on the application site and its ability to provide a sustained release, improved the
absorption of the drug into the systemic circulation, allowing a decrease of dosage and
frequency of administration and minimum impact on children lifestyle.
The second ‘case study’ have demonstrated that a flexible dosage form intended for the
administration of praziquantel to paediatric patients is a valid alternative to the
conventional tablet already available on the market. Granules can be administered with
water, milk or fruit juice, forming a very fine suspension easy to swallow. Their ease of
dose manipulation may contribute to increased compliance and drug bioavailability.
The third ‘case study’ have highlighted the possibility to develop polyelectrolyte
complexes as potential systems for the taste masking of active substances characterized
by bitter taste, leading to paediatric-friendly formulations, better tailored to children.
Finally, the results presented in this thesis demonstrated that some of the predominant
issues related to paediatric administration of medicines can be overcome by using
specific formulation strategies, in order to guarantee the complete adherence of children
to the therapy and thus the success of the treatment.
Ramona Trastullo-University of Bologna List of tables
133
LIST OF TABLES
Table 1. Summary GI tract pH data in patients of different age groups in the fasted state.
Table 2. Summary of physiological data in patients of different age groups.
Table 3. Summary of GI transit time data in patients of different age groups.
Table 4. List of commercially available paediatric oral liquid formulations.
Table 5. List of commercially available paediatric oral solid formulations.
Table 6. Correlation between surface area/body weight ratio vs age.
Table 7. Selected listing of commercially available paediatric oral formulations-
manipulation required.
Table 8. List of manipulations of the conventional dosage form for adult administration.
Table 9. Flavour type.
Table 10. Flavour preference in Europe as a function of the disease of the target group.
Table 11. Hydrophilic vehicles to mask active substances.
Table 12. Composition of the mixtures used for loaded film preparation (% w/w on wet
basis).
Table 13. Characterisation of buccal films: film thickness (µm), drug content (mg/cm2)
and water uptake ability (%).
Table 14. Composition of PZQ-loaded granules.
Table 15. Particle size analysis and flowability, expressed as Carr Index value, of raw
materials.
Table 16. Granulation yield, technological characteristics and solubility of granules.
Table 17. Drug content of the granule size fractions.
Table 18. Images of PZQ and of the granule dispersion in different liquid substrates
taken at different time.
Table 19. Composition of CAF loaded complexes.
Ramona Trastullo-University of Bologna List of figures
134
LIST OF FIGURES
Figure 1. Hedonic scale used in a taste panel.
Figure 2. Viscosity of the solutions used for the preparation of unloaded buccal films.
Figure 3. Physicochemical characterization of loaded buccal films: (a) XRPD patterns
of HPMC:CH (all the mixtures) and HPMC:HA(GEL) (all the most significant mixtures),
respect to pure ODS; (b) DSC profiles of HPMC:CH (all the mixtures) and
HPMC:HA(GEL) (all the most significant mixtures), respect to pure ODS.
Figure 4. Residence time of unloaded buccal films on porcine buccal mucosa.
Figure 5. In vitro release profile of ondansetron hydrochloride from
HPMC:CH(GEL,HA)10:0, HPMC:CH 5:5, HPMC:GEL 5:5 and HPMC:HA 5:5.
Figure 6.In vitro permeation profiles of HPMC:CH(GEL,HA) 10:0, HPMC:CH 5:5,
HPMC:GEL 5:5 and HPMC:HA 5:5.
Figure 7. Particle size distribution of granules containing 10 w/w of PZQ.
Figure 8. DSC curves of: (a) raw materials and of (b) loaded-PZQ granules in
comparison with their corresponding physical mixtures and raw PZQ
Figure 9. (a) XRD pattern of 10 % loaded-PZQ Granules (batch 5 containing Lutrol F68
and batch 6 containing Cremophor RH40) in comparison with physical mixtures and raw
PZQ; (b) FTIR spectra of batch 6, physical mixture and raw materials.
Figure 10. Particle size distribution of granules containing 20 % w/w of PZQ.
Figure 11. DSC curves of 20 % loaded PZQ granules in comparison with their
corresponding physical mixtures.
Figure 12. (a) XRD pattern of 20 % loaded-PZQ granules in comparison with physical
mixtures and raw PZQ; (b) FTIR spectra of batch 12, physical mixture and of the raw
materials.
Figure 13. Dissolution test of granules and raw PZQ in water in non-sink condition.
Figure 14. Comparison between the dissolution rate of the reconstituted suspension in
pH 1.5 buffer and of granules (batch 13) and raw PZQ in water.
Ramona Trastullo-University of Bologna List of figures
135
Figure 15. (a) Solubilisation rate of PZQ from batch 13 in different drinking media; (b)
Chemical stability of PZQ and of granules (batch 13) in milk.
Figure 16. Stability of batch 13 at different storage conditions.
Figure 17. Complex characterization: particle size and zeta potential of unheated (white)
and heated (grey) complexes.
Figure 18. Encapsulation efficiency % of CAF inside complexes for each formulation.
Figure 19. Stability studies: (a) particle size, (b) zeta potential, (c) encapsulation
efficiency.
Figure 20. Dissolution test of complexes and pure caffeine in different media: (a)
simulated saliva fluid, (b) simulated gastric fluid and (c) fasted state simulated intestinal
fluid.
